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Preface 
This project had its genesis in the hypothesis that aberrant apoptotic processing of 
cellular debris generated inflammatory mechanisms that manifested as SLE.  It was 
proposed therefore that routine laboratory investigations used in the diagnosis and 
management of SLE should be interpreted in this light, as well as other tests that may 
reflect the above hypothesis. 
The main features of the “defective apoptosis” hypothesis as one of the important 
general mechanisms underlying SLE postulates the following sub-mechanisms.  In 
normal physiological conditions cells die by way of apoptosis, and new cells are 
generated, after which the cell dies and is removed by scavenger cells such as 
macrophages and dendritic cells.  If the cells are not removed in timely manner, they 
might undergo secondary necrosis, and as they break down, they release their 
contents, such as nucleic acids like DNA.  The released materials generate an immune 
response including the activation of complement molecules, dendritic cells, T cells 
and B cells to produce large amounts of specific autoantibodies.  Alternatively, a 
deficiency in complement molecules, such as C1q, or of the enzyme DNASE I, leads 
to an accumulation of apoptotic cells and debris that are taken up by dendritic cells 
which express co-stimulatory molecules CD40 and CD40LG.  This results in 
inflammatory cytokines (i.e. IL-6) production, which, in the presence of TGF-β 
activates Th17 cells.  This process causes auto-reactive antibody-producing B cells to 
form more immune complexes (IC).  Environmental triggers, such as viral infection (in 
particular Epstein Barr virus) activate and are taken up by plasmacytoid DCs that 
specifically respond to viral infections by interferon alpha (INF-α) secretions, which, 
in association with the factors described above, leads to increased antibody 
production and formation of more immune complexes.  The end-result of this 
aberrant activation is the tissue and organ damage seen in SLE patients. 
A literature review is presented in Chapter 1 that takes an overview of the genetic 
factors that contribute to the pathogenesis of SLE; it questions the underlying 
rationale for the observed female to male gender imbalance characteristic of this 
important systemic autoimmune disease.  A shortened version of the literature 
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review was published in Autoimmunity Reviews (2017).  When topics pertaining to 
the laboratory diagnosis of SLE that were investigated further during this project they 
will be specifically identified at that time. 
Three of the four experimental chapters in this thesis have been published prior to 
submission.  A compilation of the methods used, with some additional explanatory 
notes, has been included in chapter 2 for the convenience of the readers and/or 
examiners and to avoid unnecessary repetition between chapters. 
Chapter 3 of the thesis reports on studies of some of the cellular mechanisms 
underlying SLE inflammatory pathways.  As described in the above paragraphs these 
relate to cell mediated acute and chronic inflammation and tissue damage resulting 
from defective clearance.  These include studies of myeloid dendritic cells types I and 
II (mDC1 & mDC2), plasmacytoid dendritic cells (pDCs), regulatory T cells (Treg), 
gamma delta T cells (gd T cells) and helper T cells 17 (Th17 cells).  In addition, a study 
of the inflammatory cytokine profile that include Interleukin 1 beta (IL1β), interferon 
alpha (IFNα), interferon gamma (IFNϒ), tumour necrosis factor alpha (TNF-α), 
monocyte chemoattractant protein 1 (MCP-1/ CCL2), interleukin 6 (IL-6), interleukin 
8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12p70), interleukin 17A (IL-17), 
interleukin 18 (IL-18), interleukin 23 (IL-23) and interleukin 33 (IL-33) concentrations 
in serum of SLE patients and healthy controls was undertaken. 
Activation of the classical complement pathway is well described and known to be a 
potent contributor to inflammatory processes.  Given the pivotal role of complement 
component C1q in this pathway detection and quantitation of both C1q protein and 
anti-C1q autoantibodies is described in Chapter 4. 
Low serum complement component proteins C4 and C3 have long been identified as 
an important diagnostic laboratory test for SLE.  Chapter 5 describes assays of these 
two analytes and investigates the relationship between complement component C4 
serum concentrations and gene copy numbers at this intriguing complex genomic 
region and its relationship with known silencing CT insertion in exon 29 and the 
presence of the retroviral element HERV-K (C4) in intron 4 of the C4 genes.  New 
insights are reported and under review by the Journal of Clinical Immunology.   
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Digestion of double stranded DNA from apoptotic cells is a critical step in apoptosis.  
It has been postulated that deficiency and/or variation at the DNASE I locus on 
chromosome 16, the major exogenous enzyme degrading double stranded DNA, may 
be important factors in the genetic predisposition to SLE.  Chapter 6 reports studies 
of genetic variation at the DNASE I locus in Western a population of Australian SLE 
patients.  These results have now been published also. 
A final chapter is included comprising general discussion and conclusions, together 
with additional comments and possibilities for future research into this important, 
but still enigmatic, autoimmune disease.   
 viii 
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Abstract 
Systemic lupus erythematosus (SLE) is a polygenic, multifactorial autoimmune 
disease, characterised by autoantibody production, immune complexes and 
inflammation leading to multiple organ and tissue damage.  It is postulated that 
aberrant apoptotic processing of cellular debris generates inflammatory mechanisms 
manifesting as signs and symptoms of SLE in genetically predisposed persons.  This 
project focused on the interpretation of a panel of laboratory investigations used in 
the diagnosis and management of SLE in the light of this hypothesis.  It is expected 
that the results obtained will assist clinicians in the diagnosis and ongoing treatment 
and monitoring of SLE patients in Western Australia. 
In addressing this project, those characteristics of SLE that help define this unusual 
autoimmune disease were identified.  In particular, it is suggested that laboratory 
tests used in the diagnosis and management of SLE should reflect mechanisms 
underlying immunopathology and genetic predisposition.  Consequently, the review 
of the current literature focussed on the accepted female predominance of SLE, 
including a revision of its epidemiology, and the role of genetic deficiencies in the 
predisposition to SLE.  This review included relevant research on twins, sex 
chromosomal abnormalities, genome wide association studies and possible 
environmental factors.   
Human ethics approval, incorporating informed consent, was obtained for an 
investigation of 56 diagnosed and treated SLE patients and a cohort of 33 age/sex-
matched healthy persons.  A one-time collection of fresh peripheral blood permitted 
a flow-cytometry analysis of immune related cell phenotypes in all 89 persons tested.  
Intracellular cytokine synthesis of IL17 and the cytokine transforming growth factor 
beta (TGFb) was measured together with the serum levels of a panel of 13 
inflammatory cytokines using a cytokine bead array assay.  Contrary to expectations, 
Th17 cells were at very low frequencies in the SLE cohort.  Synthesis of IL17 was 
increased in regulatory T cells and T cells expressing both the g and d markers (gd T 
  3 
cells), the latter showing the highest relative serum proportions.  SLE patients 
exhibited a reversal in the proportions of myeloid dendritic cell subsets 1 and 2 
(mDC1 & mDC2) with increased mDC2 and correlated with the frequencies of the gd 
T cell subset.  There was a relative increase in serum concentrations of the 
inflammatory cytokines IFNγ TNFα, MCP-1, IL-6, IL-8 and IL-18 in SLE patients relative 
to controls.  It is clear therefore that the SLE patient cohort exhibited inflammatory 
signatures.  We propose that the treatment regimens of the SLE patients in this study 
suppress TH17 cell numbers and another pathway involving the gd T cell/mDC2 axis 
maintains inflammation. 
It is further hypothesised that defective apoptosis permits binding of complement 
component C1q to nuclear debris with generation of a neo-C1q antigen and 
subsequent initiation of an adaptive humoral response and anti-C1q antibodies 
(aC1q ab).  Antibodies reactive with double stranded DNA antibodies (dsDNA) may 
also be produced by cognate mechanisms.  Consequently, serum concentrations of 
C1q and complement components C3 and C4 were measured together with aC1q ab 
levels and correlated with dsDNA antibody concentrations from patient files. 
It was observed that aC1q ab levels were elevated in SLE patients relative to controls, 
but all individuals tested manifested a positive result.  aC1q ab levels correlated with 
dsDNA antibody levels in SLE patients, but not with serum C1q protein levels.  It was 
concluded that measurement of aC1q ab was not specific for SLE but was useful for 
exclusion of SLE.  It was noted that higher levels of aC1q ab were present in the serum 
of those SLE patients that exhibited co-morbidities and/or received multiple 
therapeutic treatments.   
The generation of autoantibodies in patients with active SLE permits activation of the 
classical pathway of complement activation which is confirmed by the presence of 
low serum protein levels of complement components C2, C3 and C4.  The results 
obtained in this study for C4 serum protein concentrations confirmed this 
expectation.  However, deficiencies of complement proteins C1q, C2 and C4 are also 
well-known risk factors for SLE.  To address this anomalous dilemma, quantitation of 
total gene copy numbers (GCNs) was performed for the multiple paralogous C4A and 
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C4B loci that may be present in an individual, together with the presence or absence 
of the HERV-K retroviral sequence that is present in many C4 genes.  It was shown 
that for both the SLE and control cohorts serum C4 concentrations correlated with 
GCN.  However, for SLE patients, variation in serum C4 concentrations precluded 
predicting serum C4 levels.  This result confirms that consumption of C4 protein is 
responsible for low serum concentrations observed in persons with active SLE rather 
than deficient synthesis due to either lower C4A and/or C4B GCN.  Furthermore, 
these results did not support low C4A GCN as a risk factor for SLE, although this view 
is often advocated.   
Efficient apoptosis requires degradation of chromatin containing DNA by 
endonucleases.  Defective DNA degradation due to endonuclease activity would be 
expected therefore to be a significant risk factor for SLE.  Serum concentrations of 
the DNASE I enzyme were measured, together with typing of polymorphic variation 
at this locus on chromosome 16p13.3.  DNASE I protein was present in all persons 
tested with no significant differences between concentrations in the SLE and control 
cohorts.  Furthermore, of the many genotypes identified at this locus, there was no 
association between SLE and a specific genotype.  These findings do not preclude 
DNASE I deficient individuals from manifesting SLE, but do not support observations 
showing some DNASE I genotypes are associated with SLE.  We conclude therefore 
that genetic typing at the DNASE I locus is not useful in the diagnosis of SLE, or in 
predicting those individuals that are deficient in the synthesis of this important 
enzyme. 
Finally, the experimental results obtained during this project have been published in 
a series of three papers.  A shortened version of the thesis literature review has been 
published as a review of gender balance in patients with SLE.  The thesis that follows 
includes copies of the experimental papers.   
  5 
Chapter 1. Literature review: Gender balance in 
patients with Systemic Lupus 
Erythematosus 
Part of the content and ideas in this chapter have been published in Autoimmunity 
Reviews (2017).  Permissions for this article can be found in appendix B.1.1 and 
published article in B.2.1. 
Margery-Muir A A. Bundell C. Nelson D. Groth, D M. and Wetherall JD. Gender Balance in Patients with Systemic 
Lupus Erythrematosus. Autoimmunity reviews. 2017. 
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1.1 Abstract 
Factors are reviewed that contribute to the contemporary view of a disproportionate 
prevalence and incidence SLE in females.  Recent studies on the epidemiology of SLE 
report that global Incidences and prevalences of SLE for Caucasian and Black 
populations are of the order of 5.5 and 13.1 per year and 81 and 212 per 100,000 
persons respectively.  Both parameters displayed age dependent variation over a 90-
year lifespan.  The female to male (F:M) incidence of SLE varied with age, being 
approximately 1 during the first decade of life, followed by a sharp increase to 9 
during the 4th decade, thence declining in subsequent decades before an increase 
during the 7th or 8th decades.  A cognate review of SLE diagnosis in neonates 
revealed a F:M ratio of ≈1.2, consistent with the epidemiology review and the 
sporadic nature of SLE.  Notional estimates of disease duration showed a steady 
increase from a base level for both males and females.  The linear trend line for males 
was always lower than the trend line for females, supporting clinical experience that 
SLE is a more severe disease in males.  Over a 14-year interval ending in 2012, the 
notional duration of SLE increased from 10-15 years to 20-25 years, probably 
reflecting advances in diagnosis and clinical practice.   
A metastudy of SLE concordance in twins revealed a 75% discordance in monozygotic 
twins compared to a 95% discordance in dizygotic twins confirming the importance 
of environmental factors in susceptibility to SLE.  The elevated discordance in 
dizygotic SLE twins (and between siblings) suggests a role for the intrinsic genomic 
sexual dimorphism due to divergence of Y chromosome regulatory loci from their X 
chromosome homologues due to lack of recombination of mammalian sex 
chromosomes over evolutionary time. 
Estimates were made of the incidences of SLE in males and females based on 
population data for nine autosomal deficiency loci of major effect, plus expected 
male prevalence associated with Kleinfelter’s syndrome and female prevalence 
associated with Triple X syndrome.  These genetic abnormalities accounted for ≈4% 
of female and ≈23% of male Caucasoid prevalence and for SLE resulting in a F:M ratio 
of ≈0.17.  It may be deduced therefore that the impressive preponderance of SLE in 
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females arises from a combination of environmental triggers and susceptibility loci of 
relatively small effect acting between the interval from the mini-puberty of childhood 
to the peak of reproductive adulthood.  It is in this cohort of females, and especially 
in the black population, that combinations of loci of minor effect acting together with 
environmental factors initiate defective apoptosis resulting in consequential 
autoimmune disease especially SLE.  We postulate that because apoptosis is itself a 
very complex process, and defective apoptosis is an important contributor to SLE, 
there will be many combinations of susceptibility loci and environmental stimuli that 
can result in SLE (and other autoimmune disease(s)), of varying severity. 
1.2 Introduction 
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease 
characterised by the presence of autoantibodies against chromatin, including dsDNA, 
and inflammation of various organs, especially kidney and skin (recent reviews 13, 
14).  Laboratory studies on cell-mediated inflammatory mechanisms were undertaken 
and are presented in Chapter 3, page 51.  For many years SLE has been considered an 
archetypal hypersensitivity state mediated by inflammatory processes following 
organ specific deposition of immune complexes with consequential activation of 
inflammation pathways including the complement system (14).  The disease is 
managed by anti-inflammatory and immunosuppressive therapies that significantly 
reduce mortality rates, but do not effect cures (15). 
The aetiology of SLE is unclear, however ineffectual clearance of cellular debris and 
chromatin during apoptosis has been proposed as the important effector mechanism 
in many instances and there is considerable evidence to support this hypothesis 
(reviewed by 16, 17 and 18).  Laboratory studies on anti-C1q antibodies relating to 
defective clearance of apoptotic cells and debris were undertaken and are addressed 
in Chapter 4, page 65.  The incidence of SLE is sporadic, however familial disposition 
is well described and is often associated with known deficiency states.  The latter 
include deficiency states in the early acting components of the classical complement 
pathway (14) and TREX1 activity (19, 20).   
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The overall observed and widely reported gender imbalance in persons diagnosed 
with SLE is impressive.  As estimated in this report, ≈nine females are diagnosed with 
SLE for every male, although as will be seen this ratio varies between ethnic 
populations and with age of the test population.  It is proposed the extraordinary 
preponderance of SLE in females of reproductive age provides important clues to the 
underlying triggers that lead to SLE in susceptible persons.  This review will seek to 
identify those factors that contribute to the disproportionate prevalence SLE in 
females.   
1.3 Incidence and Prevalence of SLE in Human Populations 
There have been many reports of the incidence and prevalence of SLE in diverse 
human populations.  These studies have shown higher prevalences in women of 
reproductive age (20-40 years) and in women of black or Asian ancestry (reviewed by 
21, 22).  Virtually all studies report an impressive female to male (F:M) ratio.  
Estimates used in this review of incidence and prevalence of SLE for Caucasoid and 
Black populations are based on the studies of (23, 24) because they discriminate 
clearly between these two ethnic populations.  Mean incidences and prevalences of 
SLE for Caucasian and Black populations are 5.5 and 13.1, and 81 and 212 per 100,000 
persons respectively.  The F:M ratio is 9 for both ethnic groups.  Data are also included 
of estimates from two very recent European studies of ethnically mixed populations 
from the United Kingdom (UK) (25) and France (26).  A fifth report (27) includes data 
for a small population of indigenous Australians.  A summary of the prevalence and, 
incidence rates and F:M ratios from these studies is shown in Table 1.1.  It is in the 
nature of epidemiological research that results are sensitive to the methods and 
definitions used.  Differences between the four reports summarised in Table 1.1.  
reflect variations in database composition and disease definitions as well as the 
composition of the populations interrogated together with any environmental 
factors that may be involved.  Despite these limitations a consistent epidemiology of 
SLE emerges. 
Both incidences and prevalences are higher for females than for males, and the 
increased susceptibility of individuals from African descent for SLE is clearly apparent.  
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It is interesting to note that the higher incidence and prevalence rates of SLE reported 
by (27) for indigenous Australians in North Queensland are similar to those for 
European and North American Individuals from African descent.  Given the long 
isolation of indigenous Australians, this observation very likely reflects their more 
closely shared African genetic ancestry.   
The gender imbalance ratio based on prevalences is ≈10 for all studies.  The data of 
Rees and Arnaud (25, 26) included variation in both incidence and prevalence rates 
as a function of age by decade and it seems clear that SLE may be newly diagnosed 
in all decades of life.  The pronounced increase in incidence of SLE in females between 
20 and menopause is clearly seen and contrasts with the slower but steady increase 
in male diagnosed SLE over their lifetimes.  These observations translate into highly 
variable F:M ratios based on incidences (and prevalences) over a life time and 
probably account for the variation in ratios often reported in the literature.  There 
are two peaks in the F:M ratio based on incidences – these occur in the third decade 
(20-29 years) due the increased susceptibility of females of reproductive age and 
again in persons older than 79 years.  A simplistic measure of disease duration (in 
years) is the ratio of prevalence to incidence.  We have used the data of Rees et al 
(25, 28) to show this graphically in Figure 1.1 for both males and females. 
Figure 1.1 shows that over a human lifetime disease duration is shorter in males than 
females which is consistent with the many reports that conclude SLE is more severe 
in males and especially in children (29-31).  The steady increase in disease duration 
over adulthood likely reflects less severe disease profiles and rapid improvements in 
the diagnosis and treatment of this disease with consequent increased longevity.  
This point is reinforced by Rees et al (25) who estimated temporal incidences and 
prevalences for their mixed UK population over the interval 1999 to 2012.  Disease 
duration estimates for these data are presented in Figure 1.2 and show a steady 
increase in disease longevity. 
Jianguang Ji and colleagues (32) reviewed the gender specific incidence of 
autoimmune disease in 403757 subjects registered in the Swedish national disease 
databases.  Their conclusions are generally supportive of the view reported herein 
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that female predominance of autoimmune diseases may be less striking than 
previously believed.  They also reported that the median age of onset of SLE was 49 
years and 58 years for females and males respectively; these values are in close 
agreement with those of Rees et al., (25) whose data for the year 2012 implies values 
of 52 and 62 for females and males respectively in the UK populations.  In the latter 
case the median age of onset of SLE was greater for females than males only for the 
interval from the 3rd to 6th decades of life. 
1.4 Imbalance of sex ratio in offspring of SLE mothers 
A possible explanation for the female preponderance of SLE is loss of male fetuses 
during the pregnancies of mothers with SLE.  This hypothesis was initially addressed 
by Oleinick (33) who reported a significant decrease in the ratio of live born male 
siblings to total live born siblings to SLE diagnosed parents.  In 1998 Wallace (34) 
speculated the reason for the rarity of male lupus could be presence on the Y 
chromosome of a ``lethal gene'' leading to miscarriage of a male fetus, who, if born, 
would be at a very high risk of developing SLE.  Moorthy and colleagues (35) studied 
a related question by asking whether children with SLE have fewer male siblings than 
would be expected.  They reported the proportion of male siblings for SLE probands 
is 0.39, consistent with the families of children with SLE being deficient of male 
children.  The same phenomenon was not observed in the children of probands with 
pauci-articular onset juvenile rheumatoid arthritis (PaJRA) which also exhibits female 
preponderance and systemic juvenile onset rheumatoid arthritis (SoJRA) which does 
not exhibit a female preponderance (35). 
Aggarwal et al.  (36) determined the sex distribution of 6056 siblings from 2579 
women diagnosed with SLE on samples from patients registered with the “The Lupus 
Family Registry and Depository” (37).  A significant excess of female children relative 
to male children was observed in this comprehensive study; we estimated the 
decreased proportion of male siblings in families with an SLE mother to be 
approximately 13%.  A more recent large study has not confirmed the reports 
described above.  Dar and colleagues (38) used the records of the Maccabi Health 
Services (Israel) to determine the proportion of live born males in 380,472 offspring 
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of women free of rheumatoid arthritis (RA), SLE and psoriatic Arthritis (39) and in 
182,073 women with at least one of these three diseases.  Patients with SLE or RA 
did not differ from the general population by the sex of their offspring.  It is difficult 
to reconcile the differing conclusions from these two important studies.  It is possible 
that the selection of SLE patients in the Israeli Maccabi Health Services database was 
too sensitive and the inclusion of dubious cases may have obscured a deficiency of 
male offspring. 
In a related study of male only SLE, Aggarwal and colleagues (40) described five 
families with only male SLE.  They observed that white men with SLE were five times 
more likely to have a child with SLE than were white women with SLE.  This likelihood 
was not observed in Individuals from African descent.  Fluorescent in situ 
hybridisation studies in the five families with only male SLE failed to detect an 
equivalent of the “Y-linked autoimmune accelerating locus” designated Yaa.  The Yaa 
locus was initially described by Murphy and Roths as a Y chromosome locus that 
accelerated SLE disease development in male BXSB hybrid mice (41).  It is now known 
that Yaa arises from a translocation of X-linked genes onto the Y chromosome of the 
BXSB mice leading to a duplication of Ms131, TLR7, TLR8, Tmsb-4x and Rab9 loci (42, 
43).  As described above, the elevated F:M ratio for SLE only occurs during the 
reproductive stages of a woman’s life and the gender ratio of neonates and children 
diagnosed with SLE is much closer to unity.  These observations are inconsistent with 
preferential male fetal loss in SLE. 
1.5 Genetic factors affecting the gender ratio of SLE in 
humans 
1.5.1 Twin studies 
Many reports have demonstrated a familial nature of SLE.  However twin studies have 
shown only 25-30% concordance between identical twins and little or no 
concordance between fraternal twins.  Interestingly, our review of 18 case reports 
and studies of twins with SLE between 1975 and 2013 revealed a remarkable 
discordance rate.  Indeed, these reports indicate total discordance rates in 
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monozygotic and dizygotic twins of 69% and 96% respectively.  In calculating the 
overall rates for monozygotic and dizygotic twin sets, we find that 75% are discordant 
for SLE and 25% are concordant only.  The summary of individual data and references 
for each study are shown in Table 1.2.  Discordance between monozygotic twins is 
usually attributed to variation in environmental factors either in utero or within the 
interval between neonatal life and age of diagnosis of SLE.  Incomplete information 
and variation between studies prevented reliable estimates of the F:M ratio of the 
twin pairs reported in Table 1.2.   
Only a few of the twin studies in this table reported similarity of symptoms, outcomes 
and times of diagnosis/onset (44-46).  In most instances, there was considerable 
variation in pathology, serology, and time of onset (47-49).  Indeed, Kuroda and 
colleagues (47) reported a set of twins who still lived together at time of onset of 
disease; despite MHC class I and II similarity, the diagnosis of SLE for each twin 
differed by three years with only one twin manifesting a lupus psychosis.  In a 
discordant case, both twin sisters presented with Myasthenia gravis and both 
received a thymectomy 14 years apart; the twins were diagnosed two years apart 
and followed for 28 years.  The concordant twins reviewed by Del Boz and colleagues 
(45) were males with Kleinfelter’s XXY karyotype, similar pathologies and age of 
diagnosis. 
Fraga and colleagues (50) studied epigenetic profiles in monozygotic twins and 
observed distinct epigenetic patterns in each twin.  They showed these differences 
were associated with age, the time spent together and their medical history.  
Moreover, gene expression profiles showed a four-fold differential expression in 
older twins and a higher number of overexpressed genes and hypo-methylation that 
may lead to increased transcription and activation of these genes.  It seems clear that 
although twins are viewed as genetically identical, distinct epigenetic signatures 
reflecting environmental differences may generate distinct phenotypes that could 
account for discordance in autoimmune diseases, including SLE.   
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1.5.2 Neonatal SLE 
Nineteen reports of neonatal SLE between 2013 to 2016 were reviewed and are 
summarised in Table 1.3.  In 114 neonates with SLE there were 63 females and 51 
males to give a F:M ratio of 1.2.  This result is consistent with the data presented in 
Figure 1.1 showing the incidence of SLE in male and female children in the first 
decade of life.  Of the 114 neonates with SLE the mothers of 46 were not recorded as 
having tests or symptoms of autoimmune disease, especially SLE.  This result is 
consistent with sporadic SLE being frequent. 
1.6 SLE associated with chromosomal mutations  
The increased incidence of SLE in females relative to males suggests an important 
role for the X chromosome in the predisposition to SLE.  Nondisjunction of the X 
chromosome during meiosis gives rise to males with an XXY karyotype and 
subsequent abnormalities referred to as Kleinfelter’s syndrome (KS).  Although 
reported cases are low (about 30 cases between 1970 and 2009), the prevalence of 
SLE in males with KS is increased ≈14 times relative to normal males (11).  The disease 
phenotype in KS males is similar to that in females.  In a follow up study to that of 
Scofield et al.  (11), Dillon and colleagues (51) reported that 7 of 286 men with SLE 
from the Lupus Family Registry and Depository (37) manifested abnormal karyotypes 
that included 47XXY.  In contrast to non-KS men with SLE the disease symptoms of 
the KS men with SLE were less severe and did not include nephritis.  Further, it is clear 
that not all KS males develop SLE.  Men with KS who develop SLE behave as a cohort 
more like women with mild SLE.  The prevalence of KS in Australia is approximately 
1115 per 500,000 males (52) with most KS patients being initially identified as adults 
presenting with infertility.   
Harris and colleagues extended these findings by reporting that the KS karyotype was 
more frequent in males diagnosed with Sjogren’s syndrome than in either control 
populations or rheumatoid arthritis patients (53); they also confirmed excess KS in 
men diagnosed with SLE.  In a cognate study Liu et al., (54) reported an increased 
prevalence of SLE and Sjogren’s syndrome in a cohort of females with another 
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chromosomal mutation – the 47XXX karyotype, providing further evidence for dosage 
effects reflecting X chromosome copy number.  The prevalence of 47XXX in patients 
(females) with SLE was estimated to be 0.25%.  The prevalence of SLE in females with 
Turner’s syndrome (characterised by the 45XO karyotype) seems to be diminished 
relative to normal females.  Only three cases of SLE in women with the 45XO 
karyotype have been reported possibly because karyotyping is not usually performed 
in these women (12, 55, 56), although the Ruas study also described neonatal SLE in 
a 45XO female infant. 
1.7 Genomic sexual dimorphism - influence of the Y 
chromosome 
Recent sequencing and phylogenetic analysis of the human Y chromosome has 
provided important new information on intrinsic differences between male and 
female cells (57, 58).  It is now understood that the Y chromosome includes a 
complement of regulatory genes (UTX/UTY, EIF1AX/EIF1AY, ZFX/ZFY, RPS4X/RPS4Y1, 
KDM5C/KDM5D, DDX3X/DDX3Y, USP9X/USP9Y and TBL1X/TBL1Y) that have diverged 
from their X chromosome homologues due to lack of recombination of mammalian 
sex chromosomes over millions of years.  The homologues of these regulatory genes 
on the X chromosome also remain functional on the inactivated X chromosome in 
females so that they are present in both sexes in two copies, albeit that the Y 
chromosome variants have diverged significantly from their X chromosome 
counterparts.  Notwithstanding the powerful differential influence of sex hormones 
on male and female tissues, differences between the divergent regulatory 
homologues shared by the sex chromosomes create a sexual dimorphism manifested 
as X and Y-encoded protein isoforms in diverse human tissues.  David Page (see 57) 
has speculated “whether this dimorphism has a role in diseases, outside the 
reproductive tract, that occur with greater frequency or severity in males or females”.  
These studies do not explain however the frequent discordance of monozygotic twins 
with SLE, including those also manifesting Kleinfelter’s syndrome (see discussion 
above).  Genomic sexual dimorphism may be further complicated by non-random 
inactivation of the X chromosome in a female cell – a phenomenon called skewed X 
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chromosome inactivation.  Kast was the first to postulate a role for X-inactivation 
chimerism in female-prevalent autoimmune disease (59).  Jeffrey Stewart extended 
this hypothesis to propose that the discordance rate of SLE between monozygotic 
twins may be explained by such twins manifesting different X-inactivation patterns, 
possibly in a tissue specific manner (60).  There seems to be no published evidence 
to support a role for skewed X inactivation in SLE. 
1.8 Mitochondrial DNA and SLE 
The 16 Kb circular mitochondrial genome encodes thirteen proteins of the inner 
mitochondrial membrane respiratory complex; it is present in multiple copies and 
inherited matrilineally (61).  The major function of mitochondria is the production of 
energy by ATP reduction that is essential for all intracellular processes (61, 62, 63, 64, 
65).  ATP from mitochondria is also important in promoting immune responses via 
inflammasome activation and in regulating apoptosis (66).  Apoptosis is a 
programmed form of cell death involving the degradation of cellular constituents by 
a group of cysteine proteases called caspases.  The caspases may be activated 
through the mitochondrial mediated intrinsic pathway (67) or via the “death 
receptor” mediated extrinsic pathway (68).  The intrinsic pathway of apoptosis is 
initiated by intracellular signals resulting in permeabilisation of mitochondria with 
release of cytochrome c into the cytoplasm and subsequent apoptosome activation 
of the caspase cascade (67, 69).  Perl (70) has recently reviewed evidence confirming 
increased production of reactive oxygen species (ROS) and consequent oxidative 
stress in peripheral blood lymphocytes (PBL) from patients with SLE; mitochondria in 
T cells from patients with SLE exhibit dysfunction characterized by elevated 
mitochondrial transmembrane potentials (71, 72).  These events may lead to 
aberrant apoptosis, oxidative stress, and inflammatory responses (73, 74, 75).  Hence 
it is possible that variation in maternally transmitted mitochondrial DNA may 
predispose to SLE and other inflammatory autoimmune disorders.  If genetic 
variation in mitochondrial DNA is a candidate locus for predisposition to SLE It is 
unknown whether there are gender specific differences.   
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1.9 Inherited autosomal deficiency states predisposing to 
of SLE 
There have been many reports of SLE in kindred groups manifesting an autosomal 
deficiency state.  In these families, the susceptibility to SLE usually reflects a strong 
association with a specific genetic locus (Table 1.4).  The best described and longest 
known autosomal loci of major effect in predisposition to SLE encode complement 
proteins C1q, C1r, C1s, C2, C4A and C4B.  Of these, genes encoding C2 and both C4A 
and C4B (as well as Factor B) occur within the central region of the human MHC on 
chromosome 6p21.3 (reviewed by 14).  It is notable that while these associations 
between the complement component (complete) deficiency state and SLE are 
generally strong they are not absolute.  The percentage of persons with a complete 
deficiency state that are concordant for SLE varies from a low of 57% for C2 through 
to over 90% for C1q (Table 1.4). 
C1q and C1r deficiencies are very rare and associated with early childhood onset of 
SLE.  Stegert (76) and Van Schaarenburg (77) reported the median age of SLE onset 
was five and nine years old respectively.  Van Schaarenburg (77) showed early age of 
death in their C1q deficient SLE patients (F:M ratio of ≈1.3:1) with a mortality of 20% 
at time of follow up.  The C2Q0 allele has been estimated to have a frequency of 0.02 
in Caucasian populations resulting in 0.04% of persons with homozygous C2 
deficiency states (78-80).  Of these only 10% manifest SLE with a sibling concordance 
rate of approximately 50% and an F:M ratio of ≈7, the latter figure being closer to the 
overall ratio for all SLE patients (see Table 1.1). 
Humans have two forms of the complement C4 gene designated C4A and C4B.  Both 
loci encode isotypic forms of C4 protein (C4A and C4B) each with distinct biochemical 
properties and each displaying multiple electrophoretic variants reflecting allelic 
polymorphisms (81, 82).  Null alleles designated C4AQ0 and C4BQ0 exist at both loci 
as a result of several well-defined mutations (83-85).  A further level of complexity 
arises from the propensity of this chromosomal segment to duplicate resulting in as 
many as four distinct replicons per chromosome each containing either a C4A locus 
or a C4B locus (81, 82).  Males and females share this complexity and the distributions 
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of serum levels for both C4 proteins is similar in males and females (86).  Wisnieski 
and colleagues described a rare three-generation kindred with incomplete C4 
deficiency resulting from hyposynthesis of C4 protein controlled by an unidentified 
autosomal dominant non-MHC linked locus (87).  Null alleles of C4 genes were not 
involved and hyper-catabolism of C4 protein was excluded.  In this study of 28 
persons with 10 persons exhibiting low C4 serum concentrations only the proband 
was diagnosed with SLE.  This report supports the argument that low C4 serum levels 
per se are neither sufficient nor necessary for the development of SLE.  Reliable 
population data for the frequencies of C4AQ0 and C4BQ0 null alleles is limited, 
although in Caucasians the frequencies of the C4AQ0 and C4BQ0 alleles are reported 
as 1% and 3% respectively (14) complete C4 protein deficiency is therefore very rare.  
If these loci manifest Hardy Weinberg equilibrium the expected frequency of C4A and 
C4B protein deficient persons would be expected to be less than 1 in 1 million.  Both 
C4A and C4B loci, together with the complement Factor B and complement C2 loci 
are located within the central region of the MHC and behave as a genomic block 
within which recombination is restricted.  Hence it is not meaningful to consider 
these two loci individually when assessing their contributions to male and female 
differences in susceptibility to SLE.  Laboratory studies on complement C4 loci were 
undertaken and are presented in Chapter 5, page 77. 
Other loci predisposing to SLE are the inhibitory Fc gamma binding receptor 
(FcGR3B), endogenous DNASE (Trex1) and exogenous DNASEs I and II.  Fc receptors 
link humoral and cellular immunity by facilitating phagocytosis and antibody 
dependent cell mediated cytotoxicity and are important in modulating the immune 
response (88).  The human FcGR locus on chromosome 1q23 is subject to copy 
number variation (CNV) (4, 89, 90).  This genomic region contains the FcGR3B locus 
and paralogous genes FcGR2A, FcGR3A, FcGR2C, and FcGR2B, encoding low-affinity 
Fc gamma receptors (4).  The inhibitory receptor gene, FcGR2B, exhibits a 
polymorphism within the trans-membrane domain that is associated with SLE (5).  
Several groups have reported that diminished efficiency of the FcGR complex by 
either mutation or deletion is associated with SLE (4, 89, 90).  Mutations in the Fc 
region of immunoglobulin heavy chains that bind complement C1q may also reduce 
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the efficiency of removal of complement activated antibody-antigen complexes 
thereby precluding complement activation and phagocytic removal of the complexes.   
Patients with SLE demonstrate defective clearance of cell debris, which could trigger 
autoimmune responses (91).  Hence mutations in genes involved in the digestion of 
dsDNA and chromatin have been implicated in the development of SLE (1, 3, 6, 20, 
92-100), especially in patients with early age of onset and lupus nephritis (3).  TREX1 
(DNASE III) is the major 3ʹ-5ʹ DNA exonuclease within mammalian cells.  TREX1 is 
located on chromosome 3p21.31 and consists of a single exon encoding a 
homodimeric 314 amino acid polypeptide chain (7).  TREX1 is an important 
component of the SET protein, a multitasking protein complex that associates with 
the endoplasmic reticulum and translocates to the nucleus in response to oxidative 
stress.  In association with SET, TREX1 causes single-stranded DNA damage during 
caspase-independent apoptosis activated by granzyme A (7).  Crow and colleagues 
have described an IFN-driven inflammatory disease associated with TREX1 loss in 
human patients (Aicardi-Goutieres syndrome) that is characterised in part by an 
autoimmune syndrome similar to SLE (7, 101). 
Lee-Kirsch et al., (6) reported that nine of 417 SLE patients from the UK, Finland and 
Germany (males and females not specified) manifested TREX1 mutations with no 
mutations in their control cohort.  More recently Ellyard and colleagues described a 
four-year-old female with cerebral SLE caused by a rare homozygous mutation in 
TREX1 (102).  Namjou and colleagues reported that the estimated frequency of TREX1 
mutations in their mixed ethnicity SLE cohort was 0.5% (99).  These findings are 
consistent with mutant forms of TREX1 having impaired exonuclease activity and 
therefore predisposing to inflammatory diseases by reduced degradation of dsDNA 
during apoptosis.  Another recent study (9) provides important insights into the 
digestion of DNA containing microparticles (formed from reverse transcribed retro-
elements) and its role in preventing autoimmune disease.  DNA from apoptotic cells 
is degraded by the intracellular enzyme DNASE2, whose deletion in mice causes IFN-
driven auto-inflammation (103).  These rare but highly penetrant causative mutations 
are not detected in genome wide studies which may explain part of the missing 
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heritability of SLE as well as provide insights into disease pathogenesis.  We are 
unaware of any gender bias in the expression of DNASEs. 
It is also of considerable interest that endogenous DNASE activity is present in blood 
from healthy persons.  DNASE activity is increased in the serum of SLE patients 
experiencing a relapse of disease, but not in healthy controls (104).  Barcelos-Barra 
and colleagues showed that DNASE activity in blood plasma is inhibited by the anti-
coagulant EDTA which more closely mimics the physiological state of circulating 
blood (105).  The genetic basis of DNASE activity in human blood has not been 
described.  Laboratory studies on DNASE I locus polymorphisms were undertaken and 
are presented in Chapter 6, page 90. 
Crow et al., (106) has suggested that SLE is a heterogeneous collection of individually 
rare genetically distinct disorders sharing a common inflammatory pathology.  These 
deficiency states, although relatively rare, go some distance in accounting for the 
genetic complexity of SLE predisposition (see also Table 1.4).  Further, these 
autosomal deficiency states are expressed in both sexes and, as expected, do not 
contribute to the high female prevalence in SLE patients.   
1.10 Genome wide association studies of SLE 
Genome wide association studies (GWAS) interrogate individual genomes of persons 
with a specified disease or trait for the presence or absence of SNPs exhibiting 
significant linkage disequilibrium.  GWAS’ are complex, require large numbers of test 
individuals and well-defined SNP panels to achieve useful outcomes and are more 
difficult to analyse when SNPs on the single copy sex chromosomes are included 
(107).  The latter difficulty is especially relevant for SLE where the incidence shows a 
strong female bias.   
For example, Graham and colleagues (108) have performed a review of the literature 
and meta-analysis of published candidate variants from 1310 SLE cases of North 
Americans of European descent and 7589 controls.  Many of the candidate loci 
identified also functioned in B-cell signalling and development, through toll-like 
receptors seven and nine, as well as neutrophil function which are believed to be 
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important in the development of SLE.  Candidate loci identified by GWAS occur on 
both autosomes and the X sex chromosome in humans.  Seventeen variants were 
observed that accounted for about ≈30% of the genetic predisposition to SLE (108).  
Candidate loci on autosomes should contribute to SLE predisposition in both males 
and females unless there is a sex specific regulatory mechanism in place. 
Two more recent GWAS in SLE cohorts have been published and these both confirm 
and extend many earlier studies (109, 110).  Bentham et al., (109) undertook a 
comprehensive GWAS on 7219 SLE cases and 15991 controls of European ancestry 
and mapped 43 susceptibility loci that included 10 new associations.  The 
susceptibility loci included an over-representation of 16 transcription factors.  Sun 
and colleagues (110) reviewed a GWAS’ on 4478 SLE cases and 12,656 controls of 
East Asian ancestry in which the incidence of SLE is greater than Caucasians.  Ten new 
loci and 20 previously known SLE susceptibility loci were identified with many of 
these involved in immune cell (T and B) functions.  Sun et al., (110) also estimated 
the total heritability of SLE in Asians accounted for by their study to be ≈24%.  So et 
al., (111) used a statistical method to estimate the heritability of 10 complex diseases 
(including SLE) from GWAS and concluded that GWAS underestimated heritability; 
their estimate for SLE was 13% heritability.  It is of interest that neither study 
described above identified TREX1 as a susceptibility locus for SLE, although as 
reported by Ellyard et al., (3) this locus has a rare allele that when homozygous causes 
SLE.  In our view, it is likely that a greater proportion of the heritability of SLE as well 
as other autoimmune disorders will be attributable to rare alleles of major effect, 
including also the role of compound heterozygosity where two distinct mutant alleles 
create a disease predisposition reflecting a functional deficiency state. 
GWAS are based on linkage disequilibrium estimates between susceptibility loci and 
a specified trait, whether that trait is a disease diagnosis or a productivity measure in 
agriculture.  The utility of this method is diminished by the presence in human 
genomes of extended haplotypes which while polymorphic themselves remain stable 
due to suppressed recombination (112).  Given the inherent low efficiency of GWAS’ 
and this latter complication, the future of GWAS in the study of complex diseases is 
problematic.  The development of affordable powerful highly parallel genome 
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sequencing methods now permits a more direct approach to identification of 
susceptibility loci for complex diseases in general.  A subset of this technology, 
abbreviated to VAST (variant analysis of sequenced pedigrees), has been described 
by Field et al., (113) and holds much promise for identifying causal loci that may 
explain some of the discordance shown by identical twins with SLE.   
1.11 Estimated prevalence of SLE in males and females due 
to autosomal loci of major effect and Kleinfelter’s 
syndrome  
The prevalence of SLE in males and females due to chromosomal mutations of the 
sex chromosomes and known autosomal loci of major effect is estimated as shown 
in Table 1.4.  This table records prevalences of SLE in a Caucasoid population of one 
million persons (males = females).  There is a paucity of data for the prevalences of 
most of the autosomal deficiency states that are strongly associated with SLE, 
although it is clear these are mostly rare deficiency states.  To overcome this problem, 
we have therefore assumed population prevalences for complete C1q, C1r, C1s, 
C4A+C4B, and TREX1 (DNASE III) deficiency states as one in one million, based on 
inferences from the literature and consider these conservative.  Other prevalences 
are derived from the references shown in Table 1.4. 
As shown in Table 1.4, these genetic predispositions of major effect account for a 
greater proportion of male SLE diagnoses than female.  Further, based on the 
differing age dependent incidence and prevalence profiles for SLE most of these male 
diagnoses occur within the first two decades of life, or later in life.  The impressive 
female preponderance of SLE prevalence arises therefore from the dramatic increase 
in females diagnosed with SLE in the 3rd and 4th decades coinciding with the 
reproductive years.  If preconditioning in utero, or neonatal hormonal status, 
increase susceptibility to SLE in these cohorts, it is in these females that the 
underlying mechanisms and environmental triggers should be sought.  Several 
possibilities have been recognized. 
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It is interesting to compare the main features of SLE with those of ankylosing 
spondylitis (AS), another autoimmune disorder of unknown aetiology in which the 
F:M ratio strongly favours males.  It is an autoimmune seronegative spondylo-
arthropathy that exhibits a strong association the class I HLA-B27 allele (114, 115).  
HLA-B27 occurs in more than 80% of the European Caucasians diagnosed with 
ankylosing spondylitis relative to eight percent in the normal population reviewed by 
(116) to give and odds ratio of ten.  Concordance of AS in identical twins of more than 
90% has been reported reviewed by (116).  The F:M ratio for incidence of AS is 
approximately one in the 18-29 year old individuals, and doubles by the 30 to 39 year 
old (1.97) and steadily decreases to 1.38  in the 80 plus year cohort (117).However, 
the prevalence F:M ratio of AS is approximately less than 0.025% in the 16 to 19-year-
old group and steadily increases to 0.35% in the 55 to 59-year-old and above (117).  
Only four cases have been reported of AS in males with KS (118-121).  Armstrong et 
al.  noted that their AS patient with KS seemed to have a more female-like disease 
phenotype which is similar to the female disease phenotype observed in KS males 
with SLE.  Interestingly, there are only four reports also of AS occurrence in females 
with Turner’s syndrome (122-125) of which the report by Sandhya and colleagues 
(124) is describing a case of juvenile AS.  GWAS on AS individuals have found about 
30 genetic associations with autosomal loci but do not seem to have found any 
association on the X and Y chromosomes IGAS 2013; (126).  
1.11.1 Gender differences in early microbiome development and 
immune responsiveness and predisposition to SLE 
Sex based differences affecting both the innate and adaptive immune responses in 
humans are well known (reviewed by 127).  It is believed that these contribute to 
differences in the pathogenesis of infectious diseases and responses to viral vaccines 
in males and females, and the increased susceptibility in females of autoimmune 
diseases especially during their reproductive years (127, 128).  Of interest in this 
review is the study of Gaudreau and colleagues (129) who reported increased 
mucosal immune responsiveness of female (SWR x NZB) F1 (SNF1) mice compared 
with their male counterparts; female SNF1 mice are especially susceptible to SLE like 
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symptoms including proteinuria (130).  Female SNF1 mice not only showed 
profoundly higher CD154, immune cell densities, but also carried large numbers of 
interleukin (IL)-17-, IL-22- and IL-9-producing cells in the lamina propia compared to 
their male counterparts.  The intestinal mucosa of female SNF1 mice expressed 
higher levels of a large array of pro-inflammatory molecules, including type 1 
interferons and TLR seven and eight even before puberty.  This potential link between 
the immune response of the gut mucosa and SLE suggests that gender specific 
responses to environmental or dietary antigens may contribute to the gender 
imbalance of SLE incidence in humans.  A further intriguing link between the mucosal 
immunity and SLE comes from the report by Markle and colleagues that early-life 
microbial exposures influence sex hormone levels and modify progression to 
autoimmunity in the non-obese diabetic (NOD) mouse model of type 1 diabetes in an 
androgen receptor dependent mechanism (131).  The role of microbiota colonization 
in early life in modulating immune responsiveness has been reviewed by Gensollen 
et al.  (132).   
There is a clear role for hormonal factors and environmental interactions in the 
manifestation of this sexual dimorphism but possible molecular mechanisms are 
poorly understood.  Two recent reports on regulation of immune responses by sex 
steroids have shown independently that expression of the autoimmune regulator 
locus (AIRE) is decreased in the female thymus relative to the male thymus especially 
during pre-puberty and the interval known as the mini-puberty of infancy (133, 134).  
Dragin and colleagues associated diminished AIRE expression with estrogen-induced 
gene methylation, while Zhu and colleagues followed the finding of increased male 
AIRE expression by demonstrating that the androgen receptor binds the AIRE 
promoter and increases AIRE expression (both mRNA and protein).  In both studies, 
AIRE expression affected thymic expression of tissue-specific antigens.  Finally, both 
groups showed that susceptibility to autoimmunity disease (in murine models of 
multiple sclerosis and thyroiditis) depended on sex steroid production in an AIRE-
dependent manner.  These ground-breaking studies provide renewed interest in the 
role of in utero sex steroid exposure as a predisposing factor to SLE. 
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The view that sex hormones contribute indirectly to SLE predisposition is supported 
by rapid increase described previously in the incidence (and prevalence) of SLE in 
post-pubertal women relative to both pre-pubertal males and females.  It is known 
that androgen levels in female SLE patients are lower than in control groups 
regardless of treatment regimen (135). 
1.11.2 Evidence for an elevated in utero androgen receptor 
environment in SLE predisposition 
In humans, the ratio of 2nd to 4th digit length (2D4D) is sexually dimorphic with the 
mean 2D4D being longer in females than males.  Over a decade ago Lutchmaya and 
colleagues (136) showed that the 2D4D ratio on the right hand exhibited a significant 
negative association between fetal testosterone to fetal estrogen concentration 
ratios (FT/FE) in amniotic fluid that was independent of sex.  More recently Manning 
and colleagues have shown that this trait reflects the sex hormonal environment in 
utero, specifically the relative proportions of androgen versus estrogen receptors on 
the tissues of the 2nd and 4th digits respectively and is believed to be fixed early in 
development (137, 138).  Doe and colleagues (139) measured 2D4D ratios in 100 
patients with SLE each fulfilling the American College of Rheumatology criteria and 
200 controls without SLE (each cohort contained equal numbers of males and 
females).  Their study showed that patients with SLE had decreased 2D4D ratios 
relative to controls thereby providing indirect evidence that the SLE patients 
experienced high prenatal testosterone and low prenatal estrogen.  Interestingly, 
men with KS, in which the prevalence of KS is similar to that observed in women, had 
2D4D ratios similar to normal women and is consistent with the observations 
reported above that SLE in KS males is often less severe than in non-KS males and 
more closely resembles SLE in women of reproductive age (140).  A study of men with 
and without multiple sclerosis also showed a decreased 2D4D ratio in men with the 
disease and concluded that low androgen exposure during the pregnancy could be a 
risk factor for multiple sclerosis (141).  There is a large number of sexually dimorphic 
traits that show an association with the 2D4D ratio (see for example 
http://www.handresearch.com/news/digit-ratio-finger-length.htm).  It seems that 
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the lower 2D4D ratio seen in female SLE patients offers support for elevated 
androgens during pregnancy being a risk factor for SLE that may act synergistically 
with physiological synthesis of sex hormones during prepubescent development, 
especially in females. 
1.12 Sex hormone effects on disease 
Human immune responsiveness sex-based differences affecting both the innate and 
adaptive immune responses are well described.  It is believed that these contribute 
to differences in the pathogenesis of infectious diseases and responses to viral 
vaccines in males and females, and the increased female susceptibility to 
autoimmune diseases, especially during their reproductive years reviewed by (127).  
The rapid increase in the incidence (and prevalence) of SLE in post-pubertal women 
relative to both pre-pubertal males and females described above reinforces this view. 
Hormone studies in SLE have shown increased up-regulation of immune 
plasmacytoid dendritic cells (pDCs) and co-stimulatory molecules by a collaboration 
of 17β estradiol (E2) and toll-like receptor 9 (TLR9) CpG ligand (142-145).  In addition, 
immune cells express the estrogen receptors (ER) alpha and beta (α & β) that effect 
cell responses to estrogens such as 17β estradiol (146-148).  Therefore, it has been 
postulated that E2 in the presence of the CpG ligand might stimulate pDCs to produce 
large amounts of IFNα and increase B cells viability as well as their release of auto-
antigens (142).  Other groups have demonstrated collaboration of E2 and IFNα which 
lead to prolonged survival of auto-antigens (149) or by an IFNα independent 
mechanism (150).  On the contrary to the human studies, experiments in lupus mice 
models have not demonstrated specific effects from hormonal secretions (151).  
These reports suggest that hormonal regulation by itself is not pathognomonic of SLE.  
Other factors, for example dis-regulation of X-linked genes may influence disease 
outcomes.  CD40 ligand (CD154) and TLR7 (HGNC:11935; HGNC:15631 respectively, 
NCBI) are two genes involved in cellular pathways as described above. 
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1.13 Other environmental factors 
Despite well delineated genetic risks factors, serological, cellular, MHC phenotype, 
hormonal functions as seen previously in this review, it is clear that other factors, 
clearly environmental, must play a critical role in the outcomes of SLE in individuals.   
There is no well-defined association between SLE and specific infectious agents, with 
the possible exception of the Epstein Barr virus (152).  Several studies have 
demonstrated the presence of EBV antibodies in patients with SLE (153-155).  Since 
EBV is a dsDNA virus it is clearly possible that impaired degradation of intracellular 
viral DNA could result in impaired apoptosis of infected cells thereby mimicking an 
important predisposing factor for SLE and other inflammatory disorders.   
Deficiency of vitamin D correlates inversely with disease activity index in patients 
with lupus (156-159).  Other environmental factors, may also play a critical role in the 
predisposition and outcomes of individuals with SLE.  These include climate/ 
temperatures and altitude (160-162), seasonal changes and UV exposures (162-165), 
paints and colour dyes, film development, polishes (nail) (161), insecticides (166), 
exposure to compounds such as Polychlorinated biphenyls/dibenzofurans (167).  
Increased risk of SLE associated with exposure to silica from dust and industrial 
urbanisation has also been reported (161, 168-172).  Exposure to this compound 
increases the risk to SLE and rheumatoid arthritis up to eight-fold (172), and longer 
exposure increases the risk (171).   
Hence, the different environmental factors might trigger SLE pathology in susceptible 
individuals who possess other risk loci as mentioned so far herein. 
1.14 Conclusions and discussion 
As described herein, recent epidemiological data shows that SLE may be first 
diagnosed in neonates and at all ages until old age.  In contrast to males, the 
incidence and prevalence of SLE increases dramatically in post pubertal females and 
remains high during the reproductive years reaching peaks between the third and 
fifth decades.  The F:M ratio for incidence, and hence also prevalence of SLE, varies 
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markedly with chronological age and ranges from ≈1 to 10 in figures used in this 
paper.  The often quoted value of a F:M ratio of ten applies only over the third to fifth 
decades of life.  This report shows that for children under ten years the F:M ratio is 
≈1.2 and for elderly adults gradually decreases to ≈3.  The latter figure is probably 
influenced by the increased longevity of females relative to males and the more 
severe disease often seen in males.  It is noteworthy that age dependent prevalence 
of SLE divided by the age dependent incidence of the disease shows a steady increase 
over ten decades for both females and males.  This ratio is a notional measure of the 
average duration of disease and is always higher in females than males.  This 
observation supports clinical reports that SLE is a more severe disease in males than 
females with shorter survival times. 
The markedly increased F:M ratio during the third to fifth decades in women strongly 
supports a sex hormone mediated predisposition to the incidence of SLE.  A similar 
observation in males with KS, together with a more female like profile of SLE reported 
in KS males, strengthens this conclusion.  An explanation for this observation is likely 
to be found in the sex hormone modulation of genes on the X chromosome that 
modify epigenetic profiles in susceptible women.  Two observations demand 
explanation in understanding the genetic predisposition to SLE.  Firstly, there is little 
concordance between monozygotic twins, and secondly the F:M ratio of neonates 
with SLE is approximately 1.  These observations imply in utero environments 
affecting both sexes equally predispose to the development of SLE.  The obvious 
candidate is temporal differences in the in utero sex hormonal environment during 
pregnancy.  That this environmental factor is relevant is supported by both abnormal 
androgen levels during early pregnancy of mothers with SLE and especially by the 
decreased 2D4D ratios reported in both males and females with SLE.  Given the 
consistent variation of 2D4D ratios in persons with many types of traits that exhibit 
gender imbalance, temporal in utero androgen imbalance seems to be an important 
feature of SLE.  The dramatic increase in SLE incidence during the reproductive years 
in women may reflect a synergistic effect of increased estrogen levels in females 
predisposed during pregnancy to androgen imbalance. 
  28 
There is much evidence to support the hypothesis that SLE arises from defects in 
apoptosis - the complex physiological mechanism whereby the detritus of dead and 
damaged cells is removed from the body following programmed cell death (17, 18).  
Relatively rare protein deficiency states mediated by autosomal single locus mutant 
genes are closely associated with SLE as described above.  These loci occur in equal 
frequency in males and females and SLE is often inherited in kindreds in Mendelian 
fashion.  They are examples of rare genes of major predisposition for SLE.  The 
evidence to date is that in a minority of cases the rare deficiency state occurs in 
persons who not develop SLE as children but may do so later in life.  A conservative 
estimate of the proportion of SLE cases that may be accounted for by this type of 
deficiency state is ≈5% of children within the first decade of life(a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) The assumption is made based on our own meta-analysis. 
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1.15  Tables and figures 
1.15.1 Tables 
Table 1.1: Meta-analysis of Incidence and Prevalence of SLE per 100,000 person years from 4 seminal studies and 1 
Australian study. 
Data 
Source 
 Caucasians Black Overall 
 Gender Incidence Prevalence Incidence Prevalence Incidence Prevalence 
(24) Females 6.3 86.7 12.8 186.3 9.3 127.8 
 Males 1.2 8.7 2.1 19.3 1.6 12.4 
 F:M 
ratio 
5.3 10.0 6.1 9.7 6 10 
(23) Females 4.7 59 13.4 196.2 9.4 131.1 
 Males 0.7 7.5 3.2 23.7 1.7 14.9 
 F:M 
ratio 
6.7 7.9 4.2 8.3 6 9 
(26) Females     5.51 79.1 
 Males     0.92 11.83 
 F:M 
ratio 
    6.0 6.7 
(25) M & F 
 
6.73 134.53 22.5* 247.62* 8.34 167.62 
 1.44 24.82 
 F:M 
ratio 
 
    5.8 6.8 
(27)   30.2**  92.8  45.3 
(Aust.  
Indigenous
) 
F:M 
ratio 
 6.5**  5.5  6.2 
*Average from Black African, Caribbean & other.  ** Estimated from data included in paper.  Grey shaded boxes represent 
non-available or not applicable data. 
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Table 1.2: SLE concordance/discordance in Human twin  
References Gender Monozygotic 
Discordance 
Dizygotic 
Discordance 
Monozygotic 
Concordance 
Dizygotic 
Concordance 
Total 
Monozygotic 
sets 
Total 
Dizygotic 
sets 
(173) F 1 n/a 0 n/a 1 n/a 
(44) All F, 1 
M 
6 0 13 1 19 1 
(174) F 3 3 3 0 6 3 
(175) M 1 n/a 0 n/a 1 n/a 
(176) F 1 n/a 0 n/a 1 n/a 
(177) M 1 n/a 0 n/a 1 n/a 
(48) F 1 n/a 0 n/a 1 n/a 
(178) 1 MZ M 8 10 1 0 9 10 
(179) F & 1 
DZ M 
co-twin 
3 6 1 0 4 6 
(180) F, 1M 9 n/a 0 n/a 9 n/a 
(181) F 4 n/a 1 n/a 5 n/a 
(47) F 0 n/a 1 n/a 1 n/a 
(182) F 1 n/a 0 n/a 1 n/a 
(45) M 0 n/a 1 n/a 1 n/a 
(49) F 1 n/a 0 n/a 1 n/a 
(183) F, 1 DZ 
M  
6 4 0 0 6 4 
(184) F 1 n/a 0 n/a 1 n/a 
(185) F 1 n/a 0 n/a 1 n/a 
(46) F 0 n/a 1 n/a 1 n/a 
Total  48 23 22 1 70 24 
%  68.6% 95.8% 31.4% 4.2% 74.5% 25.5% 
Discordance 
Total 
 75.5%   
Concordance 
total 
  24.5%  
 Table 1.2 shows data from 19 studies published between 1975 and 2013 that included twin sets, monozygotic or dizygotic 
in which either one or both the siblings had SLE.  Grey shaded boxes represent non-available or not applicable data.  The 
gender column shows the gender of the probands: F – females, M – Males, MZ – monozygotic, DZ – dizygotic.  If the gender 
status was not clear in the original studies, it was assumed that female twin sets were included.   
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Table 1.3: Summary of neonatal births with SLE from 2013 - 2016 
Study Neonate gender Neonate ethnicity Maternal history 
(186) 7 males & 8 Females 8 Caucasians, 4 individuals from 
African descent, 2 Asians, 1 unknown 
Connective tissue 
disorder in 1 mother 
(187) Female Caucasian  
(188) Male Asian Sjögren syndrome 
(189) Male Caucasian (?)  
(190) Female   
(191) Male Arab Active rheumatoid 
Arthritis 
(192) Female Asian  
(193) Male Caucasian Antibodies positive* 
(194) Female  SLE 
 Male Black None 
 Female  Juvenile idiopathic 
arthritis 
 Female  None 
(195) 5 Females & 7 males   
(196) 2 Males, brothers 
(diagnosed 2 years apart) 
 Antibodies positive* 
(197) Male Senegalese  
(198) Male   
(199) Female   
(200) 34 females out of 58  History systemic 
sclerosis, SLE or 
both in some 
(31) 6 Females 1 male (with 
inherited complement 
deficiency) 
Arabs  
(201) Female Asian American  
(202) Male Caucasian  
 Female South American  
 Female Caucasian  
 Male Caucasian Sjögren syndrome 
(203) Male  Sjögren syndrome 
Antibodies positive* indicates that the mother was recorded with positive levels of anti RO/SM antibodies.  This table shows 
data extracted from 19 recent studies reporting on cases of neonatal lupus.  Studies included the proband’s gender, their 
ethnicity and their mother’s medical history at the time the neonate was diagnosed.  Shaded boxed indicate cases where 
no data was available.  
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Table 1.4: Counting expected SLE cases in a Caucasian population of one million persons (M:F =1) 
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1.15.2 Figures  
 
Figure 1.1: Duration of SLE per decade estimated from age based prevalence to incidence ratio in years.   
Estimates derived from the data of Rees (25, 28). 
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Figure 1.2: Estimated duration of SLE in a mixed UK population per calendar year.   
Estimated from the data of Rees (25).  Disease duration(years) = prevalence/incidence per year. 
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Chapter 2. Material and methods 
2.1 Human ethics approval 
Curtin University, Sir Charles Gairdner Hospital and Royal Perth Hospital Human 
Ethics Committees approved the human studies (approval numbers HR 202/2013, 
HREC 2013-174).  Written informed consent was obtained from all study participants.  
Individuals under 18 were excluded from participation. 
2.2  Patient cohort 
Fifty-six (56) treated systemic lupus erythematosus patients aged 47 ± 15 years (91% 
females) were recruited from Sir Charles Gairdner (SCGH) and Royal Perth Hospitals 
(RPH - Perth, Western Australia) between March 2014 and December 2015.  
Diagnoses were based on the American College of Rheumatology (ACR) classification 
criteria.  Aside from two patients with active disease, this population of SLE patients 
was well-managed, with no evidence of disease activity based on laboratory 
parameters and/or clinical examination. 
In addition to the SLE diagnosis, patients had co-morbidities including renal disease, 
liver pathologies as well as Sjögren and Raynaud’s syndromes.  SLE patients in this 
cohort were treated with various therapeutic regimens including steroids (low dose 
prednisolone (≤5mg/day)), steroid-sparing immunosuppressant therapies 
(azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate 
mofetil) and antimalarial therapy (hydroxychloroquine), summarised in Table 2.1.  
2.3 Healthy controls cohort 
Thirty-three age and sex-matched healthy control subjects (47 +/- 15 years – 80% 
females) were recruited from the Perth metropolitan area.   
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2.4 Sample collection and preparation 
Peripheral blood samples from SLE patients were collected at one time point during 
the clinical management of this cohort of pre-diagnosed SLE patients.  Blood was 
collected into ethylenediaminetetraacetic acid (EDTA), heparin and serum collection 
tubes at PathWest collection centres.  Serum samples were separated by 
centrifugation at PathWest laboratories within one hour of collection and frozen to 
between -70°C and -86°C.  Samples from healthy human controls were collected into 
EDTA, heparin and serum vacutainer tubes (Beckton Dickinson (BD), San Jose, USA) 
and processed in the same manner at Curtin University laboratory (Perth, WA). 
Peripheral blood mononuclear cells (PBMCs) were isolated by diluting the remaining 
fraction one in two in phosphate buffered saline (PBS; Sigma-Aldrich, Sydney, 
Australia), followed by density gradient centrifugation on Ficoll-PaqueTM Plus (GE 
Healthcare, Little Chalfont, United Kingdom).  PBMCs were washed three times in PBS 
and re-suspended in RPMI 1640 (Invitrogen, California, USA) supplemented with 10% 
fetal bovine serum (FBS; Thermo Fisher Scientific, Scoresby, Australia), PenStrep (at 
final concentrations of 100 units/ml penicillin and 100 μg/ml streptomycin; GE 
Healthcare), 2 mM L-glutamax (Invitrogen) and 0.05 mM 2-mercaptoethanol (Sigma-
Aldrich). 
2.5 Flow Cytometry 
2.5.1 Cell subsets identification 
PBMCs were stained with fluorescently-labelled mouse antibodies directed against 
human molecules listed in Table 2.2. 
2.5.1.1 Identification of dendritic cell subsets 
Identification of dendritic cell (DCs) subsets first involved use of an exclusion cocktail 
consisting of antibodies directed against lineage markers CD3 (T cells), CD14 
(monocytes), CD19 (B cells), CD16 (Fc receptor+ cells), CD20 (B cells) and CD56 
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(natural killer cells).  Visual graphic representation of the gating strategy for dendritic 
cell subsets is shown in Figure 2.2.   
Dendritic cell subsets sitting located in the human lineage cocktail negative gate were 
identified as: 
o Myeloid dendritic cells type 1: mDC1s (CD1c+CD123-CD303-) 
o Myeloid dendritic cells type 2: mDC2s (CD141+CD123-CD303-) 
o Plasmacytoid dendritic cells: pDCs (CD1c-CD141-CD123+CD303+)   
2.5.1.2 Identification of T cell subsets 
Visual graphic representation of the gating strategies for helper T cell subsets and 
regulatory T cells is shown in Figure 2.3 and Figure 2.4.  T cell subsets were identified 
as: 
o Gamma delta T cells (TCRαβ- TCRγδ+)  
o Regulatory T cells: Tregs (CD3+CD4+CD25+CD127low/neg) 
o T Helper cells 17: Th17 cells (CD3+CD4+CD161+CD196+) 
2.5.1.3 Gating strategies 
For all staining panels, a combination of isotype controls and single stains were used 
for compensation and determination of gates.  Viable cells were identified using 
Zombie Green™ Fixable Viability Kit (Biolegend, USA).  Analysis was performed on a 
FACSCanto II using FACSDiva software (BD) or FlowJo software (TreeStar, Oregon, 
USA).   
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2.5.2  Staining Procedure 
2.5.2.1 Dendritic cells 
PBMCs were incubated with antibodies for 30 minutes at 4°C in the dark, washed 
using PBS and re-suspended in 200 µl of fluorescence activated cell sorting (FACS) 
buffer (1x PBS/1% FBS/1% bovine serum albumin).   
2.5.2.2 T cells 
For intracellular cytokine staining (Treg, ϒδ T cells and Th17 cells) PBMCs were 
incubated with 10 μg/ml brefeldin A  (Sigma-Aldrich) for four hours in the dark at 
37°C in a 5% CO2 atmosphere to prevent protein movement from the endoplasmic 
reticulum to the golgi apparatus and inhibit cytokine secretion; centrifuged, washed 
in FACS buffer containing 2.5 μg/ml brefeldin A and then incubated with antibodies 
directed against cell surface molecules for 30 minutes at 4°C in the dark, before being 
washed twice in FACS buffer containing 2.5 μg/ml brefeldin A, and fixed with 2% 
paraformaldehyde (Sigma-Aldrich)/PBS for 15 minutes at 4°C in the dark.  After 
fixation cells were washed twice in FACS buffer and incubated in FACS buffer 
containing 0.1% saponin (Sigma-Aldrich) for 15 minutes at 4°C in the dark to allow 
target antibodies to penetrate cells, after which the cells were stained with anti-IL-
17 antibody diluted in FACS buffer containing 0.1% saponin, then washed twice in 
FACS buffer and re-suspended in 200 μl FACS buffer.   
2.5.3 Cytokine measurement 
Interleukin 1 beta (IL1β), interferon alpha (IFNα), interferon gamma (IFNg), tumour 
necrosis factor alpha (TNF-α), monocyte chemoattractant protein 1 (MCP-1/ CCL2), 
interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-
12p70), interleukin 17A (IL-17), interleukin 18 (IL-18), interleukin 23 (IL-23) and 
interleukin 33 (IL-33) concentrations in serum were measured using a human 
LEGENDplex™ cytometric bead array (CBA; Biolegend) according to the 
manufacturer’s instructions.  Briefly, samples and cytokine standards were incubated 
with cytokine capture beads in a 96-well plate for two hours, followed by incubation 
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with phycoerythrin (PE)-conjugated detection antibodies for 30 minutes, both at 
room temperature, in the dark and on a plate shaker at approximately 600 rpm.  
Incubation was followed by washing with 200 µl of 1x wash buffer per well and 
centrifugation at 1000 x g for five minutes.  Samples/standards were re-suspended 
in 200 µl of wash buffer and analysis performed on a FACS Canto II using FACS Diva 
software (BD). 
2.6 Serology 
2.6.1 Complement C1q, C3, C4 concentrations, C-reactive protein, 
double stranded DNA antibodies assays 
Patients data for dsDNA ab, C-reactive protein (CRP), C4 and C3 were collected from 
the patients’ files and corresponded to the time-point at which they were recruited 
and/or blood samples obtained for the study.  All the above parameters were assayed 
in the PathWest Diagnostic Laboratories at Royal Perth Hospital and Sir Charles 
Gairdner Hospital.  Samples tested for antibodies to double stranded DNA: (dsDNA 
ab) were assayed using a radioimmunoassay dsDNA ab kit (Trinity Biotech; NY, USA) 
as per the manufacturer’s directions.  C-reactive protein (CRP) concentrations in 
serum or plasma samples were assessed using the turbidometric anti-CRP antibody 
coated latex particle assay in an Abbott Architect C16000 instrument (Abbott 
Laboratories, Abbott Park, Illinois USA).  Complement protein C3 and C4 
concentrations in serum or plasma samples were also measured by turbidometry 
assay using the Abbott Architect C16000 instrument.  Complement C1q levels were 
assayed using a nephelometry method on a Siemens BN2 nephelometer.   
2.6.2 aC1q ab concentrations 
A solid-phase ELISA kit (Bulhmann Laboratories, Schönenbuch Switzerland) was used 
to quantify IgG aC1q ab specific for the neo-antigen generated on solid phase C1q.  
Stored patient sera were diluted in high salt buffer (0.5M NaCl) and incubated in 
microtiter wells coated with human C1q.  Horseradish peroxidase (HRP)- labelled 
anti-human IgG was then added, followed by tetramethylbenzidine (TMB) substrate.  
  40 
A washing step was included between each incubation.  The substrate reaction was 
terminated through the addition 0.25M sulphuric acid and the absorbance measured 
at 450 nm using a microtiter plate reader (Bio-Rad, California, USA).  Test sample 
concentrations were interpolated using a four-parameter logistic calibration curve 
fitted to the standards provided by the manufacturer (5, 25, 100 and 400 U/mL based 
on an international reference standard).  The manufacturer’s suggested value for 
positivity was 15 units/ml. 
2.6.3 DNASE I enzyme concentrations 
A sandwich ELISA kit (Creative Diagnostics, USA) was used to assay human DNASE I 
serum concentrations per manufacturer’s instructions.  Briefly, stored patient sera 
were incubated in microtiter wells coated with a DNASE I specific antibody.  DNASE I 
present in the samples was immobilized and unbound products removed.  Biotin 
labelled DNASE I specific antibody bound to immobilized DNASE I was detected with 
avidin conjugated Horseradish Peroxidase (HRP).  Test sample concentrations were 
interpolated using a four-parameter logistic calibration curve fitted to the standard 
sera provided by the manufacturer (100, 50, 25, 12.5, 6.25, 3.12, 1.56 and 0ng/mL).   
2.6.4 Serum C4 concentrations normal ranges 
We previously defined normal serum C4 mean concentrations and ranges for two, 
three, four and five total C4 gene copy numbers (GCN) respectively (86).   
These ranges were as follow: 
o  Two GCN: mean 0.197; 95% confidence intervals 0.059 – 0.343 
o  Three GCN: mean 0.256; 95% confidence intervals 0.117 – 0.383 
o Four GCN: mean 0.296; 95% confidence intervals 0.159 – 0.439 
o Five GCN: mean 0.425; 95% confidence intervals 0.279 – 0.571 
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2.7 Molecular assays 
2.7.1 Determination of complement C4, C4A and C4B gene copy 
number, HERV-K retroviral element in intron 9 and CT 
insertion in exon 29 of the C4 genes 
2.7.1.1 Complement C4 genes and HERV-K retroviral element in intron 
nine of the C4 genes 
The complement C4 gene copy number was assessed using TaqmanÔ real-time PCR 
methodology which was previously described (86).  The presence of the HERV-K 
retroviral element in intron nine of the C4 genes was assessed by real-time PCR on a 
VIIA 7 thermocycler (ThermoFisher Scientific) using TaqmanÔ (Life Technologies, 
California; USA) custom copy number assay designed from published primers (204) 
(see Table 2.3) and performed according to the manufacturer’s instructions in 96-
wells plates, with total volume 20µl per reaction containing: 
o 4µl of test DNA  
o 10µl of 2X TaqMan Genotyping Master Mix  
o 1µl of 20X TaqMan C4 - long (C4L) or TaqMan C4 - short (C4S) custom GCN assay  
o 1µl of 20x TaqMan copy number reference assay (RNase P component H1)  
o 4µl of nuclease free water  
PCR assays were performed with cycle parameters set at 95°C for 10 minutes and 40 
cycles consisting of 95°C for 15 seconds followed by 60°C for 60 seconds.  In each 
plate, controls were added which consisted of Major Histocompatibility Complex 
(MHC) samples (cell lines WT100BIS, MOU, SAVC, JESTHOM, HOM-2, CBG-IB CB6B 
kindly donated by the Immunology department at Fiona Stanley Hospital; Perth, 
Western Australia). 
The CT insertion in exon 29 was detected by sequencing after PCR amplification in 
PCR microfuge tubes with total volume 50µl per reaction as follow: 
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o  4µl of test DNA 
o 10µl of 5x My Taq reaction buffer (Bioline, USA) 
o 1µl each of the forward and reverse primers 20µM 
o 0.5µl of My Taq HS DNA polymerase (Bioline, USA) 
o 33.5µl of nuclease free water    
PCR assays were performed with cycle parameters set at 95°C for 1 minutes (1 cycle) 
and 35 cycles consisting of 95°C for 15 seconds followed by 53°C for 15 seconds with 
a product size of 770bp.  The primers sequences are available in Table 2.3.  The PCR 
products were then sent for sequencing (MACROGEN, Seoul; Korea) and the 
sequences were assessed for the presence of the CT insertion. 
2.7.2 Identification of phenotypes and genotypes at the DNASE I 
and intron 4 VNTR (HumDN1) loci.   
Stored DNA samples were used in a PCR reaction using MyFi™ DNA polymerase 
(Bioline, USA) to amplify exons (or part of) two, five, six, seven and eight using primers 
sets described in Table 2.4. 
The PCR amplifications were performed in total volume of 25µl per reaction in PCR 
microfuge tubes containing: 
o 1µl of test DNA 
o 5µl of 5x MyFi reaction buffer (Bioline, USA) 
o 0.5µl of each forward and reverse primers 10µM 
o 1µl of MyFi DNA polymerase (Bioline, USA) 
o 17µl of nuclease free water  
PCR assays were performed with cycle parameters set at 95°C for 1 minutes (1 cycle) 
and 35 cycles consisting of 95°C for 15 seconds followed by 61°C for 15 seconds 
(DNASE I) or 57°C for 15 seconds (VNTR – HumDN1). 
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PCR products were then then sequenced (MACROGEN) to identify exonic alleles of 
Human DNASE I as indicated in Table 6.1.  The number of VNTR (HumDN1) repeats 
within intron four of the Human DNASE I gene was determined using a PCR reaction 
with MyFi™ DNA polymerase (Bioline, USA) to amplify intron four spanned by exons 
four and five using the primers pair shown in Table 2.4.  The lengths of the amplicons 
were then estimated via electrophoresis on a 4% agarose gel using a 1kb DNA ladder 
(see Figure 2.1).  As a control measure, five samples were sent for sequencing (details 
as above) and the results compared with the gels.  Alleles manifested three, four, five 
and six repeats with corresponding molecular weights of 525, 581, 637 and 693bp 
respectively (205). 
2.8 Data analysis 
Statistical significance was calculated using Mann–Whitney ranking U-test with the 
program GraphPad PRISM 7 (GraphPad Software Inc, California, USA).  P values of < 
0.05 were considered statistically significant. 
2.8.1 Cellular assays 
Cell subsets and their expressed cytokines’ raw data were transformed using log10 (x 
+ 1) before calculating statistical significance using Mann–Whitney ranking U-test on 
the program GraphPad PRISM 7 (GraphPad Software Inc, California, USA).  P values 
of < 0.05 were considered statistically significant, but only values <0.001 were 
interpreted as experimentally significant after allowing for Bonferroni correction  
2.8.2 Molecular assays 
Gene copy number variations were analysed using CopyCaller® version 2 (Life 
Technologies, California; USA) and GraphPad PRISM 7 software (GraphPad Software 
Inc, California, USA).  Nucleotide and peptide sequences were analysed using 
Geneious software version 10 (206).  Linkage disequilibrium and population 
parameters were determined using “Genepop on the web” (207, 208), LinkDos (209) 
and SNPStats (210).  Statistical significance was calculated using Mann–Whitney rank 
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sum U-test with the GraphPad PRISM 7 application (GraphPad Software Inc, 
California, USA).  P values of < 0.05 were considered statistically significant.   
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2.9 Reference tables 
Table 2.1: SLE patients co-morbidities and treatment regimen data. 
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Table 2.2: List of antibodies used to detect surface and intracellular markers via flow cytometry  
Cell markers (all mouse anti-
human antibodies) 
Clone Fluorochrome 
Lineage 
Negative 
CD3 (T cells) UCHT1 
Fluorescein isothiocyanate (211) (211) 
CD14 (monocytes) HCD14 
CD19 (B cells) 3G8 
CD16 (Fc 
receptor+ cells) HIB19 
CD20 (B cells) 2H7 
CD56 (natural 
killer cells) HCD56 
CD1c (BDCA) L161 Alexa Fluor® 647 (AF647) 
CD141 (BDCA3/thrombomodulin) M80 Brilliant Violet 421™ (BV421) 
CD123 (BDCA2) 6H6 PerCP-Cyanine5.5 (PerCP-Cy5.5) 
CD303 (BDCA3) 201A PerCP-Cy5.5 
α/β TCR IP26 FITC 
γ/δ TCR B1 Brilliant Violet 510™ 
CD3 SK7 Streptavidin-Allophycocyanine H7 (APC-H7) 
CD4 OKT4 Phycoerythrin Cyanine 7, (PE/Cy7) 
CD25 M-A251 Brilliant Violet 510™ (BV510) 
CD127 (IL-7Rα) A019D5 Alexa Fluor® 488 (AD488) 
CD161 (killer cell lectin-like 
receptor subfamily B member 1 or 
KLRB1, also known as NK1.1) 
HP-3G10 BV510 
CD196 (chemokine receptor 6 or 
CCR6) G034E3 AF488 
IL-17A BL168 BV421 
Latency-associated peptide (LAP; 
TGFβ) TW4-2F8 PerCP-Cy5.5 
All antibodies were purchased from Biolegend (San Diego, California; US) apart from CD3 which was purchased from BD 
Biosciences (212). 
 
Table 2.3: Primers used to identify the presence/absence of the HERV-K retroviral element in intron 9 and the CT insertion 
in exon 29 of C4 genes. 
Name Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
C4 long (with HERV-K 
insertion) 
TTGCTCGTTCTGCTCATTCCTT 
(C4L: C4Fin95) 
GTTGAGGCTGGTCCCCAACA 
(C4L-3LTR-R) 
C4 short (without 
HERV-K insertion) 
TTGCTCGTTCTGCTCATTCCTT  
(C4S: C4Fin95) 
GGCGCAGGCTGCTGTATT 
(C4Sin9R-2) 
Probe C4in95 
FAM/MGB  
CTC CTC CAG TGG ACA TG  
TC insertion TTG CCC ACA ACA ACCT CA TG CCT ACT TGG GTA CTG CGG 
AA 
Primers from GeneWorks. 
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Table 2.4: Primers used to identify common alleles of the DNASE I gene and the 56bp VNTR (HumDN1) repeat. 
Genic Location Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
Exon 2 TAT GTC TCT GTG CCC TGT GC 
CAG AGC TCC TCT GCT TTT 
GG 
Exons 5 & 6 CTG GGG TCA CCT CCT CCT AGC GCT GAT CTC GGC TAC T 
Exons 7 & 8 CCT GGT AGG ACG TCA TGT TG 
TGT GCA AGG GAG GAC ACA 
TA 
VNTR (HUMDN1) Ref: 
(205) GGA CCT TTT GTT TCT TCA A ACC GCA GAC ACC TGG TCA 
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2.10 Figures 
 
Figure 2.1: Agarose electrophoresis gels representative of VNTR sizes. 
The figure shows a representative example of a 4% agarose electrophoresis gel used to assess the size of the VNTR (humDN1) 
repeats. 
 
 
Figure 2.2: Dendritic cells gating strategy. 
Figure 2.2 shows the gating strategy to identify dendritic cell subsets as described above.   
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Figure 2.3: Gamma Delta T cells gating strategy. 
The figure shows the gating strategy to identify gamma-delta T cells as described in the text. 
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Figure 2.4: T regs & Th17 cell gating strategy.  
The figure shows the gating strategy to identify regulatory T cells and Th17 cells as described in the text. 
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Chapter 3. Elevated circulating myeloid dendritic-2 
cells and gamma delta T cell-derived 
interleukin-17 contribute to inflammation 
in systemic lupus erythematosus  
 
3.1 Abstract 
Objectives: Cellular profiles and inflammatory cytokines were assayed in fresh blood 
samples from 56 SLE patients and 33 age/sex-matched controls. 
Methods: Myeloid dendritic cell (mDCs) 1 and 2, plasmacytoid DCs (pDCs), regulatory 
T cells (Tregs), gamma delta T cells (ϒδ T cells) and T helper 17 (Th17) cell frequencies 
were assayed by flow cytometry, together with the synthesis of intracellular 
interleukin 17 (IL17) and transforming growth factor beta (TGFb).  Additionally, a 
panel of 13 inflammatory cytokines were assayed by cytokine bead array in serum 
samples.  
Results: mDC1 and mDC2 proportions were decreased in SLE patients (0.1096 & 
0.1774 respectively) relative to healthy controls (0.2471 & 0.2320 respectively - p < 
0.0001 and p = 0.0121 respectively).  The proportions of Tregs and Th17 cell 
populations were similar in both groups.  In contrast, the proportion of ϒδ T cells was 
increased in SLE patients relative to controls, although the difference did not reach 
statistical significance.  Serum concentrations of 12 of the 13 inflammatory cytokines 
appeared elevated in SLE patients, with six cytokines attaining a p value ≤ 0.05 (IFNγ 
TNFα, MCP-1, IL-6, IL-8 and IL-18; p = 0.0193, 0.0317, 0.0002, 0.0190, 0.0350 and < 
0.0001 respectively). Intracellular synthesis of IL-17 occurred predominantly in ϒδ T 
cells, and concentrations were significantly higher in patients compared to healthy 
controls (p = 0.0010).  A correlation matrix revealed associations between gd 
intracellular IL17 synthesis and gd T cell subsets (p < 0.0001) and between mDC2 and 
gd T cell subsets (p = 0.0408) in SLE. 
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In summary, despite literature demonstrating an increased frequency of Th17 cells 
and elevated intracellular IL17 in other SLE cohorts, this was not observed in this SLE 
cohort.  The relative increase in gd T cells and mDC2 cells proportions is a novel 
observation and represents a potential contributor to inflammation in SLE that 
requires further investigation. 
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3.2 Introduction 
Systemic lupus erythematosus (SLE), a polygenic, multifactorial autoimmune disease, 
is characterised by self-antigen/ autoantibody production, immune complexes and 
chronic inflammation leading to multiple organ and tissue damage (213).  Recent 
studies have shown that impaired apoptosis leads to generation of immune 
complexes and aberrant inflammation (213).  
Dendritic cells (DCs) can be classified as myeloid (mDCs) and plasmacytoid (pDCs) and 
are involved in the preservation of tolerance in the healthy steady state (214).  
Apoptotic micro-molecules present in SLE patients have been shown to activate 
mDCs and pDCs, promoting a pro-inflammatory response (17), and apoptotic 
materials ingested by DCs from healthy mice stimulate CD4+ T helper 1 (Th1) and T 
helper 17 (Th17) cell polarisation (215).  The mDC1 subset synthesises a variety of 
inflammatory chemokines and cytokines and are the most abundant DC 
subpopulation, whilst mDC2 cells are the rarest in peripheral blood from healthy 
humans (216, 217) that can cross-present antigens to cytotoxic CD8 T cells, synthesise 
interleukin (IL) 12 (218) and IFNg (219).  These cells also synthesise high amounts of 
IL-12p70 upon activation by toll-like receptors (TLRs) and CD40 molecules (220).  
Active SLE patients have significantly lower numbers of peripheral blood DCs yet they 
retain adequate and similar functionality (221).  DCs cross talk with other cell types 
such as gamma delta T cells (γδ T cells) to amplify immune responses (222). 
Moreover, bacterial lipopolysaccharide can activate DCs and γδ T cells, and γδ T cells 
reciprocate by enhancing maturation of activated DCs (223). 
Few studies have investigated the role of γδ T cells in the pathogenesis of lupus, and 
those that have are contradictory.  Peripheral blood γδ T cell frequencies have been 
reported to be increased (224), decreased (225-228) or unchanged (229) in SLE 
patients.  Likewise, regulatory T cells (Tregs), a suppressive subset that expresses 
CD4, the transcription factor forkhead box P3 (Foxp3) and the interleukin 2 receptor 
(IL-2R/ CD25) (230) also demonstrate decreased (230-236), increased (237), or 
unchanged (238-241) frequencies in SLE patients, while positively (242-246) or 
inversely correlating (232) with disease activity.  Th17 cells produce IL-17A, IL-17F, IL-
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22 and IL-21 (247-250) and are a potent source of inflammation by mechanisms that 
include enhancement of neutrophil and macrophage activation and function (249, 
250).  A combination of transforming growth factor beta (TGFβ), IL-6 (251) or/and IL-
21 polarises helper T cells into Th17 cells (252).  Studies have reported increased Th17 
cell frequencies (253-256) and correlation with disease activity or pathological 
severity (253-260) as well as increased IL-17 serum concentrations (256-259, 261) in 
SLE patients and mice models of SLE (258, 262).  These reports indicate the equivocal 
nature of the current body of work on T cells and SLE. 
In this study a comprehensive phenotypic analysis of myeloid dendritic cells and 
pDCS, γδ T cells, Tregs and Th17 cells was performed in a cohort of West Australian 
lupus patients and controls.  We show that IL17 and Th17 cells are not driving 
inflammation, in contrast, mDC2s and γδ T cells are involved in the inflammatory 
response in these patients. 
3.3 Results 
3.3.1 The proportions of myeloid dendritic cells 1 & 2 are 
increased in healthy controls compared to SLE patients 
Percentages of peripheral blood mononuclear cells (PBMCs) positive for mDC1, mDC2 
and pDC, and percentages of lymphocytes positive for gamma delta (γδ), Tregs and 
Th17 are shown in Table 3.1.   
Phenotyping of cells subsets was performed using specific cell surface markers with 
multi-coloured fluorochrome panels (see methodology p36) that enabled clear 
discrimination between cell subsets.  The proportions of dendritic cells showed an 
overall decrease in SLE cohort, especially for the mDC1 and mDC2 subtypes (p < 
0.0001 and p = 0.0121 respectively) whereas the proportions of pDCs remained 
similar (NS) (see Figure 3.1).  It was noted that the proportion of mDCs in the SLE 
patients group was reversed, with a small increase in mDC2 cells compared to mDC1 
(p<0.0287) (see Table 3.1).  Regulatory T cells proportions were similar in both groups 
and we observed a small increase in the proportion of Th17 cells in healthy controls 
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(p = 0.0270).  In contrast, the γδ T cells subpopulation showed an increased 
proportion in the SLE group (p = 0.0767) (see Figure 3.2). 
3.3.2 Intracellular IL17 synthesis by γδ T cells is increased in SLE 
patients 
Intracellular IL-17 synthesis by Tregs, γδT cells and Th17 cells was investigated. We 
found that the relative amount of intracellular IL-17 was significantly higher in γδ T 
cells from SLE patients compared to healthy controls (p = 0.0010).  There was no 
meaningful difference in the relative amount of intracellular IL17 synthesised by 
Tregs and Th17 between the groups (see Table 3.2 & Figure 3.3). 
The relative amount of intracellular TGFβ was higher in Tregs from SLE patients 
compared to healthy controls (p = 0.0019), but no significant differences between the 
cohorts in the relative amounts of TGFβ synthesised by γδ T and Th17 cells were seen 
(see Table 3.2 & Figure 3.4). 
3.3.3 Elevated serum pro-inflammatory cytokines in SLE patients 
The concentrations of 13 key cytokines were investigated in patients’ and controls’ 
serum.  Concentrations (+/- 95% confidence intervals (CI)) are shown in Table 3.3.  
Interleukin 10 (IL-10) appeared elevated in controls, although this difference did not 
reach statistical significance between the groups (Table 3.3).  Briefly, most cytokines 
measured appeared to be elevated in patients compared to healthy controls with 
IFNγ TNFα, MCP-1, IL-6, IL-8 and IL-18 attaining significant differences for which the 
p value is less than 0.05 (p = 0.0193, 0.0317, 0.0002, 0.0190, 0.0350 and <0.0001 
respectively).   
3.3.4 Associations between IL17 and gd T cell 
Correlation coefficients were estimated for intracellular IL17 synthesis by T cells, DC 
subsets and several other serological analytes usually measured in SLE.  These are 
shown Table 3.4.  In SLE patients, a positive association was observed between the 
gd T cell and mDC2 cell subsets (p = 0.0408).  Intracellular IL17 concentrations by gd 
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T cell were significantly correlated with the gd T cell subset (p < 0.0001) and mDC2 
cells (p < 0.0001).  The correlation matrix also revealed no associations between 
IL17A inflammatory cytokine levels and/or intracellular IL17 cytokine levels and Th17 
cell subsets in SLE patients.  There was a slight correlation between the proportions 
of intracellular IL17 synthesised by Th17 cells and the concentration in serum of C1q; 
C3, and DNASE I (p = 0.0142; 0.0322; 0.0377, respectively), whereas in the control 
cohort the concentrations of the inflammatory cytokine IL17A was correlated with gd 
T cell (p = 0.0162) (see Table 3.4 & Table 3.5).  
3.4 Discussion 
The cytokine milieu is a key determinant of the type of immune response elicited, 
with pro-inflammatory cytokines contributing to the inflammation characteristic of 
SLE, whilst anti-inflammatory cytokines and chemokines (such as IL10 and TGFβ) 
mediate immune tolerance (of which there is a breakdown in SLE).  All cell types can 
produce TGFβ (263), including T cells (264), of which Tregs also synthesise IL10 (265-
267).  Konkel and colleagues (268) have shown that TGFβ signals are crucial for Tregs 
to regulate tissue-specific immune responses and suppress T helper cell subsets.  It 
was noted that our SLE patients had higher relative proportions than controls of TGFβ 
synthesis by Tregs and gd but not by Th17 T cells.  Moreover, SLE patients have 
significantly higher levels of several circulating pro-inflammatory cytokines including 
IFNγ, TNFα, MCP-1, IL-6, IL-8 and IL-18, implying chronic inflammation.  Tregs should 
exert a regulatory function to maintain tolerance and regulate inflammatory 
responses (268).  However, decreased proportions of peripheral blood Tregs and IL-
10 serum concentrations in the SLE patient group relative to healthy controls, 
together with the lack of TGFβ signals from other T cell subsets, implies that in the 
SLE cohort these functions might be impaired.  A number of studies have shown that 
the regulatory function of Tregs in SLE patients is diminished (269) and in the 
presence of IL-1b, (270), IL-23, TNFa, and IL-6 Tregs have been shown to synthesise 
IL-17 (271, 272) and possess the capability to become Th17 cells (273) that express 
Foxp3 and the Th17 RAR related orphan receptor C (RORc) transcription factors, 
hence acquiring an inflammatory phenotype (274). Since Th17 cells in our SLE cohort 
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are not elevated in comparison with the control cohort, and do not appear to 
synthesise IL17, the data suggest that Tregs could adopt an inflammatory phenotype; 
although it seems unlikely these cells would differentiate into mature Th17 cells 
despite the recognised plasticity between Tregs and Th17 cells (274).  Thus, another 
pathway may also be functional in this cohort of treated SLE patients, i.e. the 
Th1/Th17 network or one involving gd T cells.   
In healthy individuals, dendritic cells participate in the removal of apoptotic cells and 
maintenance of self-tolerance (reviewed by (275)).  However, Rosen et al (276) have 
shown that impaired apoptosis in SLE patients and the presence of apoptotic blebs 
from cell debris, can generate autoantigens that activate mDCs with consequential 
loss of tolerance (277).  Moreover, defective clearance of apoptotic debris drives 
autoantibody production and inflammatory responses (278), leading to further DC 
maturation.  Autoantibodies bound to apoptotic cells augment secretion of pro-
inflammatory cytokines such as IL-1b and TNF-a (279).  In agreement with other 
studies (280), we show that the frequency of peripheral blood mDCs is significantly 
lower in SLE patients than healthy individuals.  The proportion of mDC2 cells was 
elevated compared to mDC1 cells in SLE patients.  This reflects a reversal of the mDC1 
to mDC2 ratio seen in healthy humans in which mDC1s are the major myeloid DC 
subset in blood (217).  Poulin and others demonstrated a superior uptake capability 
by mDC2 to present antigens to CD8+ T cells (218); upon ingestion of apoptotic blebs, 
mDCs mature (215) and mDC2 cross-present antigens from effete and necrotic cells, 
(218, 281, 282).  Accordingly, in this study a rapid sequestration of DCs out of the 
circulation and into tissues, and skewing towards mDC2-mediated uptake of dead 
and dying cells in tissues promoting Th1 responses could be implied, rather than the 
mDC1 specialised CD4+ T cell activation toward Th17 cells (283).  A number of studies 
have also shown reciprocal regulation of gd T cells and DCs (284-286), and in SLE 
patients, we observed a positive correlation between the two subsets.  DCs foster IL-
17, IL-21 and IL-22 production by gd T cells (284, 286) and IL-1β and IL-23 influence 
gd T cell activation independent of the T cell receptor (287); both of these cytokines 
were elevated in SLE compared to healthy controls.  The relative frequency of gd T 
cells was increased in SLE patients relative to controls, and was associated with gd T 
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cell intracellular IL17 concentrations.  Moreover, we observed increased 
concentrations of IFNγ and IL-17A in serum, as well as increased intracellular TGFb 
and IL-17 synthesis by γδ T cells.  Interestingly, gd T cells can function as antigen 
presenting cells and induce apoptosis in cells at sites of inflammation (285).   
These data suggest the existence of a mDC2/gd T cell axis that promotes aberrant 
inflammatory reactions and autoimmunity in SLE patients in vivo, mediated by a 
possible dual function of gd T cells in presenting antigens released from effete cells 
and mediating IL-17-driven inflammation.  A feature of this study was the use of fresh 
blood samples that had not been subjected to laboratory manipulations.  Treatment 
regimens in this cohort might influence T cell outcomes.  Steroids and 
immunosuppressive drugs increase levels of Foxp3+ T cells and serum IL-10 
concentrations (288) in SLE but not healthy cohorts (289), and in this environment, 
Th17 might be subdued, while the environment might be conducive to gd T cells.   
We conclude that Th17 and IL17 mediated inflammation does not appear to be the 
cause of SLE pathology in this SLE cohort.  It is a possibility that increased serum levels 
of pro-inflammatory cytokines and chemokines and increased proportion of IL-17+ 
and TGFb+ gd T cells might contribute to a persistent chronic inflammatory state in 
patients with treated SLE.  Certainly, the treatment regimens in this group of patients 
seems to suppress this pathway of inflammation whilst promoting a mDC2/gd T cell 
axis.  This axis has not been investigated extensively and further work is required to 
determine its relevance and role in the pathogenesis of SLE. 
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3.5 Tables and figures 
3.5.1 Tables 
Table 3.1: Cell subsets frequencies in SLE patients and controls 
  mDC1 mDC2 pDC γδ Tregs Th17 
SLE N 55 55 55 52 55 55 
Mean (%) & 
95% CI 
0.1096 
(0.0853–
0.1339) 
0.1774 
(0.1303–
0.2244) 
0.3650 
(0.3202–
0.4099) 
0.2850 
(0.1937–
0.3763) 
0.1863 
(0.1433–
0.2293) 
0.0344 
(0.0116–
0.0573) 
HC N 33 33 33 33 33 33 
Mean (%) & 
95% CI 
0.2471 
(0.1796-
0.3145) 
0.2320 
(0.1799-
0.2840) 
0.3422 
(0.2948-
0.3897) 
0.1406 
(0.0985-
0.1828) 
0.2332 
(0.1765-
0.2900) 
0.0629 
(0.0276-
0.0982) 
P 
value 
 < 0.0001 0.0121 0.4619 0.0767 0.1417 0.0227 
Results show percentages of positive cells for each subtype.  Dendritic cells are percentages of peripheral blood gated 
mononuclear cells positive whilst T cells are percentages of gated lymphocytes positive.  The table shows the number of 
values (N), mean concentrations and 95% confidence intervals (Mean; 95% CI).  mDC1 = myloied dendritic cells type 1; mDC2 
= myeloid dendritic cells type 2; pDC = plasmacytoid dendritic cells; γδ = gamma delta T cells; Tregs = regulatory T cells; Th17 
= T helper cells 17.  P-values from Mann Whitney rank test. 
 
Table 3.2: Interleukin 17 & TGFβ synthesis in SLE patients and controls 
    IL17 by 
Tregs 
IL17 by 
γδ 
IL17 by 
Th17 
TGFβ by 
Tregs 
TGFβ by 
γδ 
TGFβ by 
Th17 
SLE N 55 53 55 55 53 55 
Mean 
(%) & 
95% 
CI 
0.03375 
(0.0108–
0.0573) 
0.1368 
(0.0722–
0.2014) 
0.0100 
(0.0007–
0.0192) 
0.0621 
(0.0418 – 
0.0823) 
0.1603 
(0.0904 – 
0.2301) 
0.0158 
(0.0034 – 
0.0282) 
HC N 33 33 33 33 33 33 
Mean 
(%) & 
95% 
CI 
0.0174 
(0.0023-
0.0323) 
0.0310 
(0.0145-
0.0474) 
0.0078 
(-0.0004 – 
0.0158) 
0.0315 
(0.0010 – 
0.0531) 
0.0572 
(0.0359 – 
0.0786) 
0.0182 
(-0.0017 – 
0.0382) 
P 
value 
 0.3345 0.0010 0.7457 0.0019 0.1451 0.1386 
Results show percentages of IL17 positive cells.  The table shows the number of values (N), mean concentrations and 95% 
confidence intervals (Mean; 95% CI).  γδ = gamma delta T cells; Tregs = regulatory T cells; Th17 = T helper cells 17; TGFβ = 
transforming growth factor beta.  P-values from Mann Whitney rank test. 
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Table 3.3: Cytokine bead array concentrations of analytes in SLE patients and controls 
  Patients  Healthy Controls 
 n Mean concentrations & 95% CI n Mean concentrations & 95% CI 
IL-1β 56 305.6 (122.7 – 488.5) 33 183 (0 – 393.1) 
IFNα 56 697.6 (327.8 – 1067) 33 342.7 (28.9 – 656.6) 
IFNγ 56 2483 (1856 – 3110) 33 1477 (721.1 - 2233) 
TNFα 56 3114 (1101 – 5127) 33 1108 (0 - 2319) 
MCP-1 56 1808 (1463 – 2154) 33 854 (576.8 - 1131) 
IL-6 56 408.2 (138.4 – 678.1) 33 198.2 (0 – 415.2) 
IL-8 56 503.9 (118 – 889.8) 33 145.2 (1.158 – 289.3) 
IL-10 56 263.5 (79.69 – 447.3) 33 309.2 (0 – 769.3) 
IL-12p70 56 192.2 (48.63 – 335.8) 33 136.3 (0 – 302.6) 
IL-17A 56 597.7(119.5 – 1076) 33 160.6 (37.81 – 283.4) 
IL-18 56 1071 (801.1 – 1340) 33 378.5 (193.6 – 563.3) 
IL-23 56 1136 (20.26 – 2251) 33 196.1 (16.53 – 375.6) 
IL-33 56 7414 (2595 – 11432) 33 4494 (0 - 9222) 
Results show concentrations (pg/mL) for each analyte.  The table shows mean and 95% confidence intervals.  IL-1β: 
interleukin 1 beta, IFNα: interferon alpha, IFNγ: interferon gamma, TNFα: tumour necrosis factor alpha, MCP-1: monocyte 
chemoattractant 1 (CCL2), IL-6: interleukin 6, IL-8: interleukin 8, IL-10: interleukin 10, IL-12p70: interleukin 12p70, IL-17A: 
interleukin 17A, IL-18: interleukin 18, IL-23: interleukin 23, and IL-33: interleukin 33. 
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Table 3.4: Correlation matrix of cellular and serological parameters for SLE patients 
 γδ Th17 IL17 Tregs IL17 γδ IL17 Th17 
C1q 0.1342 0.4525 (p = 
0.0005) -0.0757 0.1894 0.3289 (p = 0.0142) 
C3 0.1134 0.0772 0.1233 0.3495 (p = 0.0103) 0.2893 (p = 0.0322) 
αC1q 0.0716 -0.1487 -0.2477 -0.0913 -0.3596 (p = 0.0070) 
DNASE 
I 
-0.0287 0.2186 -0.0953 0.0114 0.2869 (p = 0.0337) 
mDC2 0.2847 (p = 
0.0408) -0.1479 0.0901 
0.5313 (p < 
0.0001) -0.0776 
Tregs 0.2804 0.3072 0.4442 (p = 0.0007) 0.1320 0.1349 
γδ  0.4064 0.2420 0.5327 (p < 0.0001) 0.1412 
The Table shows the Pearson correlation coefficients, and when applicable and of interest, the p value. 
 
Table 3.5: Correlation matrix of cellular and serological parameters for healthy controls 
  mDC1 pDCs γδ 
IL17 γδ 0.3802 (p = 0.0290) 0.0417 0.1100 
MCP-1 -0.2350 0.4276 (p = 0.0131) -0.0473 
IL-8 -0.0575 0.4766 (p = 0.0050) -0.0432 
IL-17A -0.1790 -0.0113 0.4154 (p = 0.0162) 
IL-23 -0.0209 0.4638 (p = 0.0066) -0.0553 
The Table shows the Pearson correlation coefficients, and when applicable and of interest, the p value. 
 
  62 
3.5.2 Figures 
  
Figure 3.1: Dendritic cell profiles in SLE patients and healthy controls.   
Cell subtypes are based on specific cell markers as indicated on the graph.  The figure shows the cell population expressed 
as percentages of peripheral blood mononuclear cells (X-axis) for SLE patients (dark circles) and the control cohort (light 
circles).  Each graph shows the mean and standard deviation for each group; mDC1 p < 0.0001; mDC2 p = 0.0121; pDCs NS 
(p = 0.4617). (Mann Whitney rank test). Mean concentrations are shown in Table 3.1.   
 
  
Figure 3.2: T cell profiles in SLE patients and healthy controls.   
Cell subtypes are based on specific cell markers as indicated on the graph.  The figure shows cell concentrations expressed 
as percentages of lymphocytes (X-axis) for SLE patients (dark circles) and the control cohort (light circles).  Each graph shows 
the mean and standard deviation for each group; Tregs NS (p =0.1417); Gamma Delta NS (p =0.0767); Th17 p = 0.0270. 
(Mann Whitney rank test). Mean concentrations are shown in Table 3.1.   
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Figure 3.3: Interleukin 17 synthesis in SLE patients and healthy controls 
The figure shows cell populations expressed as percentages of IL17 positive cells (X-axis) for SLE patients (dark circles) and 
the control cohort (light circles).  Each graph shows the mean and standard deviation for each group; IL17 synthesised by 
Tregs NS (p =0.3345); IL17 synthesised by Gamma Delta p = 0.0010; IL17 by synthesised Th17 NS (p =0.0767) (Mann Whitney 
rank test). Mean concentrations are shown in Table 3.2.  γδ = gamma delta T cells; Tregs = regulatory T cells; Th17 = T helper 
cells 17. 
 
 
Figure 3.4: Transforming Growth Factor b (TGFb) synthesis in SLE patients and healthy controls 
The figure shows cell concentrations expressed as percentages of TGFb positive cells (X-axis) for SLE patients (dark circles) 
and the control cohort (light circles).  Each graph shows the mean and standard deviation for each group; TGFb synthesised 
by Tregs p =0.0019; TGFb synthesised by Gamma Delta NS (p = 0.1451); TGFb synthesised by Th17 NS (p =0.1386) (Mann 
Whitney rank test). Mean concentrations are shown in Table 3.2.  γδ = gamma delta T cells; Tregs = regulatory T cells; Th17 
= T helper cells 17. 
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Figure 3.5: Cytokine bead array assay 13-plex.   
The figure shows cytokine concentrations (pg/mL) (X-axis) for SLE patients (dark circles) and the control cohort (light circles).  
Each graph shows the mean and standard deviation for each group; interleukin 18 p = 0.0350; interferon gamma p = 0.0193; 
monocyte chemoattractant protein 1 p = 0.0002; interleukin 6 p = 0.0190; interleukin 8 p = 0.0350; tumour necrosis factor 
alpha p = 0.0317 (Mann Whitney rank test). Mean concentrations are shown in Table 3.3.   
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Chapter 4. Anti-C1q Antibodies Concentrations by 
ELISA in Systemic Lupus Erythematosus 
The content of this chapter has been published in Lupus: Open Access (2017).  
Permissions for this article can be found in appendix B.1.2 and published article in 
B.2.2.   
Margery-Muir A A. Wetherall J D. Groth D M. and Bundel C. Anti-C1q Antibodies Concentrations by Elisa in 
Systemic Lupus Erythematosus. Lupus: Open Access. 2017. 2(1): p. 124. 
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4.1 Abstract  
Systemic lupus erythematosus (SLE) is an inflammatory disorder in which 
autoantibodies contribute to impaired apoptosis and clearance of cell debris.  Anti 
dsDNA and anti C1q antibodies have been implicated, as well as complement protein 
C1q itself.  IgG autoantibodies reacting with the collagen-like region of C1q protein 
(henceforth aC1q ab) were quantitated in serum of 56 patients diagnosed with SLE 
and undergoing treatment for variable periods, together with 33 age/sex-matched 
controls.  Analysis of the results showed optimal sensitivity and specificity of 57% and 
91% respectively at a cut-off concentration for positivity of 20 U/ml.  The assay is a 
potentially useful confirmatory test for SLE, but is not suitable as a screening test for 
SLE with the probability of a positive test and SLE in an individual within a random 
population of only ≤1%.  aC1q ab concentrations were detectable in all samples 
tested with concentrations manifesting no correlation with age and serum C1q levels 
in SLE patients and a negative correlation with age in controls.  The aC1q ab detected 
by this assay do not react therefore with native C1q.  In SLE patients, aC1q ab 
concentrations correlated with the concentrations of dsDNA antibodies, (p = 0.0001) 
and C-reactive protein and inversely with complement component C4 ([C4]) 
concentrations (p = 0.041).  aC1q ab concentrations were not associated with 
individual therapeutic regimens, but were higher in those patients receiving a 
combination of three drug therapies and with the presence of renal disease.  The 
diagnostic relevance of this complex autoantibody will require further definition of 
its antigenic specificities.   
4.2 Introduction 
There is good evidence that impaired apoptosis and clearance of cell debris induces 
autoimmune responses associated with aberrant inflammation (290).  Systemic lupus 
erythematosus (SLE) is an important systemic autoimmune disease characterised by 
the presence of autoantibodies that bind double stranded DNA (henceforth dsDNA 
ab) and often decreased levels of serum complement components C3 and C4 (16).  
Complement component C1q is one of three proteins comprising the first component 
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(C1) of the classical pathway of complement activation.  C1q molecules can activate 
the complement system by recognizing different structures on microorganisms and 
apoptotic bodies, or indirectly by means of binding to immunoglobulins and classical 
acute phase proteins such as C-reactive protein, (CRP) resulting in clearance of 
immune complexes and apoptotic material (16, 291).  The avidity of binding of C1q 
to the Fc domain of IgG antibodies is augmented by the presence of hexameric 
IgG/antigen complexes on cell surfaces or polyvalent antigens (292).  A consequence 
of high affinity binding of C1q to Fc regions is the formation of a neo-antigen on the 
collagen-like tails of the C1q molecule subunits (293).  Production of auto-antibodies 
reacting with this neo-antigen has been observed following C1q binding with immune 
complexes or nonspecific binding to chromatin (294).  The role of these 
autoantibodies in the pathogenesis of specific disease, for example SLE, is yet to be 
clearly defined (16).  Uwatoko and colleagues (295) devised an assay capable of 
quantifying anti-C1q antibodies (aC1q ab) by their interaction with C1q bound to a 
plastic surface in the presence of a high salt concentration (1M NaCl) to preclude any 
interaction with soluble C1q present in the test sample, usually serum.   
In the last decade, the relationship between aC1q ab and clinical profiles in SLE 
patients, as well as relationships with other laboratory parameters has been 
investigated.  It has been reported by several groups (294, 296-298) that the levels of 
aC1q ab titers are usually significantly higher in SLE patients than healthy controls or 
non-SLE autoimmune patients.  The concentrations of aC1q ab correlate with disease 
activity and/or severity (294, 296-307) as well as with other laboratory parameters 
including complement protein C3 and/or C4 concentrations, dsDNA ab, proteinuria 
and the presence of immune complexes (294, 296, 299, 300, 302-307).  Whether 
serum concentration of aC1q ab is a useful tool to predict up-coming flares in 
patients with nephritis remains to be confirmed.  A strong association between aC1q 
ab and active renal disease has been demonstrated (306).  Only nine studies have 
longitudinal data permitting this specific assessment (including (298, 302)), although 
other reports have supported its potential for this use (298, 300, 305).  The present 
study measured the levels of aC1q ab in a cohort of diagnosed and treated Western 
Australian SLE patients using a commercial ELISA kit. 
  68 
4.3 Results 
4.3.1 Quantitation of anti-C1q antibody in treated SLE patients 
and controls 
Multiple assays (including repeated samples) were performed in accordance with the 
manufacturers specifications using a range of international calibrator concentration 
standards (5, 25, 100 and 400 U/ml) provided with the kit.  Two quality control 
samples provided by the manufacturer were included in each assay.  These 
comprised a negative control with expected values between 4.0-7.9 U/mL and a 
positive control sample between 118-233 U/mL.  The positive control was always 
within the expected concentration range.  The negative control sample was 
marginally higher in our analysis (average of 9.9U/mL) than that stipulated by 
Buhlmann Ltd, but still lower than the 20 U/mL cut-off point for positivity used in this 
analysis (see Figure 4.1).   
The non-Gaussian distributions of the concentration of the aC1q ab in patients and 
controls are show in Figure 4.2.  The optimal specificity and sensitivity of the assay 
for inclusion or exclusion of SLE were estimated from the proportions of true positive 
and true negative results as a function of variable “cut-off” concentrations of aC1q 
ab.  From these data, a receiver-operator characteristic curve (ROC: plot of sensitivity 
(%) versus 1-specificity (%), see Figure 4.3) was generated with an area under the 
curve of 0.78 (0.68 -0.88, 95% CI p = 0.0001).  From this graph, the 20 U/mL cut-off 
concentration provided a likelihood ratio of 6.3 (ie.  probability of a positive test in 
patients with SLE/probability of a positive test in persons without SLE).  This 
compares with the likelihood ratio of 5.0 for the 15 U/mL cut-off value recommended 
by the manufacturer, and often quoted by other groups using the same international 
control samples (294).  Henceforth the 20 U/mL discrimination value has been used 
throughout this analysis.  The sensitivity and specificity of the assay for the diagnosis 
of SLE were 57% and 91% respectively (see Table A 3; Table A 4; Table A 5; Table A 
6).  Assuming an average prevalence of SLE of ≈0.1% in the WA population (308), the 
estimated predictive value of a positive and negative aC1q ab test for SLE was 91% 
and 56% respectively.  Bayesian analysis results in the probability of a positive test 
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and SLE in an individual within a random population of the order of 1-2%.  There was 
a higher percentage of positive aC1q ab concentrations in SLE patients than in 
controls (57% v 9% respectively, p = 0.0001; Mann Whitney rank test), and it was 
noted that all patients and control samples tested manifested some level of aC1q ab.   
4.3.2 Anti-C1q antibody concentrations correlate in SLE patients 
with dsDNA ab concentrations and inversely with 
complement C4 concentrations. 
Correlation coefficients were estimated for aC1q ab concentrations and those of 
several other serological analytes usually measured in SLE testing.  These are shown 
in Table 4.2.  Significant correlations were observed between aC1q ab and dsDNA ab 
(p = 0.0001); an inverse correlation between aC1q ab concentrations and 
complement component C4 concentrations was noted (p = 0.041).  The correlation 
matrix also revealed associations in SLE patients between C-Reactive Protein (CRP) 
and both dsDNA ab (p = 0.005) and C1q complement protein levels (p = 0.024).  
However, C1q protein levels in SLE patients were not significantly correlated with 
anti-dsDNA antibodies.  There was a weak negative correlation (not statistically 
significant), between the age at time of testing of individual SLE patients and the 
concentration in serum of aC1q ab, whereas in the control cohort the concentration 
of aC1q ab was negatively correlated with age at time of collection (p = 0.001).   
4.3.3 Anti-C1q ab concentrations are associated with treatments 
and renal co-morbidities in patients 
Heatmaps were used to show any patterns in the patient group linking 
concentrations of aC1q ab and therapeutic treatments, as well as co-morbidities.  
Figure 4.4A shows the association of the aC1q ab with the drug treatments offered 
to SLE patients over the course of their disease.  It was observed that patients who 
received all three treatments of steroids, anti-malarial and immune-suppressants (7th 
lane) exhibited higher levels of aC1q abs.  Figure 4.4B shows associations of aC1q 
abs with the co-morbidities of the patients.  The first lane shows an association of 
higher concentrations of aC1q abs in patients with diagnosed renal disease.  In 
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contrast, patients with hepatic involvement (3rd lane) exhibit lower levels of aC1q 
abs.   
4.4 Discussion 
C1q molecules can activate the complement system by recognizing different 
structures on microorganisms and apoptotic bodies, or indirectly by means of bound 
immunoglobulins and classical acute phase proteins such as C-reactive protein, (CRP) 
(291).  Following these processes the generation of a neo antigen on the aC1q ab 
concentrations were assayed in the serum of a cohort of SLE patients undergoing 
clinical management for varying durations, and a panel of 33 healthy controls using a 
commercially available ELISA (Buhlmann Laboratories).  The merits of the Buhlmann 
assay for aC1q ab are its commercial availability (including concentration standards), 
relative ease of use and reproducibility in a diagnostic laboratory setting.  The ROC 
graph analysis of the test result data showed that 20 U/mL was a more discriminatory 
cut-off concentration than the value of 15 U/mL recommended by the manufacturer 
and some other groups (296).  The relatively low sensitivity of the assay (57%) 
restricts the utility of the test for exclusion of SLE, however the high specificity of the 
assay (91%) provides a useful confirmatory test.  Further, the probability of a positive 
test AND SLE in an individual in a random population is only of the order of 1-2%, 
thereby ruling out the assay as a screening test for SLE.  It is noted that three of the 
33 serum samples from the healthy control cohort exhibited high levels of aC1q ab; 
we cannot explain this anomaly.   
This study reports a one point-in-time estimate of aC1q ab concentrations in the 
serum of a cohort of SLE patients under clinical management for varying durations.  
Hence, it is not possible in this study to relate aC1q ab levels to events of clinical 
significance such as flare of renal disease.  aC1q ab levels were inversely correlated 
with serum C3 and C4 concentrations in SLE patients (albeit C3 not significantly) as 
would be expected if classical pathway complement activation was contributing to 
the disease process (296), suggesting that in SLE patients, some of these analytes 
contributed directly to the disease mechanism (309).  An important cognate study 
(310) demonstrated two human monoclonal anti-DNA antibodies (R4A and G11) that 
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cross-reacted with a globular region (as opposed to the collagen-like region) antigenic 
determinant in mouse and human C1q proteins.  Both antibodies bound both soluble 
C1q as well as solid phase C1q.  Franchin et al., (310) postulated that anti-C1q 
antibodies could contribute to the development of immune complex mediated 
glomerulonephritis by direct binding to glomeruli or by removal of soluble C1q.  In 
our study aC1q ab concentrations were not correlated with serum concentrations of 
C1q in either the patient or control cohorts.  This implies that most of the aC1q ab 
detected in this assay are specific for non-globular antigenic epitopes on C1q.  The 
significant correlation of aC1q ab concentration with anti-dsDNA antibodies is 
consistent with the cross-reactivity reported by Franchin et al., (310), but may also 
just reflect two separate but related processes.  It is also of interest that Vanhecke et 
al., (311) described aC1q ab reacting with peptide epitopes on the A and B collagen-
like tails of human C1q that were not present on the C chain.  These epitopes were 
only present on bound C1q and not on soluble C1q and mapped to different regions 
of the collagen-like region of C1q.  This raises the possibility that the aC1q ab 
detected in this study may include a proportion of antibodies directed against the 
peptide epitopes described by Vanhecke (311).  It is clear the specificities of the aC1q 
ab observed in the serum of SLE patients need to be characterised in more detail, 
especially if different antibody specificities reflect distinct attributes of SLE pathology, 
for example presence of nephritis.   
aC1q ab occur in the serum of individuals with a variety of non-SLE autoimmune 
disorders and infectious diseases, as well as in a proportion of healthy individuals 
(reviewed by 293).  It is clear the presence of aC1q ab as detected by the ELISA assay 
used herein is not pathognomonic for SLE.  The enigmatic role of C1q in SLE is 
emphasized further by the recent review (by international survey) of C1q deficiency 
in humans (76) in which the authors reported a high prevalence (≈80%) of SLE, 
together with decreased survival times and increased susceptibility to infections.   
It seems there are at least two distinct mechanisms in the predisposition to SLE 
explained by C1q.  SLE occurs with high frequency in C1q protein deficient persons 
(76, 312) and SLE can also occur in the presence of normal C1q protein levels and 
relatively high concentrations of aC1q ab that contribute to inflammatory processes 
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(304).  SLE patients who received all three classes of drug therapies tended to have 
higher levels of aC1q ab.  This suggests that patients with a more severe disease 
phenotype requiring multiple therapeutic treatments to reduce organ damage also 
produce higher levels of aC1q ab.  In contrast, patients with less severe disease, 
requiring fewer therapeutic agents and manifesting lower levels of aC1q ab.  This 
observation supports, but does not confirm, reports that relate high aC1q ab levels 
to renal symptoms and/or renal flares (306).  There have been many studies over the 
past two decades of aC1q ab levels in disease, including SLE (305, 306).  These, 
together with this report, suggest that quantitation and standardization of anti-C1q 
antibodies has a useful role in the classification of subtypes of SLE and as a potential 
confirmatory diagnostic and monitoring assay.   
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4.5 Tables and figures 
4.5.1 Tables 
Table 4.1: Combination of treatment regimens and co-morbidities in SLE patients. 
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Table 4.2: Correlation matrix between aC1q ab and other serological parameters and age.   
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4.5.2 Figures 
 
 
Figure 4.1: A four-parameter logistic standard curve for the aC1q ab kit. 
Curve of the assay (Buhlmann Laboratories) over the range of 5, 25, 100 and 400 U/ml (mean ± standard deviation of optical 
density values). 
  
Figure 4.2: aC1q ab distribution and ranking test. 
Figure 3.3A: Ranking of anti-C1q concentrations and means of ranks of aC1q ab ± 95% CI (Mann Whitney rank test analysis 
p≤0.0001).  Figure 3B & 3C: Frequency distribution of the aC1q ab for SLE patients and controls respectively (mean 
concentrations - aC1q ab SLE patients: 54.70 U/mL; controls: 12.84 U/mL).
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Figure 4.3: Receiver operating characteristics (ROC) curve for quantitation of aC1q ab.   
The area above the diagonal line corresponds to 78% of the total area indicating good discrimination between disease and 
non-disease at the 20 U/ml cut-off level (p < 0.0001).   
 
 
Figure 4.4: Heatmaps of treatment regimens and SLE-comorbidities associated with αC1q antibody concentrations.   
The figure shows associations between α-C1q antibody concentrations (rows) with A.  drug therapies and B.  co-
morbidities (columns).  αC1q ab concentrations were classified as negative (<20 U/mL), mid positive (20 to 69 U/mL) and 
highly positive (> 70 U/mL). 
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Chapter 5. Insights on the relationship between 
complement component C4 serum 
concentrations and C4 gene copy numbers 
in a Western Australian systemic lupus 
erythematosus cohort  
The content of this chapter has been submitted and is under review with the Journal 
of Clinical Immunology.  Item indicating review process can be found in appendix B, 
P.150. 
Margery-Muir A A. Bundell C. Wetherall J D. Whidborne R. Martinez P. and Groth D. Insights on the 
relationship between complement component C4 serum concentrations and C4 gene copy numbers in a 
Western Australian systemic lupus erythematosus cohort. 
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5.1 Abstract 
Purpose:  The relationship between serum concentration of complement C4 ([C4]) 
and C4 gene copy number (GCN) variation was investigated in 56 SLE patients and 33 
age and sex matched controls in the Western Australian population.   
Methods: C4A and C4B genes (C4A & B) GCN were estimated by a TaqManTM assay 
and compared with a custom RT-PCR assay that detected C4 genes with and without 
a ≈6.4kb retroviral element in intron 9 (hereafter HERV-K).   
Results: Good agreement between the two methods was observed, although the 
total count by the HERV-K method showed a GCN dependent bias relative to the C4A 
& B total GCN.  Regression analysis revealed an excellent correlation between C4A & 
B GCN and [C4] in both SLE and control cohorts (R2 =88% and R2 =99% respectively), 
however individual variability in serum [C4] precluded estimating GCN for specific 
individuals.  The data reported herein agree with the reference ranges for [C4] 
reported previously.  Serum [C4] was significantly lower in the SLE patients than the 
controls (p = 0.006) but no statistical difference in C4A GCN was found between the 
groups.  The data confirmed previous reports that the C4A genes were preferentially 
associated with the presence of the HERV-K insertion relative to C4B genes.  There 
was no evidence to show that the presence of the HERV-K insertion in C4 genes 
influenced [C4].   
Conclusion: This study supports the view that low [C4] in SLE patients is due to 
consumption rather than deficient synthesis related to lower C4A & B GCN.   
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5.2 Introduction 
Complement C4 genes (C4), located within the central region of the major 
histocompatibility complex (MHC) on the short arm of chromosome 6 (C6p), displays 
strong linkage disequilibrium with neighbouring loci (313) and contributes to the 
identity of extended haplotypes that characterize this genomic region (313).  C4 
proteins are synthesized from the mRNAs of two expressed paralogous genes, 
designated C4A and C4B (81), resulting in the synthesis of proteins, sharing 99% 
identity and differing by four isotype-specific amino acids in exon 26 (314).  
Complement C4 genes are part of a sub-genomic region designated “RCCX” (82, 315, 
316).  An RCCX module contains loci for Serine/Threonine nuclear protein kinase RP 
(STK 19, OMIM*604977), complement C4 (C4A &/or C4B, OMIM*120810 & 120820 
respectively), steroid 21-hydroxylase CYP21 (CYP-21, OMIM*613815) and the extra 
cellular matrix protein tenascin X (TNX, OMIN*600985); up to four copies of the 
module may be present on each copy of C6p, although most individuals have only 
one per haplotype and hence two copies of each of the C4A and C4B genes (82).   
Both loci may also exhibit size polymorphism due to the presence of a ≈ 6.4kb HERV-
K retroviral insertion in intron nine, resulting in “long” (presence of the retroviral 
element) and “short” (absence of the retroviral element) C4 gene variants (317, 318).  
The antisense insertion and lack of promoter activity from the 5’ LTR (both sense and 
antisense) and the 3’ LTR sense orientation preclude a deleterious effect on the host 
genes, in this case complement C4 (317).  Nevertheless, Yang and colleagues (318) 
recently reported that the presence of the retroviral element is associated with lower 
C4 serum concentrations and decreased haemolytic titres of complement activity.   
Furthermore, C4A is associated with the presence of a CT insertion in exon 29 (319) 
that results in a frameshift mutation and a stop codon that effects translation of a 
non-functional C4 protein (320).  Reports suggest that the CT insertion is associated 
with C4A pseudogenes (320), is present in some C4B genes (320, 321) and 
predisposes to systemic lupus erythematosus (SLE).  Paakkanen and colleagues have 
shown this CT insertion in more than 70% of the individuals exhibiting C4A deficiency 
states, and that its prevalence is increased in SLE patients relative to controls (85).  
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However, the association between the CT insertion and C4A deficiency has not been 
demonstrated in a recent study of populations from the United Kingdom and Spain 
(322).   
The purpose of this study was to evaluate the levels of complement C4 protein in a 
cohort of West Australian individuals with SLE, and a sex/ age matched control 
cohort.  The relationship between serum C4 protein concentrations and C4A and C4B 
gene copy numbers (C4 GCNs) was investigated together with the frequencies of the 
presence of the HERV-K retroviral element and the exon 29 CT insertion in C4A and 
C4B genes.  In a previous study complement C4 reference ranges for varying C4 GCNs 
were published to assist clinicians in the interpretation of chronically low serum C4 
concentrations in SLE patients (86).  The present study extends this work.   
5.3 Results 
5.3.1 Quantitation of serum C4 concentrations ins SLE patients 
and controls. 
Serum samples for the SLE patients and controls were obtained at the time of 
recruitment.  Serum [C4] for the SLE patients show a non-Gaussian distribution with 
lower concentrations than the controls (Figure 5.1A).  Mean [C4] show statistically 
significant difference between the groups (p = 0.0060 – Figure 5.1B). 
5.3.2 Measurement of C4 gene copy number (GCN) 
C4 GCN’s were quantitated in both the SLE and control cohorts using two 
independent methods as described above.  These methods estimate the C4A and C4B 
GCN and C4 genes with (long) and without (short) the 6.4kb HERV-K retroviral 
insertion.  The results of these measures are summarised in Table 5.1.  In the SLE 
cohort, one individual (1.78%) had C4AQ0 and two (3.57%) had C4BQ0.  In the control 
cohort two individuals (6.06%) had C4AQ0 and none had C4BQ0. 
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5.3.3 Comparison of C4 GCN by Taqman™ C4A and C4B assay and 
detection of the HERV-K retroviral insertion by custom 
Taqman™ assay. 
The assays results show good agreement between the two independent methods.  A 
Bland-Altman analysis of the data for the 89 subjects tested showed a small bias of 
≈0.06.  However, a regression line of the differential gene count versus the means of 
the two estimates showed a bias that was GCN dependent; low HERV-K counts 
underestimated total C4A & C4B GCN by ≈1 gene whereas high HERV-K counts 
overestimated the total C4A & C4B GCN by ≈-1 gene.  These results are illustrated in 
Figure 5.2 and Figure A 7.3 and Figure A 7.4. 
5.3.4 Distributions of C4 A and B and C4 long and Short genes in 
SLE patients and controls 
Distributions of C4A, C4B and C4A+C4B with and without the HERV-K retroviral 
insertion are shown in Figure A 7.5 together with comparable data from Yang et al.  
(81).  The distributions of C4A, C4B and total C4 GCN’s and of the long and short 
variants of these C4 genes were similar to those reported by Yang et al.  No significant 
differences between SLE patients and control cohorts GCN were found in our study.   
5.3.5 HERV-K insertion is more frequent in C4A genes than C4B 
genes 
Analysis of the 89 combined SLE patients and controls showed that ≈74% of the total 
C4 genes counted contained the HERV-K insertion.  In contrast, the ratio of C4A to 
C4B genes was ≈1.  When the 26 subjects without the HERV-K insertion, or individuals 
exhibiting only C4 genes with the HERV-K insertion (2) were analysed, the proportion 
of C4A genes with the HERV-K insertion was 55%.  This indicates that the HERV-K 
insertion is more frequent in C4A genes than C4B genes (1.25:1).  Linear regression 
revealed a positive correlation between C4A genes and the presence of the HERV-K 
insertion (r = 0.561, p = 0.0001), while there was no significant correlation between 
C4A genes and the absence of the HERV-K insertion (r = 0.038, p = 0.726 NS).  In 
contrast, absence of the HERV-K insertion correlated with the C4B gene (r = 0.473, p 
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≤ 0.0001).  There was no significant correlation between C4B genes and the presence 
of the HERV-K insertion.  See Figure 5.3, Figure A 7.6 and Figure A 7.7.  These findings 
are consistent with those of Yang and colleagues who also reported a preferential 
association of the HERV-K insertion in C4A genes (81). 
5.3.6 Serum C4 concentrations as a function of gene copy number 
variation 
The relationship between serum [C4] and C4 GCN in SLE patients and controls was 
investigated using regression analysis.  The intercept of the regression line passes 
close to the origin with a coefficient of determination of ≈ 40% in healthy controls (y 
= 0.0647*x – 0.003077).  This is consistent with a linear overall relationship between 
serum [C4] and total C4 GCN with variability between individuals.  If the data are 
aggregated within each GCN, the relationship once again is linear, passing through 
the origin indicating that (and for which) all variation in serum [C4] is accounted for 
by GCN (r2 = 99%; y = 0.06305*x + 0.001332- Figure 5.4). 
An equivalent analysis in 56 SLE patients revealed a similar relationship but with 
increased individual variation in [C4].  In this analysis, ≈ 12% of the variability in 
individual serum [C4] was accounted for by total C4 GCN (y = 0.00452*x + 0.01846), 
while for the aggregated data 88% of the variation in [C4] was related to C4A+B GCN 
(y = 0.04711* + 0.03347- Figure 5.4).   
The relationship between serum [C4] and C4 genes with the insertion of the HERV-K 
retroviral element (long) in SLE patients and controls (aggregated data) was 
investigated using regression analysis.  The intercept of the regression line passes 
close to the origin with a coefficient of determination of ≈ 25% (y = 0.04461*x – 
0.01661-Figure A 7.8).  This is consistent with a linear relationship between serum 
[C4] and C4 long with variation between.  If the data are aggregated within each GCN, 
the relationship once again is linear, passing through the origin (and for which) all 
variation in serum [C4] is accounted for by GCN (r2 = 98%; y = 0.04524*x + 0.02175 -
Figure A 7.8).  Interestingly, a Mann-Whitney analysis (Figure A 7.8) demonstrated no 
significant difference in the mean GCN of the C4 genes with the HERV-K element 
within this subgroup (p = 0.9595).  However, the analysis demonstrated a statistically 
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significant difference between the mean [C4] of the two subgroups (p = 0.0087) with 
the SLE patients demonstrating much lower serum concentrations.   
5.3.7 The serum C4 concentrations in previously established 
ranges for two, three, four and five C4 GCN. 
We have previously established serum C4 concentration reference ranges for the C4 
GCN (86).  We compared the data obtained herein with our previously reported data 
and found that the mean serum C4 concentrations were generally within the ranges 
previously established in both cohorts with individual variations (see Figure 5.5).  In 
the SLE cohort, 27 (48%) patients have serum C4 concentrations below the 
internationally used normal range (0.160 – 0.520g/L).  Of these 27 individuals, only 
16 (28%) have serum [C4] which are still lower than our previously defined ranges 
(for the C4 GCN determined).  One of these patients, with quiescent disease activity 
has a total of six C4 genes (for which we have no ranges), chronically low serum [C4] 
of 0.0933g/L together with low serum C3 concentration.  However, the antibody 
profile for anti-C1q, ANA and dsDNA is within the reference range).  Therefore, 
chronically low serum C4 concentrations in this patient must likely be attributed to 
other factors.  Previously defined normal serum C4 mean concentrations and ranges 
(86) for two, three, four and five total C4 GCN respectively ((0.197; 0.059 – 0.343) 
(0.256; 0.117 – 0.383) (0.296; 0.159 – 0.439) (0.425; 0.279 – 0.571)). 
5.3.8 The CT insertion is not a risk factor in the Western Australian 
population 
All 89 subjects were tested for the presence of the CT insertion in exon 29 of C4 genes,  
the presence of which precludes C4 protein synthesis (323).  Only one of 56 SLE 
patients (1.8%) and no healthy controls was shown to have this insertion. 
5.4 Discussion 
Decreased serum concentrations of complement component C4 have long been a 
valuable aid in the diagnosis and management of SLE (324).  The presence of two 
polymorphic C4 genes, designated C4A and C4B, within the central major 
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histocompatibility complex has added much interest in the role of these proteins in 
the pathogenesis of SLE (325).  Further, interpreting serum [C4] in the diagnosis and 
management of SLE may be difficult because low concentrations may reflect 
consumption or low GCNs and/or the presence of null alleles (324).  In this study 
serum C4 concentrations were significantly lower in 56 confirmed SLE patients than 
in 33 sex and age matched control persons (p = 0.006).  There was no evidence that 
lower serum C4 concentrations in the SLE cohort was due to paucity of C4A and/or 
C4B GCNs.  Only one SLE patient was C4A gene deficient compared with two control 
individuals; there were two SLE patients and no control individuals deficient in C4B 
genes.  These results preclude C4A deficiency as a risk factor for SLE and support the 
extensive investigation from Boteva and colleagues (322) who demonstrated that 
partial C4A or C4B gene deficiencies, and the loss-of-function exon 29 CT insertion 
were not risk factors predisposing to SLE in large United-Kingdom and Spanish 
cohorts.  Further, there was no evidence that the presence of the HERV-K insertion 
in either C4A or C4B genes was associated with decreased serum C4 concentration in 
these Western Australian cohorts.  This observation differs from earlier reports 
proposing that the presence of the HERV-K retroviral element decreases the rate of 
C4 transcription and therefore serum C4 concentration (318).  Clinically low serum 
C4 concentrations can be explained by immune complex mediated activation of the 
classical complement pathway with subsequent loss of C4 protein in tissues where 
the rate of consumption is higher than that of synthesis (325).  Low serum C4 
concentrations in SLE patients may result therefore from ongoing consumption and 
hence represent a measure of autoimmune pathology.   
This work confirms other reports that C4A genes are preferentially associated with 
the presence of the HERV-K retroviral element relative to C4B genes (with the 
absence of the insertion) (318).  There were no significant differences between the 
SLE and control cohorts in mean number of C4A, C4B, C4A+C4B genes and C4 genes 
with and without the HERV-K insertion.  Mean C4 concentrations in persons with long 
C4 genes, and short C4 genes, were not significantly different (see Figure A 7.6).   
The positive correlation between C4A genes and the presence of the HERV-K 
insertion in the combined cohorts contrasted with the lack of correlation between 
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C4A genes and the absence of the HERV-K insertion.  Correspondingly, the absence 
of the HERV-K insertion correlated positively with the C4B gene, and contrasted with 
absence of any significant correlation between C4B genes and the presence of the 
HERV-K insertion.   
Previous reports (84, 323) have indicated the presence of a CT insertion in exon 29 
which leads to non-functional C4A and C4B genes.  Only one SLE patient (and no 
control persons) in this study was shown to have the CT insertion in exon 29.  These 
data agree with the results of Boteva et al.  (322), described above, and also of Puah 
and colleagues (326) who found no evidence for associations between SLE and the 
CT insertion (as well as three other known mutations in exons 13, and 20) in C4 genes 
in the Malaysian population. 
Two independent methods were used to count C4 GCNs in all subjects tested.  These 
were a commercial TaqMan™ assay that detected nucleotide sequences specific for 
either C4A or C4B and a custom quantitative PCR assay that detected the presence 
or absence of the ≈6.4kb retroviral HERV-K insertion in intron 9 of both C4A and C4B 
genes.  Good agreement between both methods was observed for total C4 gene 
counts, although the total count by the HERV-K method showed a GCN dependent 
positive bias relative to the C4A & B total GCN.  We reported previously that the 
TaqMan™ assay tends to underestimate total C4 GCNs when there are ≥ three C4A 
or C4B genes per person tested (86).  Wu and colleagues reported similar 
observations (204) whereby at high GCN of C4A/ C4B/ C4 short and/or C4 long genes 
the TaqMan™ assay reported equivocal results with a propensity to underestimate 
GCN.  Laboratory manipulation of DNA, including repeated freeze-thawing, may 
compromise the quality and quantity of DNA tested (86, 204) in these technically 
exigent assays, especially when high GCNs are present.  Nevertheless, as shown by 
the Bland-Altman analysis, the bias in the data is relatively small (≈6%) and both 
assays were in complete agreement around median values for GCN. 
It was of considerable interest that serum C4 concentrations in SLE patients and 
healthy controls correlated strongly with the C4A and C4B GCN.  In SLE patients and 
healthy controls, approximately 88% and 99% respectively of the variability in serum 
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C4 concentrations could be attributed to C4 GCNs despite considerable individual 
variability in [C4].  This result indicates that for healthy persons expected serum C4 
concentrations may be estimated from GCN.  While a similar relationship exists in SLE 
patients, the co-existence of a pathological process consuming C4 may result in more 
variable serum [C4] such that GCN is not a reliable predictor of concentration for 
individual SLE patients, although, in conjunction with the serum [C4] expected 
reference ranges, it may still provide insights in disease management of SLE patients 
with well-managed disease.  The results of this study are consistent with and 
supplement our earlier study of C4 GCNs in the WA Busselton population (86).  A 
direct correlation between GCN and protein concentration in body fluids is the 
default expectation unless other mechanisms act to distort this relationship.  For 
example, it has long been known that serum C2 concentrations are proportional to 
the number of expressed genes for this single dimorphic locus (327).  Pouw and 
colleagues have also shown that the complement factor H-related protein 3 serum 
levels are determined by GCN variation at the CFHR3 locus (328).  In this respect, the 
complex C4 genomic locus behaves similarly to other gene systems where protein 
synthesis correlates with GCN variation.   
In conclusion, this report confirms the utility of serum [C4] in the diagnosis and 
management of SLE.  Low C4 concentrations relative to C4 GCN are best explained by 
a mechanism involving consumption of C4 protein rather than decreased synthesis.  
Paradoxically, individuals manifesting complete deficiency in both C4A and C4B genes 
(a rare phenomenon (329)), and consequently lacking C4 protein, are also 
predisposed to SLE.  Hence, in these individuals, the mechanisms resulting in the 
symptoms of SLE must exclude consumption of complement C4 protein.  There is no 
evidence from this study that C4A GCN, the presence of the CT insertion, and/or the 
HERV-K insertion are significant risk factors for SLE. 
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5.5  Figures and Tables 
5.5.1 Tables  
Table 5.1: Summary table of the C4 quantitation data. 
 SLE Patients Healthy Controls  
 Counts (%) Mean (±SD)  Counts (%) Mean (±SD)  Significance 
Serum [C4] (g/L) 56 0.1928 (0.1073) 33 0.2342 (0.0800) P = 0.0060 
C4A GCN 109 (50.4) 1.946 (0.7488) 61 (50.8) 1.848 (0.755) NS 
C4B GCN 107 (49.6) 1.911 (0.7926) 59 (49.2) 1.788 (0.4846) NS 
Total C4 GCN 216 (100) 3.857 (0.8186) 121 (100) 3.667 (0.7773) NS 
C4 Short GCN 64 (29) 1.143 (1.151) 29 (24) 0.8788 (0.9907) NS 
C4 Long GCN 155 (71) 2.768 (0.9907) 94 (76) 2.848 (1.326) NS 
HERV-K TOTAL 
GCN 219 (100) 3.911 (1.066) 123 (100) 3.727 (1.008) NS 
The table summarises the C4A, C4B, total C4, C4 short, C4 long and total HERV-K gene counts, mean and standard deviation 
values for SLE patients and controls.  The table also indicates the serum [C4] means and standard deviations as well as the 
number of individuals (counts) in each group. 
5.5.2 Figures 
 
Figure 5.1: Serum[C4] in SLE patients and controls.   
A: The figure shows the frequency distribution of the serum [C4] (X-axis) for the SLE patients (dark bars) and the control 
cohort (light bars).  B: Distribution of [C4] showing the mean and standard deviation for each group; p = 0.0060 (Mann 
Whitney rank test).  Mean concentrations: SLE patients 0.1928g/L (range 0.033 – 0.580); controls: 0.2342g/L (range 0.072 – 
0.415).  Median concentrations: SLE patients 0.1664g/L; controls 0.2350g/L.  Serum C4 concentrations (0.160 – 0.520g/L) = 
reference ranges in the healthy population. 5.1.A “Count” refers to the number of individuals in each group. 
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Figure 5.2: A Bland Altman analysis of two assay methods. 
Bland Altman analysis plot of the difference versus average of the Taqman™ C4A + C4B and the Taqman™ Custom for HERV-
K retroviral element in C4 genes assays.  Plot shows the 95% confidence intervals (CI) of the mean difference (dashed lines) 
and 95% CI of the limit of agreement (dotted lines) between the two assays.   
 
 
Figure 5.3: Relationship between C4 and HERV-K gene copy numbers. 
Linear relationship between C4 long and C4A/ C4B genes (top graphs), and C4 short with C4A/ C4B genes (bottom graphs) 
for the 89 subjects in this study. Equations and r2 values indicated on the graphs. 
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Figure 5.4: Serum [C4] stratified with C4 gene copy number.   
The figure shows a stratification of the gene copy number for total C4 (X axis) with serum C4 concentrations (Y axis).  The 
top graphs show the linear regression based on independent values whereas the bottom graphs are the mean values 
(aggregated) with standard deviation and 95% confidence intervals of the mean of the data.  Serum C4 concentrations (0.160 
– 0.520g/L) = reference ranges in the healthy population. 
 
 
Figure 5.5: Previously defined serum [C4] ranges stratified with C4 gene copy number. 
The figure shows a stratification of the total C4 gene copy numbers (X axis) for the SLE patients and control cohort (as 
indicated on the graph) with serum C4 concentrations (Y axis) as well as the previously defined normal reference ranges 
(86) for two, three, four and five GCN.  Data shown indicate mean values for the SLE and control cohort, and mean values 
and standard deviations for the ranges previously described. 
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Chapter 6. Genetic Variation at the DNASE I Locus in 
an Australian Cohort of SLE Patients 
The content of this chapter has been published in Lupus: Open Access (2017).  
Permissions for this article can be found in appendix B.1.4 and published article in 
B.2.3. 
Margery-Muir A A. Wetherall J D. and Groth D M. Genetic Variation at the DNASE I Locus in an Australian Cohort 
of SLE Patients. Lupus: Open Access 6:130. 2017. 
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6.1 Abstract 
Objective: DNASE I serum concentrations and activity, as well as sequence mutations 
have been implicated in the pathology of systemic lupus erythematosus (SLE).  This 
study was undertaken to assess the serum DNASE I concentrations and assess the 
DNASE I sequence variation in a cohort of SLE patients and controls.   
Methods: DNASE I serum concentrations were assayed in 56 SLE patients and 33 age 
and sex matched controls.  All SLE patients and controls were genotyped for exomic 
alleles at the DNASE I locus and for the variable number tandem repeat alleles 
present in intron 4 (VNTR - HumDN1).   
Results: Skewed DNASE I protein concentration distributions were observed with the 
mean value for SLE patients being 44.2 U/mL compared to 56.4 U/mL in controls (NS).  
No sample tested negative for DNASE I protein.  Only two of the previously reported 
six exomic alleles (DNASE*1, DNASE*2) were identified, together with four VNTR 
alleles (three - six repeats).  Both loci manifested Hardy-Weinberg equilibrium.  
Linkage disequilibrium was observed between exomic alleles and the VNTR alleles, 
especially between DNASE I*! and four repeat VNTR (HumDN1) allele.  No significant 
associations were observed between DNASE I concentrations and genotypes.  
Estimations of haplotype frequencies showed similar distributions for both SLE and 
the control cohorts, although it was noted that haplotypes containing DNASE*2 had 
an elevated frequency of longer VNTR alleles than did DNASE*1.   
A meta-study of DNASE I exomic allelic frequencies showed similar frequencies to 
those obtained in other populations.  For the VNTR locus, the longer alleles (five and 
six repeats) were more frequent, although there was no difference between SLE 
patients and controls.   
Conclusion:  This study does not support the hypothesis that specific two locus DNASE 
I genotypes predispose to SLE in the Western Australian cohort.   
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6.2 Introduction 
Systemic lupus erythematosus (SLE) is an important systemic autoimmune disease 
characterised by the presence of autoantibodies binding double stranded DNA 
(henceforth dsDNA ab) and decreased levels of serum complement components C3 
and C4 (290).  It has been postulated that defective apoptotic clearance of immune 
complexes incorporating histone associated DNA predisposes to SLE (290).  DNASE I, 
is an endonuclease (330) believed to facilitate the removal of cellular debris thereby 
preventing aberrant inflammation (331-333).  There have been reports that DNASE I 
deficiency is a predisposing factor for SLE.  Lower levels of DNASE I enzyme activity 
may be associated with lupus nephritis (20, 97) and correlate with disease activity 
state and clinical parameters (104).  Yasuda and colleagues (330, 334-337) and Iida et 
al.  (338) have identified exomic polymorphisms of the DNASE I gene, some of which 
appear to be associated with susceptibility to SLE (339).  Furthermore, Koji and 
colleagues (1) have described an A-G transversion in exon two that results in 
defective synthesis of DNASE I in an SLE patient manifesting lower DNASE I activity.  
The DNASE I gene also contains a polymorphic 56bp variable number tandem repeat 
(VNTR – HumDN1) locus within intron four manifesting six alleles corresponding to 
molecular product sizes of 469, 525, 581, 637 and 693 for two, three, four, five and 
six repeats respectively (340, 341).  Yasuda and colleagues (340) reported that the 
three repeats allele of VNTR (HumDN1) was in linkage disequilibrium with DNASE I*1 
allele whilst the VNTR alleles four and five were in linkage disequilibrium with DNASE 
I*2.   
In this study, genetic polymorphisms at both the DNASE I locus and at the VNTR 
(HumDN1) locus were typed in a Western Australian population of SLE patients and 
controls with known serum concentrations of DNASE I protein.  The genetic diversity 
of DNASE I polymorphisms in these cohorts was compared with other studies and 
associations sought with disease and serological parameters indicative of SLE 
pathology. 
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6.3 Results 
6.3.1 DNASE I protein concentrations in SLE patients and controls.   
DNASE I protein concentrations observed in serum samples of SLE patients and 
controls are shown in Figure 6.1.  The distribution of concentrations in both cohorts 
was skewed; the mean concentration of DNASE I protein in SLE patients was lower 
than that of the controls (44.2 U/mL versus 56.4 U/mL) although the difference was 
not significant.  A preliminary investigation of associations between DNASE I serum 
concentrations and co-morbidities and drug therapies in the SLE patients was 
undertaken using heat maps is shown in Figure 6.2C and Figure 6.2D respectively. 
6.3.2 Allele and genotype frequencies at the DNASE I and intron 4 
VNTR (HumDN1) loci. 
Allele frequencies at the DNASE I exomic and VNTR (HumDN1) loci are summarised 
in Table 6.2.  Alleles at both intragenic loci exhibited Hardy-Weinberg equilibrium and 
linkage disequilibrium.  The frequencies of haplotypic combinations at both the 
DNASE I and VNTR (HumDN1) loci are shown in Figure 6.3.  Haplotypes with VNTR 
alleles of 4, 5 and 6 repeats were more prevalent in both the SLE and control cohorts. 
6.3.3 Ethnic variation in DNASE I polymorphisms 
The allele frequencies reported in this study are in general agreement with the 
metastudy of ethnic allele frequency variation shown (see Table 6.3).  Only the 
Ovambos’ of African origin have higher frequencies of the DNASE I*1 relative to the 
DNASE I*2 allele.  No apparent significant differences between DNASE I allele 
frequencies were observed for either the SLE patients or the healthy controls.  A 
comparison of ethnic variation in the frequencies of the internal VNTR (HumDN1) 
locus within the different ethnic groups is shown in Table 6.4.  The frequencies of the 
six alleles reported in this study were similar to those observed in other population 
with the exception that the long six repeat allele was more frequent in both the 
control and SLE populations reported herein.  The genetic differentiation of the 
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Ovambo and Japanese populations was evident with the three-repeat allele being 
more prevalent than in the other populations reported.   
6.3.4 Are serum DNASE I concentrations dependent on genotype? 
DNASE I serum concentration distributions are shown ranked by genotype in Figure 
6.4. 
There were no significant associations between DNASE I serum concentrations and 
either the DNASE I exomic genotypes or the repeat number variation of the VNTR 
(HumDN1) locus.  The lowest concentration levels of serum DNASE I were associated 
with DNASE I*2 genotype, and with the higher number of repeats at the VNTR 
(HumDN1) locus. 
6.3.5 Associations between serological parameters and DNASE I 
and VNTR (HumDN1) alleles. 
A correlation matrix was generated for age, ethnicity, (C1q), (C3), [C4] and (DNASE I) 
versus VNTR (HumDN1) and DNASE I alleles (Table A 7).  No significant correlations 
between the various parameters were observed except for serum concentrations of 
DNASE I and C1q complement protein (r = 0.653; p = 0.05).  In the SLE cohort, the 
VNTR (HumDN1) repeat number was significantly correlated with (C3) and [C4] 
(0.304; p = 0.03 and 0.279; p = 0.04 respectively).  However, specific alleles at both 
the VNTR (HumDN1) and DNASE I loci were significantly correlated in the SLE and 
control cohorts (r = 0.760; p = 0.0001; 0.569; p = 0.0005 respectively) (Table A 8 & 
Table A 9).   
In the absence of well-defined associations between specific DNASE I genotypes and 
SLE, heat maps were used to visualize trends in disease severity that may be related 
to DNASE I genotypes or serum concentrations in both the SLE patient and control 
cohorts.  The heat map analyses (Figure 6.2) show qualitatively that SLE patients with 
higher numbers of VNTR (HumDN1) repeats (≥5) had lower serum concentrations of 
DNASE I protein and required more intensive drug regimens for management of their 
disease than persons with low numbers of repeat motifs.   
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6.4 Discussion 
In this investigation only the two most frequent (ie.  DNASE I*1 and DNASE I*2) of the 
six exonic alleles defined at the DNASE I locus were observed, although the typing 
system (shotgun sequencing) would have detected them if present.  No variations in 
the nucleic acid sequence within exons two, five and seven were present in any of 
the individuals tested.  The remaining four alleles (DNASE I*3, *4, *5 and *6) are rare 
and there are few reports of their frequencies in the other populations (342).  The 
frequencies of the DNASE I*1 and 2 in persons of European and Asian ethnicity were 
similar to previously published reports (342-344).  Four alleles were observed at the 
VNTR locus with the number of repeats varying from three to six.  A greater frequency 
of the longest six repeat allele was observed in both cohorts in this study which may 
reflect improved typing techniques.  Only in the Ovambo and Ghanian populations 
did allele frequencies at both loci differ markedly from the values reported in other 
populations.  This is consistent with an ancestral version of the DNASE I gene being 
present in modern day African populations (345). 
Allele frequencies at both the DNASE I and VNTR (HumDN1) loci manifested Hardy-
Weinberg equilibrium despite the relatively small sample size of the populations 
typed.  As would be expected, both intragenic loci exhibited linkage disequilibrium 
(LD) as has been previously reported (340, 346). 
Of the 36 possible genotypes comprising observed alleles at these two loci, 13 were 
observed in the SLE patients and 12 in the control group.  These data demonstrate 
the presence of a restricted number of haplotypes in our populations.  AlFadhli and 
co-workers have shown that higher number of the VNTR (HumDN1) repeats are a risk 
factor for SLE and that the allele with five repeats was associated with a reduction of 
DNASE I enzyme activity (341).  It was not possible to measure the DNASE I enzyme 
activity, in this study however serum protein DNASE I concentrations were assayed 
in both populations.  All persons tested exhibited DNASE I protein in their serum.  
Significant differences in serum DNASE I protein concentrations between SLE patients 
and the control cohort were not observed, although the mean concentration in the 
SLE cohort was slightly lower than in the control group.  If DNASE I activity is 
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proportional to the concentration of DNASE I protein it is unlikely that non-expressed 
mutant genes were present in the cohorts investigated. 
Associations between the VNTR (HumDN1) locus and complement C3 and C4 serum 
concentrations were observed in the SLE cohort but not in the control group.  Hence, 
the number of VNTR (HumDN1) repeats in the SLE patients may influence clinical 
parameters.  AlFadhli and co-workers have shown that higher number of the VNTR 
(HumDN1) repeats are a risk factor for SLE, and moreover, that the five-repeat allele 
was associated with a reduction of DNASE I enzyme activity (341). 
 The heat map analysis (Figure 6.2) showed qualitatively that SLE patients with higher 
numbers of VNTR (HumDN1) repeats (≥five) had lower serum concentrations of 
DNASE I protein than the controls and required more intensive drug regimens for 
management of their disease.  However, quantitative analysis did not reveal any 
significant correlations between the serum concentrations of DNASE I protein and 
either phenotypes at the DNASE I and VNTR (HumDN1) loci or with disease severity 
(see Figure 6.3).  Other reports (341, 347), in particular that of AlFahdi (341), show 
that a high number of VNTR repeats are a risk factor for SLE and may cause decreased 
DNASE I activity.  Positive correlations between DNASE I and C1q serum 
concentrations and the length of the VNTR allele with serum concentrations of 
complement components C3 and C4 were observed and noted.  If low DNASE I 
activity and/or concentration impairs removal of apoptotic material thereby 
predisposing to SLE, it might be expected that VNTR alleles negatively correlate with 
C3, C4 and C1q serum concentrations in SLE patients.  Hence this report does not 
support the hypothesis that specific two locus DNASE I genotypes predispose to SLE 
in the Western Australian cohort.  
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6.5 Tables and figures 
6.5.1 Tables 
Table 6.1: DNASE I polymorphisms in exons 2, 5, 6, 7 & 8. 
DNASE I allele Exon 2 Exon 5 Exon 6 Exon 7 Exon 8 
DNASE I*1 CAG – Gln GTG – Val CCC – Pro CGC – Arg CAA – Gln 
DNASE I*2 CAG – Gln GTG – Val CCC – Pro CGC – Arg CGA – Arg 
DNASE I*3 CAG – Gln GTG – Val GCC – Ala CGC – Arg CAA – Gln 
DNASE I*4 GAG – Glu GTG – Val CCC – Pro CGC – Arg CGA – Arg 
DNASE I*5 CAG – Gln ATG – Met CCC – Pro CGC – Arg CGA – Arg 
DNASE I*6 CAG – Gln GTG – Val CCC – Pro TGC – Cys CGA – Arg 
Nucleotide/amino acid substitutions underlying the major DNASE I gene polymorphisms as summarised by Fujihara and 
colleagues (18). 
 
Table 6.2: Allele frequencies of the DNASE I and VNTR (HumDN1) loci. 
Population 
DNASE 
I*1 
DNASE 
I*2 
VNTR 
(HumDN1) 3 
VNTR 
(HumDN1) 4 
VNTR 
(HumDN1) 5 
VNTR 
(HumDN1) 6 
SLE  
(n=56) 
0.393  
(n=44) 
0.607  
(n=68) 
0.036 
 (n=4) 
0.304  
(n=34) 
0.366 
(n=41) 
0.295  
(n=33) 
Control  
(n=33) 
0.394  
(n=26) 
0.606  
(n=40) 
0.000 
0.409  
(n=27) 
0.348  
(n=23) 
0.242  
(n=16) 
Allele frequencies for the DNASE I locus and the intron 4 VNTR (HumDN1) locus in Australian SLE patients and healthy 
controls (numbers in brackets indicate the number of alleles in each group). 
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Table 6.3: Frequency data of the DNASE I*1 & *2 from published reports. 
Population (References) 
Allele 
DNASE I*1 
Not diseased 
Allele 
DNASE I*2 
Not diseased 
Allele 
DNASE I*1 
SLE 
Allele 
DNASE I*2 
SLE 
Mixed Europeans (this study) Controls 
(n = 25) (SLE n = 24) 0.380 0.620 0.375 0.625 
Mixed Asians (this study) Controls (n = 
5) SLE (n = 11) 0.500 0.500 0.454 0.545 
Mixed other (this study) Controls (n = 
3) SLE (n = 21) 0.333 0.667 0.381 0.619 
Germans (26; 27) 0.294 0.705   
Germans (28) 0.265 0.728   
Spanish (29) 0.3003 0.6997 0.2246 0.7754 
Japanese (26) 0.547 0.445   
Japanese (28) 0.595 0.405   
Koreans (28) 0.597 0.403   
Chinese (Han) (30) 0.536 0.464   
Chinese (Shenyang) (31) 0.5670 0.4330   
Chinese (Guangzhou) (31) 0.5417 0.4583   
Argentineans (14) 0.280 0.720 0.340 0.660 
Turks (18) 0.221 0.779   
Ovambos (18) 0.872 0.128   
Ovambos (32) 0.872 0.128   
Ovambos (28) 0.889 0.111   
Indian Tamils (33) 0.520 0.490 0.495 0.505 
Frequency data for the DNASE alleles *1 and *2 are derived from published reports.  The rare DNASE I*3; *4; *5 and *6 
alleles are not included due to insufficient published data.  “Mixed other” control group contained individuals of Middle 
Eastern and Indian ethnicity whereas the “Mixed other SLE” group included individuals from African, South American and 
Australian Indigenous ethnicities which were grouped together as there were only a small number of individuals in each. 
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Table 6.4: VNTR (humDN1) repeat frequencies from published reports. 
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6.5.2 Figures 
 
Figure 6.1: Serum DNASE I concentrations.   
A: dark bars - the frequency distribution (U/mL) in the SLE (mean = 44.2 U/mL) and light bars - control (mean = 56.4 U/mL) 
populations.  B: Ranks of serum DNASE I concentrations in SLE and control cohorts showing means ± standard deviation – 
not significantly different. 
 
Figure 6.2: Heatmaps for the SLE patients.   
Heatmaps showing associations between mean concentrations of serum DNASE I in SLE patients stratified in three groups 
defined as low concentration range, mid-concentration range and high concentration range with mean concentrations of 
DNASE I = 29U/mL top row, DNASE I = 59U/mL middle row, and DNASE I = 103U/mL bottom row respectively.  Figures 2A 
and 2B: DNASE I concentrations versus DNASE I genotypes and VNTR (HumDN1) repeats genotypes respectively.  Figures 2C 
and 2D: DNASE I concentrations in SLE patients versus co-morbidities and drug therapies respectively. 
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Figure 6.3: DNASE I (left number) & VNTR  (HumDN1) (right number) Loci Haplotypes.   
The figure shows percentage haplotype frequencies in both loci for the SLE patients and control cohort.   
 
Figure 6.4: Serum [C4] associated with DNASE I and VNTR (HumDN1) phenotypes. 
The figure shows the mean concentrations (U/mL ± SD) of the DNASE I protein in SLE patients (A & C) and controls (B & D) 
associated with DNASE I phenotype DNASE I*1 or DNASE I*2 (A and B) and with the VNTR (HumDN1) number of repeats (C 
and D). 
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Chapter 7. Final discussion and concluding comments 
7.1 Discoveries and Discussion 
7.1.1 Introduction to the hypothesis 
Systemic lupus erythematosus (SLE) is a polygenic, multifactorial autoimmune 
disease, characterised by autoantibody production, immune complexes and 
inflammation leading to multiple organ and tissue damage.  Recently, it has been 
proposed that defective clearance of apoptotic materials generates inflammatory 
mechanisms manifesting as SLE in genetically predisposed individuals. This project 
focused on the investigation and interpretation of a panel of laboratory assays used 
to diagnose and management SLE with this hypothesis as a guide for mechanism(s).  
It is anticipated that the results obtained will provide clinicians with valuable insights 
for diagnosing, treating and monitoring SLE patients in Western Australia. 
Characteristics of SLE pathology that define this multisystem autoimmune disease 
were identified in this project; specifically, it was proposed that underlying 
immunopathology and genetic predisposition should be reflected in the laboratory 
assays used in the diagnosis and management of SLE.  The review of contemporary 
literature centred therefore on the conventional female preponderance of SLE, and 
included a refinement of its epidemiology, together with the role of genetic 
deficiencies in the predisposition to SLE.  Moreover, contemporary relevant SLE 
research on twins, sex chromosomal abnormalities, genome wide association studies 
and possible environmental factors were investigated.   
Mechanisms underlying the pathology of SLE have recently been reviewed in a 
comprehensive publication by Tsokos and co-workers (344).  Despite a wide body of 
information available in the form of published articles, reviews and books readily 
available via institutions, the multiple potential aetiologies of SLE still remain 
frustratingly unresolved.  Based on the defective apoptosis processes hypothesis, we 
generated a mechanistic model that formed the basis of the potential cellular, 
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serological and genetic pathways that were investigated in the practicum of this 
project.  Details of this model are summarised in  Figure A 7.2.   
7.1.2 Important outcomes of the project 
Outcomes from this project that convey new information relevant to the laboratory 
based diagnosis and management of SLE, or which imply mechanistic information are 
summarised below. 
v Quantitation of IL-17 and Th17 cells in treated SLE patients is not justified.  
Future research will be required to confirm the relevance and potential role 
of gd T cells and the mDC2 cells in both newly diagnosed and treated SLE 
patients. 
v Quantitation of αC1q ab in serum is not a useful assay for the diagnosis of SLE, 
however it is a useful assay for the exclusion of a diagnosis of SLE.  Anti-C1q 
ab levels should be investigated further for their utility in monitoring SLE 
patients for disease activity. 
v C4 gene copy number can be estimated by two real time PCR quantification 
methods.  These are a commercial TaqMan® assay detecting a five-amino acid 
difference between C4A and C4B genes in exon 26, and a custom assay 
detecting the presence or absence of a retroviral HERV-K element in intron 
nine of C4 genes.  Both assays agreed well, but the C4A and C4B specific assay 
is more practicable for investigative use.  
v Concentrations of C4 protein in serum correlate with total C4 GCN (ie both 
C4A and C4B genes) in human populations, but variance, especially in SLE 
patients, makes prediction of individual serum C4 concentrations from C4 
GCN unreliable, except in rare instances of C4 gene deficiency.  Hence, despite 
the complexity of the complement C4 genomic region, with an average of four 
C4A and B genes per individual, the synthesis of C4 protein behaves in the 
same manner as other conventional protein synthesising genes for which 
serum concentration reflects gene copy number (see also Chapter 5). 
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v Low C4 serum concentrations in SLE would appear to be the result of 
consumption rather than defective synthesis.  In this study low C4A or C4B 
GCNs are not risk factors for SLE.  Furthermore, deficient synthesis due to the 
rare frameshift CT insertion in C4 genes, nor the presence of the HERV-K 
retroviral element does not appear to contribute significantly to serum C4 
concentrations. 
v Assays for the presence of either the CT frameshift insertion, or the presence 
of the HERV-K retroviral element, in C4 genes is not useful in the diagnosis 
and monitoring of SLE.   
v Specific genotypes at the polymorphic DNASE I locus are not associated with 
SLE, and serum concentrations of DNASE I are not useful in the diagnosis of 
SLE. 
7.1.3 Commentary  
It was expected that IL17 concentrations and proportions of Th17 cells would be 
increased in managed SLE patients.  In contrast, we found very low frequencies in the 
SLE cohort, and synthesis of IL17 was increased in gd T cells as opposed to Th17.  We 
also found a reversal in the proportions of mDC1 & mDC2 in SLE patients, and mDC2 
correlated with the frequencies of the gd T cell subset.  In SLE patients, we found a 
relative increase in serum concentrations of inflammatory cytokines IFNγ TNFα, MCP-
1, IL-6, IL-8 and IL-18, indicating inflammatory signatures despite treatments.  Low 
dose prednisolone (349), hydroxychloroquine, azathioprine, methotrexate and 
mycophenolate mophetil are widely used drug treatments for SLE (350, 351).  Anti-
malarial treatments exert their effect via multiple molecular pathways that include 
anti-thrombic, anti-lipidic and anti-inflammatory (352).  Plasmacytoid dendritic cells 
producing IFNa promoting B and T cell proliferation are targeted by anti-CD20 
therapies (353).  Mycophenolate mofetil regulates CD4+ T cell polarisation by 
inhibiting the expression of CD40L (354).  Hence, these treatments should suppress 
plasmacytoid DCs, preventing T cell activation and further differentiation of Th17 
cells.  We suggest therefore that the drug therapies of the SLE patients investigated 
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suppressed TH17 cell numbers, while permitting a gd T cell/mDC2 axis to maintain 
ongoing inflammations 
Defective apoptosis is accompanied by binding of complement C1q to apoptotic 
debris with subsequent aC1q ab generation.  It was observed that aC1q ab levels 
were elevated in SLE patients compared to controls, with all individuals tested 
manifesting some, albeit below the advocated cut-off level recommended by the 
manufacturer.  In addition, quantitation of αC1q ab serum concentrations 
demonstrated that groups of SLE patients can be identified based on their 
concentrations levels, which are associated with specific co-morbidities (i.e. renal 
syndrome) and combined treatment regimen comprised of steroids, anti-malarial 
and immune-suppressant therapies.  The levels of serum aC1q ab correlated with 
dsDNA antibody but not with serum C1q protein levels in the SLE patients.  
Measurement of aC1q ab is not advocated for diagnosis of SLE, but is certainly useful 
for its exclusion.  
Quantitation of serum protein levels of complements C1q, C2, C3 and C4 are used in 
routine testing for the monitoring of SLE as autoantibodies generated in active 
disease leads to activation and consumption of the classical pathway complement 
proteins, which is reflected in the low serum levels of these components.  In our 
study, low C4 serum protein concentrations were clearly of diagnostic importance for 
SLE.  However, deficiencies of complement proteins C1q, C2 and C4 remain as 
anomalous well-known risk factors for SLE for which the mechanism(s) remain 
elusive.   
It was shown that for both the SLE and control cohorts the concentrations of serum 
C4 proteins were correlated with GCN, but variation in individuals precluded it 
usefulness in predicting one from the other.  Consumption of C4 in tissues is probably 
the mechanism by which the serum concentrations remain low despite treatments in 
some individuals, rather than deficient synthesis due to either lower C4A and/or C4B 
GCN.  Furthermore, these results did not support low C4A or C4B GCN as a risk factor 
for SLE, although this view is often advocated (81).  Contrary to published reports 
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(318, 320), the HERV-K retroviral element had no effect on the serum C4 protein 
synthesis, nor was the CT insertion associated with SLE.   
Endonucleases such as DNASE I are important for the degradation of apoptotic 
material (330).  Hence, defective DNASE I activity/ protein synthesis would imply a 
significant risk factor for SLE by way of deficient clearance of apoptotic debris.   
Decreased DNASE I concentrations in patients relative to controls were not observed 
and similar levels in diseased and non-diseased groups imply a functioning enzyme in 
both.  In addition, the typing of polymorphisms and genotypes identified at the 
DNASE I locus indicated no association with SLE pathology, although individuals with 
a deficiency of DNASE I are associated with symptoms of SLE.   
Based on the above results, we propose a variation of this mechanistic process by 
which, in the presence of treatment regimens, mDC2 and gd T cells recognise 
apoptotic material and cooperate leading to the synthesis of intracellular IL17 by gd 
T cells, resulting in chronic inflammation.  Irrespective of DNASE I enzyme status, 
apoptotic material is recognised and targeted by C1q molecules, which induces the 
production of αC1q ab in the kidneys of SLE patients.  Bound C4 and αC1q ab to ICs 
and synthesis of intracellular IL17 are events which result in chronic inflammation 
and tissue damage.  For the convenience of the reader an updated version of our 
proposed mechanisms (Figure A 7.2) is now available in Figure 7.1.   
7.2 Caveats 
In the recruitment of patients, we were reliant on generous colleagues and clinicians 
from the hospitals involved.  It was extremely beneficial to have direct contact with 
them.  This enabled a clear understanding of the processes involved in the monitoring 
and treatment of patients.  However, we found that hospital records did not report 
the same information consistently, resulting in incomplete data for some patients.  
Furthermore, hard copies of the patients’ records varied considerably, often 
containing disparate information which frustrated comparisons.   The digitisation of 
medical records, which is gaining pace in developed nations, will reduce this type of 
problem in future studies.  
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With the advantage of hindsight, it became clear that working with SLE patients that 
included only diagnosed and treated individuals imposed some limitations on the 
interpretation of results.  At the commencement of the project it was expected that 
some of the cohort would compromise newly diagnosed SLE patients, but 
unfortunately this did not eventuate.  In addition, due to ethical, funding constraints 
and time limitations, we were unable to collect blood samples sequentially for 
longitudinal studies.   
In retrospect, the cellular studies should have included an assay for mediators of 
apoptosis, together with additional cluster of differentiation and activation markers 
for characterisation of DCs and T cells.  However, these were not included initially 
and there was no opportunity for repeating many of these flow cytometry based 
assays.  In similar vein, it was planned to assay DNASE I activity as well as DNASE I 
protein concentration.  However, the late withdrawal from the market of commercial 
kits for this assay prevented this outcome.  
Many differences were observed throughout this project between the test cohort of 
SLE patients and the control group.  The interpretation of these differences was 
initially determined by estimating a “p-value” relative to the null hypothesis, usually 
that there is no real difference between groups.  As the project progressed, it was 
clear that this simplistic approach to identifying a discovery was unsatisfactory and 
should no longer be used (for example, see editorial comment, Nature 551, page 557 
30/11/17).  A p-value represents a statement of the probability that the differences 
observed are real.  However, estimating the probability of a false discovery is also 
equally important in concluding whether a “real” discovery has been observed.  
Hence, many research publications now require a more rigorous interpretation of 
research data.  Consequently, in this thesis and cognate publications, we have 
reported conventional p values for all “results”; however only those results with p 
values less than 0.001 are interpreted as possible ‘discoveries’ that should in general 
terms be reproducible.  The availability of complex datasets incorporating genomic 
sequences and other aspects of bioinformatical research increases the necessity for 
more rigorous statistical evaluation of numerical data.   
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7.3 The Forward View 
Over recent decades the diagnosis and management of SLE has improved 
dramatically.  Mortality from SLE has declined largely due to the use of 
immunosuppressive and anti-inflammatory drugs, and improved laboratory medicine 
to monitor and diagnose this multifaceted autoimmune disease.  It is noteworthy that 
juvenile SLE is still associated with a high mortality rate and overall, cures remain 
elusive.  Despite intensive research efforts over past decades, the aetiology of SLE 
remains incompletely understood.  Indeed, it seems likely that the pathology of SLE 
derives from aberrant inflammatory responses arising from multiple distinct 
mechanisms in genetically predisposed individuals.  Although the mechanism of 
deficient apoptosis explored in this project has been useful in interpreting outcomes, 
this hypothesis will not explain all occurrences of SLE.  
With the advantage of hindsight, identifying genetic and environmental factors that 
predispose to SLE seem important topics for future research.  The incidence of SLE in 
most communities seems to have remained relatively stable over many years.  Hence, 
it seems that more research to identify genetic factors that predispose to SLE are 
likely to provide new knowledge clarifying mechanistic pathways in SLE with the 
potential for more curative treatments.  The advent of affordable whole genome 
sequencing together with sophisticated software for interrogating sequence 
databases opens a door to exciting progress for many diseases including SLE.  The 
impressive discordance between both monozygotic and dizygotic twins requires an 
explanation that will probably answer many important questions relating to the role 
of both genetic and environmental factors in the pathology spectrum of SLE.  In our 
opinion therefore, a comparison of genomic sequences of both monozygotic and 
dizygotic twins, for which at least one twin is diagnosed with SLE, will be a productive 
way forward in identifying the factors that contribute and/or predispose to SLE in 
humans.  Such twins, although relatively rare, occur sufficiently frequently that 
creating a national or international database is possible.  This approach will be more 
informative, than extending genome wide association studies that are open to many 
levels of interpretation.  The way ahead is exciting and holds the promise of cures 
rather than treatments. 
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7.4 Figures 
 
Figure 7.1: The figure shows the final adjusted mechanisms pertaining to SLE pathology in this cohort. 
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230. Crispin JC, Martıńez A, Alcocer-Varela J. Quantification of regulatory T cells in 
patients with systemic lupus erythematosus. J Autoimmun. 2003;21(3):273-6. 
231. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global 
natural regulatory T cell depletion in active systemic lupus erythematosus. J 
Immunol. 2005;175(12):8392-400. 
232. Lee JH, Wang LC, Lin YT, Yang YH, Lin DT, Chiang BL. Inverse correlation 
between CD4+ regulatory T-cell population and autoantibody levels in paediatric 
patients with systemic lupus erythematosus. Immunology. 2006;117(2):280-6. 
233. Habibagahi M, Habibagahi Z, Jaberipour M, Aghdashi A. Quantification of 
regulatory T cells in peripheral blood of patients with systemic lupus erythematosus. 
Rheumatol Int. 2011;31(9):1219-25. 
234. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory 
cell function in patients with active systemic lupus erythematosus. J Immunol. 
2007;178(4):2579-88. 
235. Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN. Reduced 
number and function of CD4+CD25highfoxp3+ regulatory T cells in patients with 
systemic lupus erythematosus. Adv Exp Med Biol. 2007;601:113-9. 
236. Barath S, Soltesz P, Kiss E, Aleksza M, Zeher M, Szegedi G, et al. The severity 
of systemic lupus erythematosus negatively correlates with the increasing number of 
CD4+CD25(high)foxp3+ regulatory t cells during repeated plasmapheresis treatments 
of patients. Autoimmunity. 2007;40(7):521-8. 
237. Golding A, Hasni S, Illei G, Shevach EM. The percentage of foxp3+helios+ treg 
cells correlates positively with disease activity in systemic lupus erythematosus. 
Arthritis Rheum. 2013;65(11):2898-906. 
238. Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, Blank N, et al. Reduced 
CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -
/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis 
Rheum. 2008;58(7):2120-30. 
239. Yates J, Whittington A, Mitchell P, Lechler RI, Lightstone L, Lombardi G. 
Natural regulatory T cells: Number and function are normal in the majority of patients 
with lupus nephritis. Clin Exp Immunol. 2008;153(1):44-55. 
240. Franz B, Fritzsching B, Riehl A, Oberle N, Klemke CD, Sykora J, et al. Low 
number of regulatory T cells in skin lesions of patients with cutaneous lupus 
erythematosus. Arthritis Rheum. 2007;56(6):1910-20. 
241. Zhao SS, Li XM, Li XP, Zhai ZM, Chen Z, Ma Y, et al. Expression of CD4+ CD25+ 
CD127(low/-) T cells in patients with systemic lupus erythematosus. Zhonghua Yi Xue 
Za Zhi. 2008;88(7):453-6. 
242. Bonelli M, Savitskaya A, Von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, et 
al. Quantitative and qualitative deficiencies of regulatory T cells in patients with 
systemic lupus erythematosus (SLE). Int Immunol. 2008;20(7):861-8. 
243. Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis 
of peripheral blood foxp3-expressing T cells in systemic lupus erythematosus and 
rheumatoid arthritis patients. Eur J Clin Invest. 2007;37(12):987-96. 
  
 125 
244. Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+,CD25+ 
regulatory T cells in untreated active systemic lupus erythematosus secondary to 
interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 
2008;58(3):801-12. 
245. Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE. Clinical significance of 
increased CD4CD25foxp3 T cells in patients with new-onset systemic lupus 
erythematosus. Ann Rheum Dis. 2008;67(7):1037. 
246. Jury EC, Flores-Borja F, Kalsi HS, Lazarus M, Isenberg DA, Mauri C, et al. 
Abnormal CTLA-4 function in T cells from patients with systemic lupus 
erythematosus. Eur J Immunol. 2010;40(2):569-78. 
247. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage 
of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat 
Immunol. 2005;6(11):1133-41. 
248. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et 
al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from 
the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123-32. 
249. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. 
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and 
granulocyte colony-stimulating factor expression, neutrophil recruitment, and host 
defense. J Exp Med. 2001;194(4):519-27. 
250. Barin JG, Baldeviano GC, Talor MV, Wu L, Ong S, Quader F, et al. Macrophages 
participate in il-17-mediated inflammation. Eur J Immunol. 2012;42(3):726-36. 
251. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, 
Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human 
interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8(6):639-46. 
252. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, et al. Th17 and natural treg cell 
population dynamics in systemic lupus erythematosus. Arthritis Rheum. 
2009;60(5):1472-83. 
253. Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 
and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-
mediated inflammation in auto-immunity. Clin Immunol. 2008;127(3):385-93. 
254. Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J, et al. Dysregulated balance 
of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther. 
2010;12(2):R53. 
255. Dolff S, Quandt D, Wilde B, Feldkamp T, Hua F, Cai X, et al. Increased 
expression of costimulatory markers 134 and CD80 on interleukin-17 producing T 
cells in patients with systemic lupus erythematosus. Arthritis Res Ther. 
2010;12(4):R150. 
256. Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, Lan JL. The potential role of 
Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus. 
2012;21(13):1385-96. 
257. Rana A, Minz RW, Aggarwal R, Anand S, Pasricha N, Singh S. Gene expression 
of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic 
lupus erythematosus. Lupus. 2012;21(10):1105-12. 
258. Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S. Interleukin-17 expression positively 
correlates with disease severity of lupus nephritis by increasing anti-double-stranded 
  
 126 
DNA antibody production in a lupus model induced by activated lymphocyte derived 
DNA. E58161. PloS One. 2013;8(3). 
259. Mengya Z, Hanyou M, Dong L, Xiaohong L, Lihua Z. Th17/treg imbalance 
induced by increased incidence of atherosclerosis in patients with systemic lupus 
erythematosus (SLE). J Int League Ass Rheum. 2013;32(7):1045-52. 
260. Estrada-Capetillo L, Hernandez-Castro B, Monsivais-Urenda A, Alvarez-
Quiroga C, Layseca-Espinosa E, Abud-Mendoza C, et al. Induction of Th17 
lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with 
rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol. 
2013;2013:584303. 
261. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, et al. 
Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology 
and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 
2009;10(7):778-85. 
262. Pisitkun P, Ha HL, Wang H, Claudio E, Tivy CC, Zhou H, et al. Interleukin-17 
cytokines are critical in development of fatal lupus glomerulonephritis. Immunity. 
2012;37(6):1104-15. 
263. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 
controls t cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 
2007;26(5):579-91. 
264. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, 
et al. Production of transforming growth factor beta by human T lymphocytes and its 
potential role in the regulation of T cell growth. J Exp Med. 1986;163(5):1037-50. 
265. Nakamura K, Kitani A, Strober W. Cell contact-dependent 
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-
bound transforming growth factor beta. J Exp Med. 2001;194(5):629-44. 
266. Kitani A, Chua K, Nakamura K, Strober W. Activated self-MHC-reactive T cells 
have the cytokine phenotype of Th3/t regulatory cell 1 T cells. J Immunol. 
2000;165(2):691-702. 
267. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W. Transforming 
growth factor (TGF)-beta1-producing regulatory T cells induce SMAD-mediated 
interleukin 10 secretion that facilitates coordinated immunoregulatory activity and 
amelioration of TGF-beta1-mediated fibrosis. J Exp Med. 2003;198(8):1179-88. 
268. Konkel JE, Zhang D, Zanvit P, Chia C, Zangarle-Murray T, Jin W, et al. 
Transforming growth factor-beta signaling in regulatory T cells controls T helper-17 
cells and tissue-specific immune responses. Immunity. 2017;46(4):660-74. 
269. Su D, Shen M, Li X, Sun L. Roles of T cells in the pathogenesis of autoimmune 
diseases. Clin Dev Immunol. 2013;2013:6. 
270. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et 
al. IL-17-producing human peripheral regulatory T cells retain suppressive function. 
Blood. 2009;113(18):4240. 
271. Voo K, Wang YH, Santori F, Boggiano C, Wang YH, Arima K, et al. Identification 
of IL-17-producing foxp3 super(+) regulatory T cells in humans. Proc Natl Acad Sci. 
2009;106(12):4793-8. 
272. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, 
et al. Dc activated via Dectin-1 convert Treg into IL-17 producers. Eur J Immunol. 
2008;38(12):3274-81. 
  
 127 
273. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: Regulatory T cells induce 
CD4+CD25-foxp3- T cells or are self-induced to become Th17 cells in the absence of 
exogenous TGF- J Immunol. 2007;178(11):6725-9. 
274. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and 
inflammatory diseases. Autoimmun Rev. 2014;13(6):668-77. 
275. Klarquist J, Zhou Z, Shen N, Janssen EM. Dendritic cells in systemic lupus 
erythematosus: From pathogenic players to therapeutic tools. 2016;2016. 
276. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic 
lupus erythematosus are clustered in two populations of surface structures on 
apoptotic keratinocytes. J Exp Med. 1994;179(4):1317-30. 
277. Chan VS, Nie YJ, Shen N, Yan S, Mok MY, Lau CS. Distinct roles of myeloid and 
plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev. 
2012;11(12):890-7. 
278. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus 
erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2001;76:227-
324. 
279. Rovere P, Sabbadini MG, Vallinoto C, Fascio U, Rescigno M, Crosti M, et al. 
Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory 
context - role of opsonizing anti-beta(2)-glycoprotein I antibodies. Arthritis Rheum. 
1999;42(7):1412-20. 
280. Jin O, Kavikondala S, Mok MY, Sun L, Gu J, Fu R, et al. Abnormalities in 
circulating plasmacytoid dendritic cells in patients with systemic lupus 
erythematosus. Arthritis Res Ther. 2010;12(4):R137. 
281. Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. 
Superior antigen cross-presentation and XCR1 expression define human 11c + 141 + 
cells as homologues of mouse CD8 + dendritic cells. J Exp Med. 2010;207(6):1273-81. 
282. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human 
141 + (BDCA-3) + dendritic cells (DCs) represent a unique myeloid dc subset that cross-
presents necrotic cell antigens. J Exp Med. 2010;207(6):1247-60. 
283. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology. 
2013;140(1):22-30. 
284. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. 
Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, 
amplifying Th17 responses and autoimmunity. Immunity. 2009;31(2):331-41. 
285. Su D, Shen M, Li X, Sun L. Roles of gammadelta T cells in the pathogenesis of 
autoimmune diseases. Clin Dev Immunol. 2013;2013:985753. 
286. Barros-Martins J, Schmolka N, Fontinha D, Pires de Miranda M, Simas JP, Brok 
I, et al. Effector γδ t cell differentiation relies on master but not auxiliary Th cell 
transcription factors. J Immunol. 2016;196(9):3642. 
287. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, et al. 
Gamma/delta T cells are the predominant source of interleukin-17 in affected joints 
in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum. 
2009;60(8):2294-303. 
288. Ma L, Zhao P, Jiang Z, Shan Y, Jiang Y. Imbalance of different types of CD4(+) 
forkhead box protein 3 (foxp3)(+) T cells in patients with new-onset systemic lupus 
erythematosus. Clin Exp Immunol. 2013;174(3):345-55. 
  
 128 
289. Da Silva JC, Mariz HA, Da Rocha Júnior LF, Santana de Oliveira PS, Dantas AT, 
Duarte ALBP, et al. Hydroxychloroquine decreases Th17-related cytokines in systemic 
lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013;68(6):766-71. 
290. Mahajan A, Herrmann M, Munoz LE. Clearance deficiency and cell death 
pathways: A model for the pathogenesis of SLE. Front Immunol. 2016;7:35. 
291. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A key system for 
immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-97. 
292. Diebolder CA, Beurskens FJ, De Jong RN, Koning RI, Strumane K, Lindorfer MA, 
et al. Complement is activated by igg hexamers assembled at the cell surface. Science. 
2014;343(6176):1260-3. 
293. Beurskens FJ, Van Schaarenburg RA, Trouw LA. C1q, antibodies and anti-C1q 
autoantibodies. Mol Immunol. 2015;68(1):6-13. 
294. Fang QY, Yu F, Tan Y, Xu LX, Wu LH, Liu G, et al. Anti-C1q antibodies and IgG 
subclass distribution in sera from chinese patients with lupus nephritis. Nephrol Dial 
Transplant. 2009;24(1):172-8. 
295. Uwatoko S, Aotsuka S, Okawa M, Egusa Y, Yokohari R, Aizawa C, et al. C1q 
solid-phase radioimmunoassay: Evidence for detection of antibody directed against 
the collagen-like region of c1q in sera from patients with systemic lupus 
erythematosus. Clin Exp Immunol. 1987;69(1):98-106. 
296. Katsumata Y, Miyake K, Kawaguchi Y, Okamoto Y, Kawamoto M, Gono T, et al. 
Anti-c1q antibodies are associated with systemic lupus erythematosus global activity 
but not specifically with nephritis: A controlled study of 126 consecutive patients. 
Arthritis Rheum. 2011;63(8):2436-44. 
297. Zivković V, Stanković A, Cvetković T, Mitić B, Kostić S, Nedović J, et al. Anti-
dsdna, anti-nucleosome and anti-C1q antibodies as disease activity markers in 
patients with systemic lupus erythematosus. Srpski arhiv za celokupno 
lekarstvo.142(7-8):431-6. 
298. Chi S, Xue J, Li F, Zhu C, Yu Y, Li H, et al. Correlation of serum soluble 
interleukin-7 receptor and anti-C1q antibody in patients with systemic lupus 
erythematosus. Autoimmun Dis. 2016;2016:8252605-. 
299. Sinico RA, Radice A, Ikehata M, Giammarresi G, Corace C, Arrigo G, et al. Anti-
C1q autoantibodies in lupus nephritis: Prevalence and clinical significance. Ann N Y 
Acad Sci. 2005;1050:193-200. 
300. De Liso F, Matinato C, Novembrino C, Radice A, Raffiotta F, Ronchi M, et al. 
Value of a commercial kit for detecting anti-C1q autoantibodies and correlation with 
immunological and clinical activity of lupus nephritis. Clin Chem Lab Med. 
2015;53(11):1771-7. 
301. Tan Y, Song D, Wu LH, Yu F, Zhao MH. Serum levels and renal deposition of 
C1q complement component and its antibodies reflect disease activity of lupus 
nephritis. BMC Nephrol. 2013;14:63. 
302. Chen Z, Wang GS, Wang GH, Li XP. Anti-C1q antibody is a valuable biological 
marker for prediction of renal pathological characteristics in lupus nephritis. Clin 
Rheumatol. 2012;31(9):1323-9. 
303. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q 
antibodies in nephritis: Correlation between titres and renal disease activity and 
positive predictive value in systemic lupus erythematosus. Ann Rheum Dis. 
2005;64(3):444-8. 
  
 129 
304. Abdel Kader MSEM, Abd Elaziz MM, Ahmed DH. Role of serum anti-C1q 
antibodies as a biomarker for nephritis activity in pediatric and adolescent Egyptian 
female patients with SLE. Expert Opin Med Diagn. 2012;6(6):489-98. 
305. Chi S, Yu Y, Shi J, Zhang Y, Yang J, Yang L, et al. Antibodies against C1q are a 
valuable serological marker for identification of systemic lupus erythematosus 
patients with active lupus nephritis. Dis Markers. 2015;2015:450351-. 
306. Bock M, Heijnen I, Trendelenburg M. Anti-C1q antibodies as a follow-up 
marker in SLE patients. PloS One. 2015;10(4):e0123572-e. 
307. Magro-Checa C, Schaarenburg RA, Beaart HJL, Huizinga TWJ, Steup-Beekman 
GM, Trouw LA. Complement levels and anti-C1q autoantibodies in patients with 
neuropsychiatric systemic lupus erythematosus. Lupus. 2016;25(8):878-88. 
308. Margery-Muir AA, Bundell C, Nelson D, Groth DM, Wetherall JD. Gender 
balance in patients with systemic lupus erythrematosus. Autoimmun Rev. 2017. 
309. Matthew CP, Marina B. Are anti-C1q antibodies different from other SLE 
autoantibodies? Nat Rev Rheumatol. 2010;6(8):490. 
310. Franchin G, Son M, Kim SJ, Ben-Zvi I, Zhang J, Diamond B. Anti-DNA antibodies 
cross-react with C1q. J Autoimmun. 2013;44:34-9. 
311. Vanhecke D, Roumenina LT, Wan H, Osthoff M, Schaller M, Trendelenburg M. 
Identification of a major linear C1q epitope allows detection of systemic lupus 
erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked 
immunosorbent assay. Arthritis Rheum. 2012;64(11):3706-14. 
312. Grootscholten C, Dieker JW, McGrath FD, Roos A, Derksen RH, van der Vlag J, 
et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients 
with proliferative lupus nephritis treated with cyclophosphamide pulses or 
azathioprine/methylprednisolone. Ann Rheum Dis. 2007;66(5):693-6. 
313. Carroll MC, Campbell RD, Bentley DR, Porter RR. A molecular map of the 
human major histocompatibility complex class III region linking complement genes 
C4, C2 and factor B. Nature. 1984;307(5948):237-41. 
314. Yu CY, Belt KT, Giles CM, Campbell RD, Porter RR. Structural basis of the 
polymorphism of human complement components C4A and C4B: Gene size, reactivity 
and antigenicity. EMBO J. 1986;5(11):2873-81. 
315. Yu CY. The complete exon-intron structure of a human complement 
component C4A gene. DNA sequences, polymorphism, and linkage to the 21-
hydroxylase gene. J Immunol. 1991;146(3):1057-66. 
316. Szilagyi A, Blasko B, Szilassy D, Fust G, Sasvari-Szekely M, Ronai Z. Real-time 
PCR quantification of human complement C4A and C4B genes. BMC Genet. 2006;7:1. 
317. Dangel AW, Mendoza AR, Baker BJ, Daniel CM, Carroll MC, Wu LC, et al. The 
dichotomous size variation of human complement C4 genes is mediated by a novel 
family of endogenous retroviruses, which also establishes species-specific genomic 
patterns among old world primates. Immunogenetics. 1994;40(6):425-36. 
318. Yang Y, Chung EK, Zhou B, Blanchong CA, Yu CY, Fust G, et al. Diversity in 
intrinsic strengths of the human complement system: Serum C4 protein 
concentrations correlate with C4 gene size and polygenic variations, hemolytic 
activities, and body mass index. J Immunol. 2003;171(5):2734-45. 
319. Dragon-Durey MA, Rougier N, Clauvel JP, Caillat-Zucman S, Remy P, Guillevin 
L, et al. Lack of evidence of a specific role for C4A gene deficiency in determining 
  
 130 
disease susceptibility among C4-deficient patients with systemic lupus 
erythematosus (SLE). Clin Exp Immunol. 2001;123(1):133-9. 
320. Ittiprasert W, Kantachuvesiri S, Pavasuthipaisit K, Verasertniyom O, 
Chaomthum L, Totemchokchyakarn K, et al. Complete deficiencies of complement 
C4A and C4B including 2-bp insertion in codon 1213 are genetic risk factors of 
systemic lupus erythematosus in thai populations. J Autoimmun. 2005;25(1):77-84. 
321. Lokki. ML, Circolo. A, Ahokas. P, Rupert. KL, Yu. CY, Colten HR. Deficiency of 
human complement protein C4 due to identical frameshift mutations in the C4A and 
C4B genes. J Immunol. 1999;162:3687-93. 
322. Boteva L, Morris DL, Cortes-Hernandez J, Martin J, Vyse TJ, Fernando MM. 
Genetically determined partial complement C4 deficiency states are not independent 
risk factors for SLE in uk and spanish populations. Am J Hum Genet. 2012;90(3):445-
56. 
323. Boteva L, IMAGEN, Wu YL, Cortes-Hernandez J, Martin J, Vyse TJ, et al. 
Determination of the loss of function complement C4 exon 29 CT insertion using a 
novel paralog-specific assay in healthy uk and spanish populations. PloS One. 
2011;6(8):e22128. 
324. Ardoin SP, Jarjour WN. Biomarkers in systemic lupus erythematosus.  
Systemic lupus erythematosus. Boston: Academic Press; 2016. p. 43-51. 
325. Atkinson JP, Yu CY. The complement system in systemic lupus erythematosus.  
Systemic lupus erythematosus. Boston: Academic Press; 2016. p. 81-112. 
326. Puah SM, Lian LH, Chew CH, Chua KH, Tan SY. A study of association of the 
complement C4 mutations with systemic lupus erythematosus in the malaysian 
population. Lupus. 2007;16(9):750-4. 
327. Polley MJ. Inherited C2 deficiency in man: Lack of immunochemically 
detectable C2 protein in serums from deficient individuals. Science. 
1968;161(3846):1149-51. 
328. Pouw RB, Brouwer MC, GeisSLEr J, van Herpen LV, Zeerleder SS, Wuillemin 
WA, et al. Complement factor H-related protein 3 serum levels are low compared to 
factor H and mainly determined by gene copy number variation in CFHR3. PloS One. 
2016;11(3):e0152164. 
329. Wu YL, Hauptmann G, Viguier M, Yu CY. Molecular basis of complete 
complement C4 deficiency in two North-African families with systemic lupus 
erythematosus. Genes Immun. 2009;10(5):433-45. 
330. Yasuda T, Kishi K, Yanagawa Y, Yoshida A. Structure of the human 
deoxyribonuclease-I (DNASE-I) gene - identification of the nucleotide substitution 
that generates its classical genetic-polymorphism. Ann Hum Genet. 1995;59(Pt 1):1-
15. 
331. Gaipl US, Beyer TD, Heyder P, Kuenkele S, Bottcher A, Voll RE, et al. 
Cooperation between C1q and DNASE I in the clearance of necrotic cell-derived 
chromatin. Arthritis Rheum. 2004;50(2):640-9. 
332. Napirei M, Wulf S, Mannherz HG. Chromatin breakdown during necrosis by 
serum DNASE1 and the plasminogen system. Arthritis Rheum. 2004;50(6):1873-83. 
333. Koyama R, Arai T, Kijima M, Sato S, Miura S, Yuasa M, et al. DNASE gamma, 
DNASE i and caspase-activated DNASE cooperate to degrade dead cells. Genes Cells. 
2016;21(11):1150-63. 
  
 131 
334. Yasuda T, Nadano D, Tenjo E, Takeshita H, Sawazaki K, Nakanaga M, et al. 
Genotyping of human deoxyribonuclease I polymorphism by the polymerase chain 
reaction. Electrophoresis. 1995;16(10):1889-93. 
335. Yasuda T, Takeshita H, Iida R, Kogure S, Kishi K. A new allele, DNASE1*6, of 
human deoxyribonuclease I polymorphism encodes an ARG to CYS substitution 
responsible for its instability. Biochem Biophy res comm. 1999;260(1):280-3. 
336. Yasuda T, Nadano D, Takeshita H, Tenjo E, Kishi K. Moelecular analysis of the 
third allele of human deoxyribonuclease I polymorphism. Ann Hum Genet. 
1995;59:139 - 47. 
337. Yasuda T, Nadano D, Takeshita H, Tenjo E, Sawazaki K, Ootani M, et al. The 
molecular basis for genetic polymorphism of human deoxyribonuclease I: 
Identification of the nucleotide substitution that generates the fourth allele. FEBS 
Lett. 1995;359:211-4. 
338. Iida R, Yasuda T, Aoyama M, Tsubota E, Kobayashi M, Yuasa I, et al. The fifth 
allele of the human deoxyribonuclease I (DNASE I) polymorphism. Electrophoresis. 
1997;18(11):1936-9. 
339. Camicia G, Aranda F, Munoz SA, Allievi A, Orden AO, Trobo R, et al. Association 
between severe disease course and nephritis with q222r polymorphism in DNASE I 
gene among lupus patients: An argentine multicenter study. Acta Reumatol Port. 
2016;41(2):138-44. 
340. Yasuda T, Iida R, Ueki M, Tsukahara T, Nakajima T, Kominato Y, et al. A novel 
56-bp variable tandem repeat polymorphism in the human deoxyribonuclease I gene 
and its population data. Leg Med. 2004;6(4):242-5. 
341. AlFadhli S, AlTamimy B, Kharrat N, AlSaeid K, Haider MZ, Rebai A. Molecular 
analysis of HumDn1 VNTR polymorphism of the human deoxyribonuclease I in 
systemic lupus erythematosus. Int J Immunogenet. 2010;37(1):5-8. 
342. Takeshita H, Yasuda T, Nakashima Y, Mogi K, Kishi K, Shiono H, et al. 
Geographical north-south decline in DNASE1*2 in Japanese populations. Hum Biol. 
2001;73(1):129-34. 
343. Yasuda T, Takeshita H, Iida R, Yuasa I, Kishi K. Population studies of human 
deoxyribonuclease I polymorphism. Hum Hered. 1997;47(3):121-4. 
344. Fujihara J, Ueki M, Yasuda T, Iida R, Soejima M, Koda Y, et al. Functional and 
genetic survey of all known single-nucleotide polymorphisms within the human 
deoxyribonuclease I gene in wide-ranging ethnic groups. DNA Cell Biol. 
2011;30(4):205-17. 
345. Fujihara J, Hieda Y, Takayama K, Xue Y, Nakagami N, Imamura S, et al. Analysis 
of genetic polymorphism of deoxyribonuclease I in Ovambo and Turk populations 
using a genotyping method. Biochem Genet. 2005;43(11-12):629-35. 
346. Ni. Y, Zhang. J, Sun. B. Deoxyribonuclease I gene polymorphism in Han Chinese 
population: Frequency and effect on glucose and lipid parameters. Mol Biol Rep. 
2008;35:5. 
347. Mohammadoo-Khorasani M, Musavi M, Mousavi M, Moossavi M, 
Khoddamian M, Sandoughi M, et al. Deoxyribonuclease I gene polymorphism and 
susceptibility to systemic lupus erythematosus. Clin Rheumaltol. 2016;35(1):101-5. 
348. Tsokos GC. Systemic lupus erythematosus in 2015: Cellular and metabolic 
requirements of effector T cells. Nat Rev Rheumatol. 2016;12(2):74-6. 
  
 132 
349. Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high 
versus low-medium prednisone doses for the treatment of systemic lupus 
erythematosus patients with high activity at diagnosis. Autoimmun Rev. 
2015;14(10):875-9. 
350. Elfving P, Puolakka K, Kautiainen H, Virta L, Pohjolainen T, Kaipiainen-Seppa ̈ 
nen O. Drugs used in incident systemic lupus erythematosus – results from the 
Finnish nationwide register 2000–2007. Lupus. 2016;25:4. 
351. Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal treatment 
patterns and associated outcomes in patients with newly diagnosed systemic lupus 
erythematosus. Clin Ther. 2016;38(3):610-24. 
352. Hodkinson B, Makda MA. Evidence-based treatment of systemic lupus 
erythematosus and its complications. S Afr Med J. 2015;105(12):1075. 
353. Bakshi J, Ismajli M, Rahman A. New therapeutic avenues in SLE. Best Pract Res 
Clin Rheumatol. 2015;29(6):794-809. 
354. Yang Y, Tang Q, Zhao M, Liang G, Wu H, Li D, et al. The effect of mycophenolic 
acid on epigenetic modifications in lupus CD4+T cells. Clin Immunol. 2015;158(1):67-
76. 
 
 
 
Every reasonable effort has been made to acknowledge the owners of copyright 
material.  I would be pleased to hear from any copyright owner who has been omitted 
or incorrectly acknowledged.   
  
 133 
Appendix A List of figures and tables  
A.1 Tables 
A.1.1 Chapter 2 tables 
Table A 1: Serology parameters for the SLE patients 
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Table A 2: Serology parameters for the control cohort. 
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A.1.2 Chapter 4 tables 
Table A 3: Sensitivity & specificity of the aC1q assay. 
aC1q ab Sensitivity Specificity *PVP + **PVN - 
Units/mL % SLE in true 
positive (TP) 
% non-SLE in 
true negative 
(TN) 
(TP/(TP+FP))%*** (TN(TN+FN))%*** 
5 89.3 24.2 65.4 54.5 
10 69.6 84.8 87.0 62.8 
20 57.1 90.9 91.4 55.6 
25 50.0 90.9 90.0 50.8 
30 41.1 90.9 88.0 46.9 
40 33.9 93.9 85.7 44.9 
100 16.1 100.0 100.0 41.3 
* Predictive positive value = likelihood a positive result indicates presence of disease 
** Predictive negative value = likelihood a negative result indicates absence of disease 
*** TP = number of values (individuals) above cut-off of interest in the SLE cohort; FP = number of values (individuals) above 
cut-off of interest in the control cohort; TN = number of values (individuals) below cut-off of interest in the control cohort; 
FN = number of values (individuals) below cut-off of interest in the SLE cohort. 
 
Table A 4: GraphPad Prism data (detailed) for the above Table A 3. 
Cut-off 
Sensitivit
y% Sensitivity 95% CI 
Specificity
% 95% CI 
Likelihood 
ratio 
Sensitivity 
% 
> 3.209 98.21 0.9821 90.45% to 99.95% 0 0% to 10.58% 0.9821 98.2 
> 3.48 96.43 0.9643 87.69% to 99.56% 0 0% to 10.58% 0.9643 96.4 
> 3.793 94.64 0.9464 85.13% to 98.88% 0 0% to 10.58% 0.9464 94.6 
> 4.056 94.64 0.9464 85.13% to 98.88% 3.03 0.07669% to 15.76% 0.976 94.6 
> 4.336 92.86 0.9286 82.71% to 98.02% 3.03 0.07669% to 15.76% 0.9576 92.9 
> 4.551 92.86 0.9286 82.71% to 98.02% 6.061 0.7426% to 20.23% 0.9885 92.9 
> 4.763 92.86 0.9286 82.71% to 98.02% 9.091 1.915% to 24.33% 1.021 92.9 
> 4.86 91.07 0.9107 80.38% to 97.04% 9.091 1.915% to 24.33% 1.002 91.1 
> 4.923 91.07 0.9107 80.38% to 97.04% 12.12 3.403% to 28.2% 1.036 91.1 
> 4.967 91.07 0.9107 80.38% to 97.04% 15.15 5.109% to 31.9% 1.073 91.1 
> 5.018 91.07 0.9107 80.38% to 97.04% 18.18 6.979% to 35.46% 1.113 91.1 
> 5.07 91.07 0.9107 80.38% to 97.04% 21.21 8.98% to 38.91% 1.156 91.1 
> 5.132 91.07 0.9107 80.38% to 97.04% 24.24 11.09% to 42.26% 1.202 91.1 
> 5.43 89.29 0.8929 78.12% to 95.97% 24.24 11.09% to 42.26% 1.179 89.3 
> 5.83 89.29 0.8929 78.12% to 95.97% 27.27 13.3% to 45.52% 1.228 89.3 
> 6.003 89.29 0.8929 78.12% to 95.97% 30.3 15.59% to 48.71% 1.281 89.3 
> 6.044 89.29 0.8929 78.12% to 95.97% 33.33 17.96% to 51.83% 1.339 89.3 
> 6.113 87.5 0.875 75.93% to 94.82% 33.33 17.96% to 51.83% 1.313 87.5 
> 6.215 85.71 0.8571 73.78% to 93.62% 33.33 17.96% to 51.83% 1.286 85.7 
> 6.411 85.71 0.8571 73.78% to 93.62% 36.36 20.4% to 54.88% 1.347 85.7 
> 6.576 83.93 0.8393 71.67% to 92.38% 36.36 20.4% to 54.88% 1.319 83.9 
> 6.646 83.93 0.8393 71.67% to 92.38% 39.39 22.91% to 57.86% 1.385 83.9 
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> 6.689 83.93 0.8393 71.67% to 92.38% 42.42 25.48% to 60.78% 1.458 83.9 
> 6.692 82.14 0.8214 69.6% to 91.09% 42.42 25.48% to 60.78% 1.427 82.1 
> 6.706 82.14 0.8214 69.6% to 91.09% 45.45 28.11% to 63.65% 1.506 82.1 
> 7.009 82.14 0.8214 69.6% to 91.09% 48.48 30.8% to 66.46% 1.595 82.1 
> 7.317 82.14 0.8214 69.6% to 91.09% 51.52 33.54% to 69.2% 1.694 82.1 
> 7.344 80.36 0.8036 67.57% to 89.77% 51.52 33.54% to 69.2% 1.657 80.4 
> 7.388 80.36 0.8036 67.57% to 89.77% 54.55 36.35% to 71.89% 1.768 80.4 
> 7.472 80.36 0.8036 67.57% to 89.77% 57.58 39.22% to 74.52% 1.894 80.4 
> 7.678 80.36 0.8036 67.57% to 89.77% 60.61 42.14% to 77.09% 2.04 80.4 
> 7.907 80.36 0.8036 67.57% to 89.77% 63.64 45.12% to 79.6% 2.21 80.4 
> 8.003 80.36 0.8036 67.57% to 89.77% 66.67 48.17% to 82.04% 2.411 80.4 
> 8.123 78.57 0.7857 65.56% to 88.41% 66.67 48.17% to 82.04% 2.357 78.6 
> 8.276 78.57 0.7857 65.56% to 88.41% 69.7 51.29% to 84.41% 2.593 78.6 
> 8.382 78.57 0.7857 65.56% to 88.41% 72.73 54.48% to 86.7% 2.881 78.6 
> 8.5 78.57 0.7857 65.56% to 88.41% 75.76 57.74% to 88.91% 3.241 78.6 
> 8.573 76.79 0.7679 63.58% to 87.02% 75.76 57.74% to 88.91% 3.167 76.8 
> 8.585 75 0.75 61.63% to 85.61% 75.76 57.74% to 88.91% 3.094 75.0 
> 8.833 73.21 0.7321 59.7% to 84.17% 75.76 57.74% to 88.91% 3.02 73.2 
> 9.173 71.43 0.7143 57.79% to 82.7% 75.76 57.74% to 88.91% 2.946 71.4 
> 9.627 71.43 0.7143 57.79% to 82.7% 78.79 61.09% to 91.02% 3.367 71.4 
> 10.02 71.43 0.7143 57.79% to 82.7% 81.82 64.54% to 93.02% 3.929 71.4 
> 10.07 71.43 0.7143 57.79% to 82.7% 84.85 68.1% to 94.89% 4.714 71.4 
> 10.16 69.64 0.6964 55.9% to 81.22% 84.85 68.1% to 94.89% 4.596 69.6 
> 10.29 69.64 0.6964 55.9% to 81.22% 87.88 71.8% to 96.6% 5.746 69.6 
> 10.73 67.86 0.6786 54.04% to 79.71% 87.88 71.8% to 96.6% 5.598 67.9 
> 11.5 66.07 0.6607 52.19% to 78.19% 87.88 71.8% to 96.6% 5.451 66.1 
> 12.45 64.29 0.6429 50.36% to 76.64% 87.88 71.8% to 96.6% 5.304 64.3 
> 13.59 62.5 0.625 48.55% to 75.08% 87.88 71.8% to 96.6% 5.156 62.5 
> 14.98 60.71 0.6071 46.75% to 73.5% 87.88 71.8% to 96.6% 5.009 60.7 
> 16.1 58.93 0.5893 44.98% to 71.9% 87.88 71.8% to 96.6% 4.862 58.9 
> 18.14 57.14 0.5714 43.22% to 70.29% 87.88 71.8% to 96.6% 4.714 57.1 
> 20.18 57.14 0.5714 43.22% to 70.29% 90.91 75.67% to 98.08% 6.286 57.1 
> 20.77 55.36 0.5536 41.47% to 68.66% 90.91 75.67% to 98.08% 6.089 55.4 
> 21.1 53.57 0.5357 39.74% to 67.01% 90.91 75.67% to 98.08% 5.893 53.6 
> 22.44 51.79 0.5179 38.03% to 65.34% 90.91 75.67% to 98.08% 5.696 51.8 
> 24.74 50 0.5 36.34% to 63.66% 90.91 75.67% to 98.08% 5.5 50.0 
> 25.99 48.21 0.4821 34.66% to 61.97% 90.91 75.67% to 98.08% 5.304 48.2 
> 26.68 46.43 0.4643 32.99% to 60.26% 90.91 75.67% to 98.08% 5.107 46.4 
> 27.21 44.64 0.4464 31.34% to 58.53% 90.91 75.67% to 98.08% 4.911 44.6 
> 27.32 42.86 0.4286 29.71% to 56.78% 90.91 75.67% to 98.08% 4.714 42.9 
> 29.9 41.07 0.4107 28.1% to 55.02% 90.91 75.67% to 98.08% 4.518 41.1 
> 34.41 39.29 0.3929 26.5% to 53.25% 90.91 75.67% to 98.08% 4.321 39.3 
> 36.56 37.5 0.375 24.92% to 51.45% 90.91 75.67% to 98.08% 4.125 37.5 
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> 36.85 37.5 0.375 24.92% to 51.45% 93.94 79.77% to 99.26% 6.188 37.5 
> 37.47 35.71 0.3571 23.36% to 49.64% 93.94 79.77% to 99.26% 5.893 35.7 
> 39.76 33.93 0.3393 21.81% to 47.81% 93.94 79.77% to 99.26% 5.598 33.9 
> 45.97 32.14 0.3214 20.29% to 45.96% 93.94 79.77% to 99.26% 5.304 32.1 
> 52.29 30.36 0.3036 18.78% to 44.1% 93.94 79.77% to 99.26% 5.009 30.4 
> 58.75 28.57 0.2857 17.3% to 42.21% 93.94 79.77% to 99.26% 4.714 28.6 
> 65.07 28.57 0.2857 17.3% to 42.21% 96.97 84.24% to 99.92% 9.429 28.6 
> 67.45 26.79 0.2679 15.83% to 40.3% 96.97 84.24% to 99.92% 8.839 26.8 
> 70.87 25 0.25 14.39% to 38.37% 96.97 84.24% to 99.92% 8.25 25.0 
> 75.39 23.21 0.2321 12.98% to 36.42% 96.97 84.24% to 99.92% 7.661 23.2 
> 80.16 21.43 0.2143 11.59% to 34.44% 96.97 84.24% to 99.92% 7.071 21.4 
> 84.07 19.64 0.1964 10.23% to 32.43% 96.97 84.24% to 99.92% 6.482 19.6 
> 86.95 17.86 0.1786 8.91% to 30.4% 96.97 84.24% to 99.92% 5.893 17.9 
> 99.43 16.07 0.1607 7.622% to 28.33% 96.97 84.24% to 99.92% 5.304 16.1 
> 110.4 16.07 0.1607 7.622% to 28.33% 100 89.42% to 100% 
 
16.1 
> 111.3 14.29 0.1429 6.375% to 26.22% 100 89.42% to 100% 
 
14.3 
> 116 12.5 0.125 5.176% to 24.07% 100 89.42% to 100% 
 
12.5 
> 135.1 10.71 0.1071 4.035% to 21.88% 100 89.42% to 100% 
 
10.7 
> 160.7 8.929 0.08929 2.963% to 19.62% 100 89.42% to 100% 
 
8.9 
> 181.1 7.143 0.07143 1.98% to 17.29% 100 89.42% to 100% 
 
7.1 
> 237.5 5.357 0.05357 1.119% to 14.87% 100 89.42% to 100% 
 
5.4 
> 290.7 3.571 0.03571 
0.4355% to 
12.31% 100 89.42% to 100% 
 
3.6 
> 334.1 1.786 0.01786 
0.0452% to 
9.553% 100 89.42% to 100% 
 
1.8 
 
Table A 5: Anti-C1q levels data for SLE patients and controls used to calculate column 4 and 5 in table A 3. 
SLE patients Controls 
3.1910 3.8525 
3.2260 4.4120 
3.7330 4.6890 
4.2585 4.8817 
4.8365 4.9630 
5.1885 4.9700 
6.0700 5.0657 
6.1560 5.0735 
6.5475 5.6700 
6.6900 5.9885 
7.3340 6.0165 
8.0260 6.2737 
8.5675 6.6027 
8.5770 6.6875 
8.5920 6.6935 
9.0740 6.7180 
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10.0910 7.3003 
10.3470 7.3540 
11.1125 7.4215 
11.8820 7.5210 
13.0140 7.8335 
14.1623 7.9785 
15.8010 8.2200 
16.3940 8.3315 
20.4620 8.4310 
21.0725 9.2717 
21.1180 9.9820 
23.7610 10.0557 
25.7150 10.2315 
26.2553 19.8890 
27.1040 36.8000 
27.3095 63.3603 
27.3260 109.9157 
32.4830  
36.3280  
36.9090  
38.0385  
41.4870  
50.4440  
54.1350  
66.7855  
68.1115  
73.6193  
77.1538  
83.1695  
84.9740  
88.9340  
110.9030  
111.6880  
120.3260  
149.8655  
171.4375  
190.7380  
284.3430  
297.0940  
371.1618  
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Table A 6: Data shows the number of individuals above/below cut-offs used for calculation in table A 3. 
Cut-off Above   Below Above   Below 
5.022 51 5 27 6 
> 10.02 40 16 6 27 
> 20.18 32 24 3 30 
> 25.99 27 29 3 30 
> 34.41 22 34 3 30 
> 45.97 18 38 3 31 
> 52.29 17 39 3 31 
> 65.07 16 40 3 32 
> 70.87 14 42 3 32 
> 80.16 12 44 3 32 
> 99.43 9 47 3 32 
> 110.4 9 47 0 33 
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A.1.3 Chapter 6 tables 
Table A 7: Correlation matrix between DNASE I and VNTR (HumDN1) loci and other parameters in SLE patients and healthy 
controls.
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Table A 8: Contingency table of DNASE I and VNTR (HumDN1) loci in SLE patients and healthy controls. 
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Table A 9:  Linkage disequilibria for haplotypes comprising the loci DNASE I on the left and VNTR (HumDN1) on the right. 
Population 
Haplotype 
(DNASE 
I/VNTR 
(HumDN1)) 
Number 
(%) 
p-
value 
(X2) 
Population 
Haplotype 
(DNASE 
I/VNTR 
(HumDN1)) 
Number 
(%) 
p-value 
(X2) 
SLE 
1/3 3 (2.7) 0.0821 (3.02) 
Controls 
1/3  Not observed 
1/4 22 (19.6) 
0.0001 
(32.67) 1/4 
15.5 
(23.5) 
0.0001 
(19.03) 
1/5 12 (10.7) 
0.0127 
(6.21) 1/5 7 (10.6) 
0.0652 
(3.40) 
1/6 7 (6.2) 0.0002 (13.97) 1/6 3.5 (5.3) 
0.0098 
(6.67) 
2/3 1 (0.8) 0.0821 (3.02) 2/3  
Not 
observed 
2/4 12 (10.7) 
0.0001 
(32.67) 2/4 
11.5 
(17.5) 
0.0001 
(19.03) 
2/5 29 (25.9) 
0.0127 
(6.21) 2/5 
16 
(24.2) 
0.0652 
(3.40) 
2/6 26 (23.2) 
0.0002 
(13.97) 2/6 
12.5 
(18.9) 
0.0098 
(6.67) 
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A.2 Figures 
A.2.1 Chapter 2 figures 
 
Figure A 7.1: Gates locations based on single stains and isotype controls. 
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A.2.2 Chapter 3 figures 
 
Figure A 7.2: Proposed theoretical cellular mechanism underlying SLE pathology. 
A.2.3 Chapter 5 figures 
 
Figure A 7.3: Graphical representation of two assay comparison in ascending order of serum [C4]. 
Differences between the Taqman™ C4A + C4B assay and the Taqman™ Custom assay for HERV-K retroviral element in C4 
genes.  Aggregate of SLE patients and controls in ascending order of serum concentrations 
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Figure A 7.4: Regression analysis of the C4 and HERV-K gene copy numbers. 
Linear regression showing the association between the C4A & C4B GCN and C4 short & long in SLE patients and healthy 
controls.  Linear equation and correlation coefficients are indicated on the graphs.   
 
 
Figure A 7.5: Distribution of gene copy numbers compared to published data. 
Data showing total C4, C4A, C4B, and HERV-K present (C4 long) or HERV-K absent (C4 short) genes in SLE and control cohorts 
compared with previously published data from Yang and colleagues (81). 
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Figure A 7.6: Linear relationship between C4A genes and HERV-K retroviral element. 
Linear relationship between C4 short, Long and C4A genes in SLE patients (left hand side graphs) and healthy controls (right 
hand side graphs).  Equations and r2 values indicated on the graphs. 
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Figure A 7.7: Relationship between HERV-K and C4B genes. 
Linear relationship between C4 short, Long and C4B genes in SLE patients (left hand side graphs) and healthy controls (right 
hand side graphs).  Equations and r2 values indicated on the graphs. 
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Figure A 7.8: Serum [C4] stratified with HERV-K gene copy number in C4 long genes only. 
The top two graphs show a linear regression analysis in SLE patients (left hand side graphs) and healthy controls (right hand 
side graphs) with C4 long genes only (i.e.  they do not have any short C4 genes).  Serum C4 concentrations (0.160 – 0.520g/L) 
= reference ranges in the healthy population.  Equation indicated and r2 values correspond to the analysis performed on 
individual data points and the mean within the data points respectively.  The bottom two graphs show a Mann-Whitney 
analysis of ranks for the C4 long GCN (left hand side) (P = 0.9595 NS) and for the serum [C4] mean concentrations (right 
hand side) (P = 0.0087) between the SLE patients and healthy control.   
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in this thesis 
B.1 Permissions 
B.1.1 Gender Balance in patients with systemic lupus 
erythematosus 
As per signed agreement below, no permissions were required to use the content of 
this article in this thesis. 
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B.1.2 Anti-C1q Antibodies by Elisa in Systemic Lupus 
Erythematosus 
The article was published in an open access journal; therefore, no permissions were 
required to use the content in this work. 
B.1.3 Insights on the relationship between complement 
component C4 serum concentrations and C4 gene copy 
numbers in a Western Australian systemic lupus 
erythematosus cohort 
The article is currently under review by the “Journal Lupus”, awaiting editor in chief 
decision post reviewing process. 
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B.1.4 Genetic Variation at the DNASE I Locus in an Australian 
Cohort of SLE Patients 
The article was published in an open access journal; therefore, no permissions were 
required to use the content in this work. 
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Cohort of SLE Patients (Lupus: Open Access) 
 
  
 170 
  
 171 
  
 172 
  
 173 
  
 174 
  
 175 
 
 
  
 176 
Appendix C Authors authorisation forms  
C.1 Gender Balance in patients with systemic lupus 
erythematosus 
 
 
  
 177 
C.2 Anti-C1q Antibodies Concentrations by Elisa in 
Systemic Lupus erythematosus  
 
 
  
 178 
C.3 Insights on the relationship between complement 
component C4 serum concentrations and C4 gene copy 
numbers in a Western Australian systemic lupus 
erythematosus cohort 
 
 
 
  
 179 
C.4 Genetic Variation at the DNASE I Locus in an Australian 
Cohort of SLE Patients 
 
 
 
